Broadly neutralizing antibodies against influenza neuraminidase
Patent Information
- Application Number
- JP2023531064
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-09-21
- Filing Date
- 2021-11-19
- Publication Date
- 2024-11-08
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current treatments for influenza virus infections, particularly those targeting neuraminidase, face challenges due to naturally acquired mutations that reduce susceptibility to existing drugs, necessitating the development of broad-spectrum antiviral agents.
Development of broadly neutralizing monoclonal antibodies (FNI3 and FNI9) against influenza A virus neuraminidase (NA) subtypes N1, N2, and N9, which are engineered to inhibit sialidase activity and neutralize a wide range of influenza strains, including those with oseltamivir resistance mutations.
The antibodies demonstrate potent inhibition of sialidase activity and neutralization of various influenza strains, including oseltamivir-resistant variants, providing a prophylactic and therapeutic benefit in animal models.
Smart Images

Figure 00000000_0000_ABST
Abstract
Description
[Technical Field]
[0001] Sequence Listing Declaration The Sequence Listing associated with this application is provided in text format in lieu of a paper copy and is incorporated herein by reference. The name of the text file containing the Sequence Listing is 930585_414WO_SEQUENCE_LISTING.txt. This text file is 137 KB, was created on November 16, 2021, and is being submitted electronically via EFS-Web. [Background technology]
[0002] Influenza is an infectious disease that spreads worldwide in annual outbreaks, resulting in approximately 3 to 5 million cases of severe illness and 290,000 to 650,000 respiratory deaths per year (WHO, Influenza (Seasonal) Fact Sheet, November 6, 2018). The most common symptoms include sudden fever, a (usually dry) cough, headache, muscle and joint pain, severe fatigue (feeling unwell), sore throat, and runny nose. The incubation period varies between one and four days, but symptoms usually begin about two days after exposure to the virus. Complications of influenza can include pneumonia, sinus infections, and worsening of preexisting health problems (such as asthma or heart failure), sepsis, or worsening of underlying chronic conditions.
[0003] Influenza is caused by a group of antigenically and genetically diverse influenza viruses of the Orthomyxoviridae family, which contain a negative-sense, single-stranded, segmented RNA genome. There are four types of influenza viruses (A, B, C, and D), of which three (A, B, and C) are known to affect humans. Influenza viruses can be classified based on the subtypes of their major surface proteins, hemagglutinin (HA) and neuraminidase (NA). At least 18 influenza A subtypes exist, defined by their hemagglutinin (HA) protein. HAs can be divided into two groups: Group 1 includes subtypes H1, H2, H5, H6, H8, H9, H11, H12, H13, H16, and H17, while Group 2 includes subtypes H3, H4, H7, H10, H14, and H15. There are at least 11 distinct neuraminidase subtypes (N1-N11 (cdc.gov / flu / about / viruses / types.htm)). Neuraminidase functions in viral mobility and spread by catalyzing the hydrolysis of sialic acid residues on the virion prior to release from infected host cells and on surface glycoproteins on target cells. While drugs designed to inhibit neuraminidase (NAI) (e.g., oseltamivir, zanamivir, peramivir, and laninamivir) have been developed, naturally acquired mutations in IAV subtypes reduce their susceptibility to current NAIs (Hussain et al., Infection and Drug Resistance 10:121-134 (2017)). Summary of the Invention
[0004] New modalities for treating influenza virus infections are needed. [Brief explanation of the drawings]
[0005] [Figure 1]Figure 1 shows the workflow for anti-"NA" (neuraminidase) monoclonal antibody discovery. Donor selection was performed by screening sera from tonsil donor samples (n = 50) for reactivity to neuraminidase subtypes N1 and N2 antigens and sera from PBMC (peripheral blood mononuclear cell) donor samples (n = 124) for reactivity to neuraminidase subtypes N4, N3, and N9. For screening, neuraminidase antigens were expressed in mammalian cells, and binding was assessed by flow cytometry. B memory cells from five donors were sorted by flow cytometry and entered into the discovery workflow. B cells from one sort (n = 39,350) were cultured with mesenchymal stromal cells (MSCs) in 50 μl cultures to stimulate antibody secretion. Secreted antibodies were assessed by binding assays and NA inhibition assays. Inhibition of N1 sialidase activity was assessed using an enzyme-linked lectin assay (ELLA), and inhibition of N1, N2, and N9 sialidase activity was measured using a fluorescence-based assay measuring the cleavage of 2'-(4-methylumbelliferyl)-α-DN-acetylneuraminic acid (MUNANA). "NI activity" refers to neuraminidase inhibitory activity. Binding to NAs from group 1 IAV N1 A / Vietnam / 1203 / 2004 and group 2 IAV N2 A / Tanzania / 205 / 2010 and N9 A / Hong Kong / 56 / 2015 was assessed by ELISA to determine breadth. Antibody sequences from selected B cells were cloned and sequenced. [Figure 1-1]Figure 1 shows the workflow for anti-"NA" (neuraminidase) monoclonal antibody discovery. Donor selection was performed by screening sera from tonsil donor samples (n = 50) for reactivity to neuraminidase subtypes N1 and N2 antigens and sera from PBMC (peripheral blood mononuclear cell) donor samples (n = 124) for reactivity to neuraminidase subtypes N4, N3, and N9. For screening, neuraminidase antigens were expressed in mammalian cells, and binding was assessed by flow cytometry. B memory cells from five donors were sorted by flow cytometry and entered into the discovery workflow. B cells from one sort (n = 39,350) were cultured with mesenchymal stromal cells (MSCs) in 50 μl cultures to stimulate antibody secretion. Secreted antibodies were assessed by binding assays and NA inhibition assays. Inhibition of N1 sialidase activity was assessed using an enzyme-linked lectin assay (ELLA), and inhibition of N1, N2, and N9 sialidase activity was measured using a fluorescence-based assay measuring the cleavage of 2'-(4-methylumbelliferyl)-α-DN-acetylneuraminic acid (MUNANA). "NI activity" refers to neuraminidase inhibitory activity. Binding to NAs from group 1 IAV N1 A / Vietnam / 1203 / 2004 and group 2 IAV N2 A / Tanzania / 205 / 2010 and N9 A / Hong Kong / 56 / 2015 was assessed by ELISA to determine breadth. Antibody sequences from selected B cells were cloned and sequenced.
[0006] [Figure 2A] FIG. 2A shows an alignment of VH domain sequences of monoclonal antibodies (prefixed "FNI") against influenza A virus ("IAV") isolated from human donor PBMCs.
[0007] [Figure 2B]Figure 2B shows an alignment of the VH domain sequences of "FNI3" (VH: SEQ ID NO: 26; VL: SEQ ID NO: 32) and "FNI9" (VH: SEQ ID NO: 86; VL: SEQ ID NO: 92), as well as the unmutated common ancestor "UCA" (VH: SEQ ID NO: 228; VL: SEQ ID NO: 230).
[0008] [Figure 3A] Figures 3A-3C show the binding of FNI3 and FNI9 to NAs N1 (Figure 3A), N2 (Figure 3B), and N9 (Figure 3C) measured by enzyme-linked immunosorbent assay (ELISA) and reported as OD vs. concentration (ng / ml). Binding by the control antibody 1G01-LS and a negative control antibody against an unrelated antigen, "K-," was also measured. [Figure 3B] Figures 3A-3C show the binding of FNI3 and FNI9 to NAs N1 (Figure 3A), N2 (Figure 3B), and N9 (Figure 3C) measured by enzyme-linked immunosorbent assay (ELISA) and reported as OD vs. concentration (ng / ml). Binding by the control antibody 1G01-LS and a negative control antibody against an unrelated antigen, "K-," was also measured. [Figure 3C] Figures 3A-3C show the binding of FNI3 and FNI9 to NAs N1 (Figure 3A), N2 (Figure 3B), and N9 (Figure 3C) measured by enzyme-linked immunosorbent assay (ELISA) and reported as OD vs. concentration (ng / ml). Binding by the control antibody 1G01-LS and a negative control antibody against an unrelated antigen, "K-," was also measured.
[0009] [Figure 4A]Figures 4A-4C show the binding kinetics of FNI3 with M428L / N434S Fc mutations (referred to as "FNI3-LS" in the figures) and FNI9 with M428L / N434S Fc mutations (referred to as "FNI9-LS" in the figures) to NAs N1 (Figure 4A), N2 (Figure 4B), and N9 (Figure 4C) measured by biolayer interferometry (BLI). Dissociation is reported as kdis (1 / sec), association is reported as kon (1 / Msec), and KD was calculated from the ratio of kdis / kon. Binding by the control antibody 1G01-LS was also measured. [Figure 4B] Figures 4A-4C show the binding kinetics of FNI3 with M428L / N434S Fc mutations (referred to as "FNI3-LS" in the figures) and FNI9 with M428L / N434S Fc mutations (referred to as "FNI9-LS" in the figures) to NAs N1 (Figure 4A), N2 (Figure 4B), and N9 (Figure 4C) measured by biolayer interferometry (BLI). Dissociation is reported as kdis (1 / sec), association is reported as kon (1 / Msec), and KD was calculated from the ratio of kdis / kon. Binding by the control antibody 1G01-LS was also measured. [Figure 4C] Figures 4A-4C show the binding kinetics of FNI3 with M428L / N434S Fc mutations (referred to as "FNI3-LS" in the figures) and FNI9 with M428L / N434S Fc mutations (referred to as "FNI9-LS" in the figures) to NAs N1 (Figure 4A), N2 (Figure 4B), and N9 (Figure 4C) measured by biolayer interferometry (BLI). Dissociation is reported as kdis (1 / sec), association is reported as kon (1 / Msec), and KD was calculated from the ratio of kdis / kon. Binding by the control antibody 1G01-LS was also measured.
[0010] [Figure 5]Figure 5 summarizes the results from flow cytometry assays examining the binding of FNI3 and FNI9, as well as the binding of the comparative antibody 1G01, to NAs of group I IAV, group II IAV, and a panel of influenza B virus (IBV) viruses. Bold text indicates NAs from influenza viruses isolated from humans. The values on the scale to the right indicate the range of calculated EC50 values. Values were selected based on the lowest concentration at which binding was observed.
[0011] [Figure 6] Figure 6 shows the phylogenetic relatedness of NAs from group 1 IAV, group 2 IAV, and IBV.
[0012] [Figure 7A] Figures 7A-7C show the activity of FNI3 and FNI9 against NAs containing glycosylation sites. Figure 7A shows the glycosylation sites of the N2 subtype NAs of group 2 IAVs at positions 245 (245Gly+) and 247 (247Gly+) in A / South Australia / 34 / 2019, A / Switzerland / 8060 / 2017, A / Singapore / INFIMH-16-0019 / 2016, and A / Switzerland / 9715293 / 2013. [Figure 7B] Figures 7A-7C show the activity of FNI3 and FNI9 against NAs containing glycosylation sites. Figure 7B summarizes the inhibition of sialidase activity (NAI) in live virus stocks of A / Switzerland / 8060 / 2017, A / Singapore / INFIMH-16-0019 / 2016, and A / Switzerland / 9715293 / 2013, reported as EC50 (μg / ml). [Figure 7C] Figures 7A-7C show the activity of FNI3 and FNI9 against NAs containing glycosylation sites. Figure 7C shows the results of flow cytometry assay of FNI3 and FNI9 binding to NAs in mammalian cells infected with A / South Australia / 34 / 2019 (245Gly+). Mock staining is shown as a negative control. [Figure 7C-1] Figures 7A-7C show the activity of FNI3 and FNI9 against NAs containing glycosylation sites. Figure 7C shows the results of flow cytometry assay of FNI3 and FNI9 binding to NAs in mammalian cells infected with A / South Australia / 34 / 2019 (245Gly+). Mock staining is shown as a negative control.
[0013] [Figure 8] Figure 8 shows the binding of FNI3 and FNI9 to NA expressed on the surface of mammalian cells infected with the H1N1 swine Eurasian avian (EA) strain, A / Swine / Jiangsu / J004 / 2018, measured by flow cytometry. Mock staining is shown as a negative control. [Figure 8-1] Figure 8 shows the binding of FNI3 and FNI9 to NA expressed on the surface of mammalian cells infected with the H1N1 swine Eurasian avian (EA) strain, A / Swine / Jiangsu / J004 / 2018, measured by flow cytometry. Mock staining is shown as a negative control.
[0014] [Figure 9] Figure 9 shows the lack of polyreactivity in the binding of FNI3 and FNI9 using human epithelial type 2 (HEP-2) cells. The anti-HA antibody FI6v3 was used as a positive control, and the anti-paramyxovirus antibody MPE8 was included as a negative control.
[0015] [Figure 10] Figure 10 summarizes the inhibition of sialidase activity ("NAI") by FNI3 and FNI9 against NAs from group I IAV, group II IAV, and a panel of influenza B virus (IBV) as measured by MUNANA assay. Bold indicates NAs from influenza viruses isolated from humans.
[0016] [Figure 11]FIG. 11 shows the in vitro inhibition (reported as IC50 in μg / ml) of sialidase activity by FNI3 and FNI9 against NA of group I (H1N1) IAV, group II (H3N2) IAV, and IBV.
[0017] [Figure 12A] Figures 12A-12B show the in vitro inhibition (reported as IC50 in μg / ml) of sialidase activity by FNI3 and FNI9 against NAs of group I (H1N1) IAV, group II (H3N2) IAV, and IBV. Figure 12A shows the inhibitory activity against group I IAV, group II IAV, and IBV in the same plot, and Figure 12B shows the inhibitory activity against these IAVs in separate plots. [Figure 12B] Figures 12A-12B show the in vitro inhibition (reported as IC50 in μg / ml) of sialidase activity by FNI3 and FNI9 against NAs of group I (H1N1) IAV, group II (H3N2) IAV, and IBV. Figure 12A shows the inhibitory activity against group I IAV, group II IAV, and IBV in the same plot, and Figure 12B shows the inhibitory activity against these IAVs in separate plots.
[0018] [Figure 13A] FIG. 13A shows a panel of IAV and IBV strains tested in an in vitro inhibition assay of sialidase activity.
[0019] [Figure 13B] Figure 13B shows the results from the assay for FNI3, FNI9, FNI14 (VH: SEQ ID NO: 134; VL: SEQ ID NO: 140), FNI17 (VH: SEQ ID NO: 146; VL: SEQ ID NO: 152), and FNI19 (VH: SEQ ID NO: 158; VL: SEQ ID NO: 164), reported as IC50 in μg / ml. The asterisk in the figure legend indicates the presence of a glycosylation site at position 245.
[0020] [Figure 14A]Figures 14A-14D show the neutralization (reported as IC50 (μg / ml)) of antibodies FNI1 (VH: SEQ ID NO: 2; VL: SEQ ID NO: 8), FNI3, FNI9, FNI14, FNI17, and FNI19 against the NA of H1N1 A / California / 07 / 2009 (Figure 14A), H3N2 A / Hong Kong / 8 / 68 (Figure 14B), B / Malaysia / 2506 / 2004 (Figure 14C), and B / Jiangsu / 10 / 2003 (Figure 14D). [Figure 14B] Figures 14A-14D show the neutralization (reported as IC50 (μg / ml)) of antibodies FNI1 (VH: SEQ ID NO: 2; VL: SEQ ID NO: 8), FNI3, FNI9, FNI14, FNI17, and FNI19 against the NA of H1N1 A / California / 07 / 2009 (Figure 14A), H3N2 A / Hong Kong / 8 / 68 (Figure 14B), B / Malaysia / 2506 / 2004 (Figure 14C), and B / Jiangsu / 10 / 2003 (Figure 14D). [Figure 14C] Figures 14A-14D show the neutralization (reported as IC50 (μg / ml)) of antibodies FNI1 (VH: SEQ ID NO: 2; VL: SEQ ID NO: 8), FNI3, FNI9, FNI14, FNI17, and FNI19 against the NA of H1N1 A / California / 07 / 2009 (Figure 14A), H3N2 A / Hong Kong / 8 / 68 (Figure 14B), B / Malaysia / 2506 / 2004 (Figure 14C), and B / Jiangsu / 10 / 2003 (Figure 14D). [Figure 14D] Figures 14A-14D show the neutralization (reported as IC50 (μg / ml)) of antibodies FNI1 (VH: SEQ ID NO: 2; VL: SEQ ID NO: 8), FNI3, FNI9, FNI14, FNI17, and FNI19 against the NA of H1N1 A / California / 07 / 2009 (Figure 14A), H3N2 A / Hong Kong / 8 / 68 (Figure 14B), B / Malaysia / 2506 / 2004 (Figure 14C), and B / Jiangsu / 10 / 2003 (Figure 14D).
[0021] [Figure 15A]Figures 15A and 15B show antibody activation of FcγRIIIa (Figure 15A; F158 allele) and FcγRIIa (Figure 15B; H131 allele). Activation was measured using an NFAT-mediated luciferase reporter in engineered Jurkat cells. In addition to FNI3 and FNI9, the comparative antibody FM08 ("FM08_LS" in the figures; VH: SEQ ID NO: 194; VL: SEQ ID NO: 195) and a negative control antibody (FY1-GRLR) were tested. [Figure 15B] Figures 15A and 15B show antibody activation of FcγRIIIa (Figure 15A; F158 allele) and FcγRIIa (Figure 15B; H131 allele). Activation was measured using an NFAT-mediated luciferase reporter in engineered Jurkat cells. In addition to FNI3 and FNI9, the comparative antibody FM08 ("FM08_LS" in the figures; VH: SEQ ID NO: 194; VL: SEQ ID NO: 195) and a negative control antibody (FY1-GRLR) were tested.
[0022] [Figure 16A] Figures 16A and 16B show the annual frequencies of NA antiviral resistance mutations in (Figure 16A) N1 (H1N1, swine H1N1, and avian H5N1) and (Figure 16B) N2 (H3N2, H2N2) subtypes. [Figure 16B] Figures 16A and 16B show the annual frequencies of NA antiviral resistance mutations in (Figure 16A) N1 (H1N1, swine H1N1, and avian H5N1) and (Figure 16B) N2 (H3N2, H2N2) subtypes.
[0023] [Figure 17A] Figures 17A-17E show the neutralization of H1N1 A / California / 07 / 2009 viruses engineered by reverse genetics to oseltamivir (OSE) resistance mutations (H275Y, E119D and H275Y, or S247N and H275Y) by anti-full antibodies or oseltamivir. The neutralizing activities of FNI3 (Figure 17A), FNI9 (Figure 17B), and oseltamivir (Figure 17C) were measured, as well as the neutralizing activities of the comparative antibodies FM08 (Figure 17D) and 1G01 (Figure 17E). [Figure 17B]Figures 17A-17E show the neutralization of H1N1 A / California / 07 / 2009 viruses engineered by reverse genetics to oseltamivir (OSE) resistance mutations (H275Y, E119D and H275Y, or S247N and H275Y) by anti-full antibodies or oseltamivir. The neutralizing activities of FNI3 (Figure 17A), FNI9 (Figure 17B), and oseltamivir (Figure 17C) were measured, as well as the neutralizing activities of the comparative antibodies FM08 (Figure 17D) and 1G01 (Figure 17E). [Figure 17C] Figures 17A-17E show the neutralization of H1N1 A / California / 07 / 2009 viruses engineered by reverse genetics to oseltamivir (OSE) resistance mutations (H275Y, E119D and H275Y, or S247N and H275Y) by anti-full antibodies or oseltamivir. The neutralizing activities of FNI3 (Figure 17A), FNI9 (Figure 17B), and oseltamivir (Figure 17C) were measured, as well as the neutralizing activities of the comparative antibodies FM08 (Figure 17D) and 1G01 (Figure 17E). [Figure 17D] Figures 17A-17E show the neutralization of H1N1 A / California / 07 / 2009 viruses engineered by reverse genetics to oseltamivir (OSE) resistance mutations (H275Y, E119D and H275Y, or S247N and H275Y) by anti-full antibodies or oseltamivir. The neutralizing activities of FNI3 (Figure 17A), FNI9 (Figure 17B), and oseltamivir (Figure 17C) were measured, as well as the neutralizing activities of the comparative antibodies FM08 (Figure 17D) and 1G01 (Figure 17E). [Figure 17E] Figures 17A-17E show the neutralization of H1N1 A / California / 07 / 2009 viruses engineered by reverse genetics to oseltamivir (OSE) resistance mutations (H275Y, E119D and H275Y, or S247N and H275Y) by anti-full antibodies or oseltamivir. The neutralizing activities of FNI3 (Figure 17A), FNI9 (Figure 17B), and oseltamivir (Figure 17C) were measured, as well as the neutralizing activities of the comparative antibodies FM08 (Figure 17D) and 1G01 (Figure 17E).
[0024] [Figure 18A] Figures 18A and 18B show the neutralization (reported as IC50 in μg / ml) of group I (H1N1) IAV viruses, group II (H3N2) IAV viruses, IBV viruses, and IAV and IBV viruses engineered by reverse genetics to harbor OSE resistance mutations (H275Y, E119D / H275Y, H275Y / S247N, I222V, or N294S) by anti-NA antibodies. Asterisks (x-axis) in Figure 18A indicate viruses with OSE resistance mutations. The neutralizing activities of FNI3, FNI9, and the comparative antibody 1G01 were measured. Figure 18A shows the neutralization of individual virus strains, and Figure 18B shows the neutralization of virus strains grouped by neutralizing anti-NA antibody. [Figure 18B] Figures 18A and 18B show the neutralization (reported as IC50 in μg / ml) of group I (H1N1) IAV viruses, group II (H3N2) IAV viruses, IBV viruses, and IAV and IBV viruses engineered by reverse genetics to harbor OSE resistance mutations (H275Y, E119D / H275Y, H275Y / S247N, I222V, or N294S) by anti-NA antibodies. Asterisks (x-axis) in Figure 18A indicate viruses with OSE resistance mutations. The neutralizing activities of FNI3, FNI9, and the comparative antibody 1G01 were measured. Figure 18A shows the neutralization of individual virus strains, and Figure 18B shows the neutralization of virus strains grouped by neutralizing anti-NA antibody.
[0025] [Figure 19] FIG. 19 shows data from a crystal structure study showing the docking of NA with the antigen-binding fragment (Fab) domain of the FNI3 antibody.
[0026] [Figure 20A]Figures 20A and 20B show schematic diagrams constructed from crystal structure studies of the heavy chain complementarity-determining region 3 (H-CDR3) of the FNI3 heavy chain when unbound (Figure 20A) or bound (Figure 20B) to the NA of N2. The crystal structure of the unbound FNI3 H-CDR3 (Figure 20A) shows a beta-sheet conformation and intact main-chain hydrogen bonds between the carboxylic acid (CO) and amino groups (NH) of residues: E111(CO)-D102(NH), E111(NH)-D102(CO), G109(CO)-F104(NH), G109(NH)-N105(CO), and L108(NH)-N105(CO). The crystal structure of FNI3-N2 (Figure 20B) shows a disrupted H-CDR3 beta-sheet conformation and one intact main-chain hydrogen bond between G109(CO)-F104(NH). [Figure 20B] Figures 20A and 20B show schematic diagrams constructed from crystal structure studies of the heavy chain complementarity-determining region 3 (H-CDR3) of the FNI3 heavy chain when unbound (Figure 20A) or bound (Figure 20B) to the NA of N2. The crystal structure of the unbound FNI3 H-CDR3 (Figure 20A) shows a beta-sheet conformation and intact main-chain hydrogen bonds between the carboxylic acid (CO) and amino groups (NH) of residues: E111(CO)-D102(NH), E111(NH)-D102(CO), G109(CO)-F104(NH), G109(NH)-N105(CO), and L108(NH)-N105(CO). The crystal structure of FNI3-N2 (Figure 20B) shows a disrupted H-CDR3 beta-sheet conformation and one intact main-chain hydrogen bond between G109(CO)-F104(NH).
[0027] [Figure 21A]Figures 21A and 21B are diagrams derived from crystal structure studies showing the docking angles of the antigen-binding fragment (Fab) domain of FNI3 in complex with NA subtypes and the Fab domains of comparative antibodies 1G01, 1G04, and 1E01. Lines in all figures indicate the docking angles, and Protein Data Bank (PDB) identification codes are shown for comparative antibodies 1G01, 1G04, and 1E01. Figure 21A shows 1G01 in complex with N1 NA (top) and 1G04 in complex with N9 NA (bottom). Figure 21B shows FNI3 in complex with N2 NA (top) and 1E01 in complex with N2 NA (bottom). [Figure 21B] Figures 21A and 21B are diagrams derived from crystal structure studies showing the docking angles of the antigen-binding fragment (Fab) domain of FNI3 in complex with NA subtypes and the Fab domains of comparative antibodies 1G01, 1G04, and 1E01. Lines in all figures indicate the docking angles, and Protein Data Bank (PDB) identification codes are shown for comparative antibodies 1G01, 1G04, and 1E01. Figure 21A shows 1G01 in complex with N1 NA (top) and 1G04 in complex with N9 NA (bottom). Figure 21B shows FNI3 in complex with N2 NA (top) and 1E01 in complex with N2 NA (bottom).
[0028] [Figure 22] Figure 22 shows the conformation and interactions of the FNI3 CDRs H-CDR3, H-CDR2, and L-CDR. To generate these data, the protein was "prepared on the fly" using MOE (Molecular Operating Environment).
[0029] [Figure 23]Figure 23 shows the crystal structure of FNI3 in complex with NA of N2, including residues from the light chain CDRs (L-1, L-2, L-3) and heavy chain CDRs (H-1, H-2, H-3). The interaction of H-CDR3 with NA of N2 is shown at increased resolution in the right panel. Negative numbers are interaction energies (units: kcal / mol). The protein was "prepared on the fly" using MOE (Molecular Operating Environment) software.
[0030] [Figure 24] Figure 24 shows a crystal structure representation of FNI3 in complex with the NA of N2 bound to oseltamivir, which is shown to interact with R292, R371, and R118 of the NA of N2.
[0031] [Figure 25] FIG. 25 shows another view of the crystal structure showing FNI3 in complex with the NA of oseltamivir-bound N2.
[0032] [Figure 26A]Figures 26A and 26B show an analysis of the conservation of the FNI3 epitope in N2 NA sequences from H3N2 (n = 60,597) isolated between 2000 and 2020. The table in Figure 26A shows the frequency of amino acids at specific positions in the analyzed N2 NA sequences. Circled values indicate the three least frequently occurring amino acids: Glu221 (E221, 17.41%), Ser245 (S245, 33.69%), and Ser247 (S247, 36.16%). Acidic amino acids include aspartic acid and glutamic acid; basic amino acids include arginine, histidine, and lysine; hydrophobic amino acids include isoleucine, leucine, tryptophan, valine, alanine, and proline; neutral amino acids include asparagine and glutamine; and polar amino acids include serine, threonine, glycine, and tyrosine. Figure 26B shows the interactions between Y60 and Y94 of VH from FNI3 and E221, S245, and S247 of NA of N2. [Figure 26B] Figures 26A and 26B show an analysis of the conservation of the FNI3 epitope in N2 NA sequences from H3N2 (n = 60,597) isolated between 2000 and 2020. The table in Figure 26A shows the frequency of amino acids at specific positions in the analyzed N2 NA sequences. Circled values indicate the three least frequently occurring amino acids: Glu221 (E221, 17.41%), Ser245 (S245, 33.69%), and Ser247 (S247, 36.16%). Acidic amino acids include aspartic acid and glutamic acid; basic amino acids include arginine, histidine, and lysine; hydrophobic amino acids include isoleucine, leucine, tryptophan, valine, alanine, and proline; neutral amino acids include asparagine and glutamine; and polar amino acids include serine, threonine, glycine, and tyrosine. Figure 26B shows the interactions between Y60 and Y94 of VH from FNI3 and E221, S245, and S247 of NA of N2.
[0033] [Figure 27] Figure 27 shows a comparison of the conservation of the FNI3 epitope in the N2 NA (top; shown in Figures 26A and 26B) with the conservation of the FNI3 epitope in the N1 NA sequences from H1N1 (n=57,597) isolated between 2000 and 2020 (bottom). Acidic amino acids include aspartic acid and glutamic acid; basic amino acids include arginine, histidine, and lysine; hydrophobic amino acids include isoleucine, leucine, tryptophan, valine, alanine, and proline; neutral amino acids include asparagine and glutamine; and polar amino acids include serine, threonine, glycine, and tyrosine.
[0034] [Figure 28A] Figures 28A and 28B show the design of an in vivo study to evaluate the prophylactic activity of FNI3 ("mAb-03" in Figure 28A) and FNI9 ("mAb-09" in Figure 28A) in BALB / c mice infected with IAV A / Puerto Rico / 8 / 34 or A / Hong Kong / 8 / 68. Figure 28A shows the doses and virus strains used in the study. Figure 28B shows the timeline and endpoints of the study. [Figure 28B] Figures 28A and 28B show the design of an in vivo study to evaluate the prophylactic activity of FNI3 ("mAb-03" in Figure 28A) and FNI9 ("mAb-09" in Figure 28A) in BALB / c mice infected with IAV A / Puerto Rico / 8 / 34 or A / Hong Kong / 8 / 68. Figure 28A shows the doses and virus strains used in the study. Figure 28B shows the timeline and endpoints of the study.
[0035] [Figure 29A]Figures 29A-29D show body weight measurements over 15 days in BALB / c mice treated with FNI3 and then infected with H1N1 A / Puerto Rico / 8 / 34. Antibody was administered at 6 mg / kg (Figure 29A), 2 mg / kg (Figure 29B), 0.6 mg / kg (Figure 29C), or 0.2 mg / kg (Figure 29D) one day before infection with the LD90 (90% lethal dose) of A / Puerto Rico / 8 / 34. Body weights were also measured in mice treated with vehicle control (left graph in each figure). [Figure 29B] Figures 29A-29D show body weight measurements over 15 days in BALB / c mice treated with FNI3 and then infected with H1N1 A / Puerto Rico / 8 / 34. Antibody was administered at 6 mg / kg (Figure 29A), 2 mg / kg (Figure 29B), 0.6 mg / kg (Figure 29C), or 0.2 mg / kg (Figure 29D) one day before infection with the LD90 (90% lethal dose) of A / Puerto Rico / 8 / 34. Body weights were also measured in mice treated with vehicle control (left graph in each figure). [Figure 29C] Figures 29A-29D show body weight measurements over 15 days in BALB / c mice treated with FNI3 and then infected with H1N1 A / Puerto Rico / 8 / 34. Antibody was administered at 6 mg / kg (Figure 29A), 2 mg / kg (Figure 29B), 0.6 mg / kg (Figure 29C), or 0.2 mg / kg (Figure 29D) one day before infection with the LD90 (90% lethal dose) of A / Puerto Rico / 8 / 34. Body weights were also measured in mice treated with vehicle control (left graph in each figure). [Figure 29D] Figures 29A-29D show body weight measurements over 15 days in BALB / c mice treated with FNI3 and then infected with H1N1 A / Puerto Rico / 8 / 34. Antibody was administered at 6 mg / kg (Figure 29A), 2 mg / kg (Figure 29B), 0.6 mg / kg (Figure 29C), or 0.2 mg / kg (Figure 29D) one day before infection with the LD90 (90% lethal dose) of A / Puerto Rico / 8 / 34. Body weights were also measured in mice treated with vehicle control (left graph in each figure).
[0036] [Figure 30A] Figures 30A-30D show body weight measurements over 15 days in BALB / c mice pretreated with FNI9 and then infected with H1N1 A / Puerto Rico / 8 / 34. Antibody was administered at 6 mg / kg (Figure 30A), 2 mg / kg (Figure 30B), 0.6 mg / kg (Figure 30C), or 0.2 mg / kg (Figure 30D) one day before infection with the LD90 (90% lethal dose) of A / Puerto Rico / 8 / 34. Body weights were also measured in mice treated with vehicle control (left graph in each figure). [Figure 30B] Figures 30A-30D show body weight measurements over 15 days in BALB / c mice pretreated with FNI9 and then infected with H1N1 A / Puerto Rico / 8 / 34. Antibody was administered at 6 mg / kg (Figure 30A), 2 mg / kg (Figure 30B), 0.6 mg / kg (Figure 30C), or 0.2 mg / kg (Figure 30D) one day before infection with the LD90 (90% lethal dose) of A / Puerto Rico / 8 / 34. Body weights were also measured in mice treated with vehicle control (left graph in each figure). [Figure 30C] Figures 30A-30D show body weight measurements over 15 days in BALB / c mice pretreated with FNI9 and then infected with H1N1 A / Puerto Rico / 8 / 34. Antibody was administered at 6 mg / kg (Figure 30A), 2 mg / kg (Figure 30B), 0.6 mg / kg (Figure 30C), or 0.2 mg / kg (Figure 30D) one day before infection with the LD90 (90% lethal dose) of A / Puerto Rico / 8 / 34. Body weights were also measured in mice treated with vehicle control (left graph in each figure). [Figure 30D]Figures 30A-30D show body weight measurements over 15 days in BALB / c mice pretreated with FNI9 and then infected with H1N1 A / Puerto Rico / 8 / 34. Antibody was administered at 6 mg / kg (Figure 30A), 2 mg / kg (Figure 30B), 0.6 mg / kg (Figure 30C), or 0.2 mg / kg (Figure 30D) one day before infection with the LD90 (90% lethal dose) of A / Puerto Rico / 8 / 34. Body weights were also measured in mice treated with vehicle control (left graph in each figure).
[0037] [Figure 31A] Figures 31A-31D show body weight measurements over 15 days in BALB / c mice pretreated with FNI3 and then infected with H3N2 A / Hong Kong / 8 / 68. Antibody was administered at 6 mg / kg (Figure 31A), 2 mg / kg (Figure 31B), 0.6 mg / kg (Figure 31C), or 0.2 mg / kg (Figure 31D) one day before infection with the LD90 (90% lethal dose) of A / Hong Kong / 8 / 68. Body weights were also measured in mice treated with vehicle control (left graph in each figure). [Figure 31B] Figures 31A-31D show body weight measurements over 15 days in BALB / c mice pretreated with FNI3 and then infected with H3N2 A / Hong Kong / 8 / 68. Antibody was administered at 6 mg / kg (Figure 31A), 2 mg / kg (Figure 31B), 0.6 mg / kg (Figure 31C), or 0.2 mg / kg (Figure 31D) one day before infection with the LD90 (90% lethal dose) of A / Hong Kong / 8 / 68. Body weights were also measured in mice treated with vehicle control (left graph in each figure). [Figure 31C]Figures 31A-31D show body weight measurements over 15 days in BALB / c mice pretreated with FNI3 and then infected with H3N2 A / Hong Kong / 8 / 68. Antibody was administered at 6 mg / kg (Figure 31A), 2 mg / kg (Figure 31B), 0.6 mg / kg (Figure 31C), or 0.2 mg / kg (Figure 31D) one day before infection with the LD90 (90% lethal dose) of A / Hong Kong / 8 / 68. Body weights were also measured in mice treated with vehicle control (left graph in each figure). [Figure 31D] Figures 31A-31D show body weight measurements over 15 days in BALB / c mice pretreated with FNI3 and then infected with H3N2 A / Hong Kong / 8 / 68. Antibody was administered at 6 mg / kg (Figure 31A), 2 mg / kg (Figure 31B), 0.6 mg / kg (Figure 31C), or 0.2 mg / kg (Figure 31D) one day before infection with the LD90 (90% lethal dose) of A / Hong Kong / 8 / 68. Body weights were also measured in mice treated with vehicle control (left graph in each figure).
[0038] [Figure 32A] Figures 32A-32D show body weight measurements over 15 days in BALB / c mice pretreated with FNI9 and then infected with H3N2 A / Hong Kong / 8 / 68. Antibody was administered at 6 mg / kg (Figure 32A), 2 mg / kg (Figure 32B), 0.6 mg / kg (Figure 32C), or 0.2 mg / kg (Figure 32D) one day before infection with the LD90 (90% lethal dose) of A / Hong Kong / 8 / 68. Body weights were also measured in mice treated with vehicle control (left graph in each figure). [Figure 32B]Figures 32A-32D show body weight measurements over 15 days in BALB / c mice pretreated with FNI9 and then infected with H3N2 A / Hong Kong / 8 / 68. Antibody was administered at 6 mg / kg (Figure 32A), 2 mg / kg (Figure 32B), 0.6 mg / kg (Figure 32C), or 0.2 mg / kg (Figure 32D) one day before infection with the LD90 (90% lethal dose) of A / Hong Kong / 8 / 68. Body weights were also measured in mice treated with vehicle control (left graph in each figure). [Figure 32C] Figures 32A-32D show body weight measurements over 15 days in BALB / c mice pretreated with FNI9 and then infected with H3N2 A / Hong Kong / 8 / 68. Antibody was administered at 6 mg / kg (Figure 32A), 2 mg / kg (Figure 32B), 0.6 mg / kg (Figure 32C), or 0.2 mg / kg (Figure 32D) one day before infection with the LD90 (90% lethal dose) of A / Hong Kong / 8 / 68. Body weights were also measured in mice treated with vehicle control (left graph in each figure). [Figure 32D] Figures 32A-32D show body weight measurements over 15 days in BALB / c mice pretreated with FNI9 and then infected with H3N2 A / Hong Kong / 8 / 68. Antibody was administered at 6 mg / kg (Figure 32A), 2 mg / kg (Figure 32B), 0.6 mg / kg (Figure 32C), or 0.2 mg / kg (Figure 32D) one day before infection with the LD90 (90% lethal dose) of A / Hong Kong / 8 / 68. Body weights were also measured in mice treated with vehicle control (left graph in each figure).
[0039] [Figure 33A] Figures 33A and 33B show survival over 15 days in BALB / c mice treated with FNI3 or FNI9 and then infected with A / Puerto Rico / 8 / 34 (Figure 33A) or A / Hong Kong / 8 / 68 (Figure 33B). Survival was also measured in mice pre-treated with vehicle control. [Figure 33B]Figures 33A and 33B show survival over 15 days in BALB / c mice treated with FNI3 or FNI9 and then infected with A / Puerto Rico / 8 / 34 (Figure 33A) or A / Hong Kong / 8 / 68 (Figure 33B). Survival was also measured in mice pre-treated with vehicle control.
[0040] [Figure 34A] Figures 34A and 34B show weight loss (reported as area under the curve) from days 4 to 14 post-infection in BALB / c mice pre-treated with FNI3 or FNI9 and then infected with A / Puerto Rico / 8 / 34 (Figure 34A) or A / Hong Kong / 8 / 68 (Figure 34B). Weight loss was also measured in mice pre-treated with vehicle control. [Figure 34B] Figures 34A and 34B show weight loss (reported as area under the curve) from days 4 to 14 post-infection in BALB / c mice pre-treated with FNI3 or FNI9 and then infected with A / Puerto Rico / 8 / 34 (Figure 34A) or A / Hong Kong / 8 / 68 (Figure 34B). Weight loss was also measured in mice pre-treated with vehicle control.
[0041] [Figure 35A] Figures 35A and 35B show the negative area under the curve peak values compared to serum IgG from an area under the curve analysis of weight loss in BALB / c mice treated with FNI3 or FNI9 and then infected with A / Puerto Rico / 8 / 34 (Figure 35A) or A / Hong Kong / 8 / 68 (Figure 35B). [Figure 35B] Figures 35A and 35B show the negative area under the curve peak values compared to serum IgG from an area under the curve analysis of weight loss in BALB / c mice treated with FNI3 or FNI9 and then infected with A / Puerto Rico / 8 / 34 (Figure 35A) or A / Hong Kong / 8 / 68 (Figure 35B).
[0042] [Figure 36]Figure 36 shows the in vivo pharmacokinetics of FNI3 ("FNI3-LS"), FNI9 ("FNI9-LS"), and comparison antibodies FM08 and 1G01 ("1G01-LS") (all with M428L / N434S mutations) in tg32 mice. Calculated half-lives are highlighted by rectangles. [Figure 36-1] Figure 36 shows the in vivo pharmacokinetics of FNI3 ("FNI3-LS"), FNI9 ("FNI9-LS"), and comparison antibodies FM08 and 1G01 ("1G01-LS") (all with M428L / N434S mutations) in tg32 mice. Calculated half-lives are highlighted by rectangles.
[0043] [Figure 37] Figure 37 summarizes the results from a flow cytometry assay examining binding by the indicated concentrations (μg / mL) of FNI3, FNI9, FNI17, and FNI19 to a panel of NAs from group I IAV, group II IAV, and influenza B virus (IBV) transiently expressed on the surface of mammalian cells. Bold indicates NAs from influenza viruses isolated from humans. Values on the scale to the right indicate the range of calculated EC50 values. Values were selected based on the lowest concentration at which binding was observed.
[0044] [Figure 38] Figure 38 shows the in vitro inhibition of sialidase activity (reported as IC50 in μg / ml) by FNI3, FNI9, FNI17, and FNI19 against group I (H1N1) and group II (H3N2) NAs from IAVs circulating in humans. Rectangles represent group II (H3N2) NAs with glycosylation at position 245 and the corresponding sialidase inhibition values (reported as IC50 in μg / ml).
[0045] [Figure 39]FIG. 39 shows the in vitro inhibition of sialidase activity (reported as IC50 in μg / ml) by FNI3, FNI9, FNI17, and FNI19 against the NA of a panel of IBVs of human ancestral, Victoria, and Yamagata lineages.
[0046] [Figure 40] Figure 40 shows the in vitro neutralizing activity of FNI3, FNI9, FNI17, and FNI19 against the NA of group I (H1N1) IAV, group II (H3N2) IAV, and IBV, as measured by nucleoprotein (NP) staining. The neutralizing activity of the comparative anti-HA antibodies "FM08_LS" and "FHF11v9" was also measured.
[0047] [Figure 41] Figure 41 shows the in vitro neutralization activity of FNI3, FNI9, FNI17, FNI19, and oseltamivir (OSE) against the NA of group I (H1N1) IAV, group II (H3N2) IAV, and IBV as measured by nucleoprotein (NP) staining. 1 nM = 150 μl.
[0048] [Figure 42A] Figures 42A and 42B show the in vitro inhibition (reported as IC50 (μg / ml)) of sialidase activity by FNI3 and FNI9 against NA from OSE-resistant influenza viruses, measured by MUNANA assay. OSE-resistant IAVs were engineered to carry oseltamivir (OSE) resistance mutations using reverse genetics. Figure 42A shows the inhibition of sialidase activity against Cal / 09 N1 and Cal / 09 N1 OSE-resistant (H1N1). Figure 42B shows the inhibition of sialidase activity against Aichi / 68 N2 and Aichi / 68 N2 OSE-resistant NA (H3N2). [Figure 42B]Figures 42A and 42B show the in vitro inhibition (reported as IC50 (μg / ml)) of sialidase activity by FNI3 and FNI9 against NA from OSE-resistant influenza viruses, measured by MUNANA assay. OSE-resistant IAVs were engineered to carry oseltamivir (OSE) resistance mutations using reverse genetics. Figure 42A shows the inhibition of sialidase activity against Cal / 09 N1 and Cal / 09 N1 OSE-resistant (H1N1). Figure 42B shows the inhibition of sialidase activity against Aichi / 68 N2 and Aichi / 68 N2 OSE-resistant NA (H3N2).
[0049] [Figure 43] Figure 43 shows antibody activation of FcγRIIIa (F158 allele) and FcγRIIa (H131 allele). Activation was measured using an NFAT-mediated luciferase reporter in engineered Jurkat cells. Activation was assessed after incubation with A549 cells infected with H1N1 influenza strain A / Puerto Rico / 8 / 34 at a multiplicity of infection (MOI) of 6. In addition to FNI3, FNI9, FNI17, and FNI19, a comparison antibody "FM08_MLNS" with the M428L / N434S mutations and a negative control antibody (FY1-GRLR) were tested.
[0050] [Figure 44A] Figures 44A and 44B show antibody activation of FcγRIIIa (V158 allele) after incubation with IAV (Figure 44A) and IBV (Figure 44B) NAs. Activation was measured using an NFAT-mediated luciferase reporter in engineered Jurkat cells after incubation with Expi-CHO cells transiently transfected with plasmids encoding different IAV and IBV NAs. FNI3, FNI9, FNI17, and FNI19 were tested, along with a negative control antibody (FY1-GRLR). [Figure 44A-1]Figures 44A and 44B show antibody activation of FcγRIIIa (V158 allele) after incubation with IAV (Figure 44A) and IBV (Figure 44B) NAs. Activation was measured using an NFAT-mediated luciferase reporter in engineered Jurkat cells after incubation with Expi-CHO cells transiently transfected with plasmids encoding different IAV and IBV NAs. FNI3, FNI9, FNI17, and FNI19 were tested, along with a negative control antibody (FY1-GRLR). [Figure 44B] Figures 44A and 44B show antibody activation of FcγRIIIa (V158 allele) after incubation with IAV (Figure 44A) and IBV (Figure 44B) NAs. Activation was measured using an NFAT-mediated luciferase reporter in engineered Jurkat cells after incubation with Expi-CHO cells transiently transfected with plasmids encoding different IAV and IBV NAs. FNI3, FNI9, FNI17, and FNI19 were tested, along with a negative control antibody (FY1-GRLR).
[0051] [Figure 45A] Figures 45A and 45B show antibody activation of FcγRIIa (H131 allele) after incubation with IAV (Figure 45A) and IBV (Figure 45B) NAs. Activation was measured using an NFAT-mediated luciferase reporter in engineered Jurkat cells after incubation with Expi-CHO cells transiently transfected with plasmids encoding different IAV and IBV NAs. FNI3, FNI9, FNI17, and FNI19 were tested, along with a negative control antibody (FY1-GRLR). [Figure 45A-1]Figures 45A and 45B show antibody activation of FcγRIIa (H131 allele) after incubation with IAV (Figure 45A) and IBV (Figure 45B) NAs. Activation was measured using an NFAT-mediated luciferase reporter in engineered Jurkat cells after incubation with Expi-CHO cells transiently transfected with plasmids encoding different IAV and IBV NAs. FNI3, FNI9, FNI17, and FNI19 were tested, along with a negative control antibody (FY1-GRLR). [Figure 45B] Figures 45A and 45B show antibody activation of FcγRIIa (H131 allele) after incubation with IAV (Figure 45A) and IBV (Figure 45B) NAs. Activation was measured using an NFAT-mediated luciferase reporter in engineered Jurkat cells after incubation with Expi-CHO cells transiently transfected with plasmids encoding different IAV and IBV NAs. FNI3, FNI9, FNI17, and FNI19 were tested, along with a negative control antibody (FY1-GRLR).
[0052] [Figure 46] Figure 46 shows the negative area under the curve peak values (reported as EC50 in μg / ml) compared to serum IgG from the area under the curve analysis of weight loss in BALB / c mice treated with FNI3, FNI9, or FM08_LS and then infected with A / Puerto Rico / 8 / 34 (H1N1) or A / Hong Kong / 8 / 68 (H3N2). For fitting purposes, the area of the negative peak from the vehicle group was calculated at an IgG concentration of 10 μg / ml.
[0053] [Figure 47A]Figures 47A and 47B show the design of an in vivo study to evaluate the prophylactic activity of FNI3_MLNS ("mAb-03" in Figure 47A) and FNI9_MLNS ("mAb-09" in Figure 47A) in DBA / 2J mice infected with IBV B / Victoria / 504 / 2000 (Yamagata) or B / Brisbane / 60 / 2008 (Victoria). Figure 47A shows the doses and virus strains used in the study. Figure 47B shows the timeline and endpoints of the study. [Figure 47B] Figures 47A and 47B show the design of an in vivo study to evaluate the prophylactic activity of FNI3_MLNS ("mAb-03" in Figure 47A) and FNI9_MLNS ("mAb-09" in Figure 47A) in DBA / 2J mice infected with IBV B / Victoria / 504 / 2000 (Yamagata) or B / Brisbane / 60 / 2008 (Victoria). Figure 47A shows the doses and virus strains used in the study. Figure 47B shows the timeline and endpoints of the study.
[0054] [Figure 48A] Figures 48A-48D show body weight measurements over 15 days in DBA / 2 mice pretreated with FNI3 or FNI9 and then infected with IBV B / Victoria / 504 / 2000 (Yamagata). Antibodies were administered at 6 mg / kg (Figure 48A), 2 mg / kg (Figure 48B), 0.6 mg / kg (Figure 48C), or 0.2 mg / kg (Figure 48D) one day before infection with the LD90 (90% lethal dose) of IBV B / Victoria / 504 / 2000 (Yamagata). Body weights were also measured in mice treated with vehicle control (left graph in each figure). [Figure 48A-1]Figures 48A-48D show body weight measurements over 15 days in DBA / 2 mice pretreated with FNI3 or FNI9 and then infected with IBV B / Victoria / 504 / 2000 (Yamagata). Antibodies were administered at 6 mg / kg (Figure 48A), 2 mg / kg (Figure 48B), 0.6 mg / kg (Figure 48C), or 0.2 mg / kg (Figure 48D) one day before infection with the LD90 (90% lethal dose) of IBV B / Victoria / 504 / 2000 (Yamagata). Body weights were also measured in mice treated with vehicle control (left graph in each figure). [Figure 48B] Figures 48A-48D show body weight measurements over 15 days in DBA / 2 mice pretreated with FNI3 or FNI9 and then infected with IBV B / Victoria / 504 / 2000 (Yamagata). Antibodies were administered at 6 mg / kg (Figure 48A), 2 mg / kg (Figure 48B), 0.6 mg / kg (Figure 48C), or 0.2 mg / kg (Figure 48D) one day before infection with the LD90 (90% lethal dose) of IBV B / Victoria / 504 / 2000 (Yamagata). Body weights were also measured in mice treated with vehicle control (left graph in each figure). [Figure 48B-1] Figures 48A-48D show body weight measurements over 15 days in DBA / 2 mice pretreated with FNI3 or FNI9 and then infected with IBV B / Victoria / 504 / 2000 (Yamagata). Antibodies were administered at 6 mg / kg (Figure 48A), 2 mg / kg (Figure 48B), 0.6 mg / kg (Figure 48C), or 0.2 mg / kg (Figure 48D) one day before infection with the LD90 (90% lethal dose) of IBV B / Victoria / 504 / 2000 (Yamagata). Body weights were also measured in mice treated with vehicle control (left graph in each figure). [Figure 48C]Figures 48A-48D show body weight measurements over 15 days in DBA / 2 mice pretreated with FNI3 or FNI9 and then infected with IBV B / Victoria / 504 / 2000 (Yamagata). Antibodies were administered at 6 mg / kg (Figure 48A), 2 mg / kg (Figure 48B), 0.6 mg / kg (Figure 48C), or 0.2 mg / kg (Figure 48D) one day before infection with the LD90 (90% lethal dose) of IBV B / Victoria / 504 / 2000 (Yamagata). Body weights were also measured in mice treated with vehicle control (left graph in each figure). [Figure 48C-1] Figures 48A-48D show body weight measurements over 15 days in DBA / 2 mice pretreated with FNI3 or FNI9 and then infected with IBV B / Victoria / 504 / 2000 (Yamagata). Antibodies were administered at 6 mg / kg (Figure 48A), 2 mg / kg (Figure 48B), 0.6 mg / kg (Figure 48C), or 0.2 mg / kg (Figure 48D) one day before infection with the LD90 (90% lethal dose) of IBV B / Victoria / 504 / 2000 (Yamagata). Body weights were also measured in mice treated with vehicle control (left graph in each figure). [Figure 48D] Figures 48A-48D show body weight measurements over 15 days in DBA / 2 mice pretreated with FNI3 or FNI9 and then infected with IBV B / Victoria / 504 / 2000 (Yamagata). Antibodies were administered at 6 mg / kg (Figure 48A), 2 mg / kg (Figure 48B), 0.6 mg / kg (Figure 48C), or 0.2 mg / kg (Figure 48D) one day before infection with the LD90 (90% lethal dose) of IBV B / Victoria / 504 / 2000 (Yamagata). Body weights were also measured in mice treated with vehicle control (left graph in each figure). [Figure 48D-1]Figures 48A-48D show body weight measurements over 15 days in DBA / 2 mice pretreated with FNI3 or FNI9 and then infected with IBV B / Victoria / 504 / 2000 (Yamagata). Antibodies were administered at 6 mg / kg (Figure 48A), 2 mg / kg (Figure 48B), 0.6 mg / kg (Figure 48C), or 0.2 mg / kg (Figure 48D) one day before infection with the LD90 (90% lethal dose) of IBV B / Victoria / 504 / 2000 (Yamagata). Body weights were also measured in mice treated with vehicle control (left graph in each figure).
[0055] [Figure 49A] Figures 49A-49D show body weight measurements over 15 days in DBA / 2 mice pretreated with FNI3 or FNI9 and then infected with IBV B / Brisbane / 60 / 2008 (Victoria). Antibodies were administered at 6 mg / kg (Figure 49A), 2 mg / kg (Figure 49B), 0.6 mg / kg (Figure 49C), or 0.2 mg / kg (Figure 49D) one day before infection with the LD90 (90% lethal dose) of IBV B / Brisbane / 60 / 2008 (Victoria). Body weights were also measured in mice treated with vehicle control (left graph in each figure). [Figure 49A-1] Figures 49A-49D show body weight measurements over 15 days in DBA / 2 mice pretreated with FNI3 or FNI9 and then infected with IBV B / Brisbane / 60 / 2008 (Victoria). Antibodies were administered at 6 mg / kg (Figure 49A), 2 mg / kg (Figure 49B), 0.6 mg / kg (Figure 49C), or 0.2 mg / kg (Figure 49D) one day before infection with the LD90 (90% lethal dose) of IBV B / Brisbane / 60 / 2008 (Victoria). Body weights were also measured in mice treated with vehicle control (left graph in each figure). [Figure 49B]Figures 49A-49D show body weight measurements over 15 days in DBA / 2 mice pretreated with FNI3 or FNI9 and then infected with IBV B / Brisbane / 60 / 2008 (Victoria). Antibodies were administered at 6 mg / kg (Figure 49A), 2 mg / kg (Figure 49B), 0.6 mg / kg (Figure 49C), or 0.2 mg / kg (Figure 49D) one day before infection with the LD90 (90% lethal dose) of IBV B / Brisbane / 60 / 2008 (Victoria). Body weights were also measured in mice treated with vehicle control (left graph in each figure). [Figure 49B-1] Figures 49A-49D show body weight measurements over 15 days in DBA / 2 mice pretreated with FNI3 or FNI9 and then infected with IBV B / Brisbane / 60 / 2008 (Victoria). Antibodies were administered at 6 mg / kg (Figure 49A), 2 mg / kg (Figure 49B), 0.6 mg / kg (Figure 49C), or 0.2 mg / kg (Figure 49D) one day before infection with the LD90 (90% lethal dose) of IBV B / Brisbane / 60 / 2008 (Victoria). Body weights were also measured in mice treated with vehicle control (left graph in each figure). [Figure 49C] Figures 49A-49D show body weight measurements over 15 days in DBA / 2 mice pretreated with FNI3 or FNI9 and then infected with IBV B / Brisbane / 60 / 2008 (Victoria). Antibodies were administered at 6 mg / kg (Figure 49A), 2 mg / kg (Figure 49B), 0.6 mg / kg (Figure 49C), or 0.2 mg / kg (Figure 49D) one day before infection with the LD90 (90% lethal dose) of IBV B / Brisbane / 60 / 2008 (Victoria). Body weights were also measured in mice treated with vehicle control (left graph in each figure). [Figure 49C-1]Figures 49A-49D show body weight measurements over 15 days in DBA / 2 mice pretreated with FNI3 or FNI9 and then infected with IBV B / Brisbane / 60 / 2008 (Victoria). Antibodies were administered at 6 mg / kg (Figure 49A), 2 mg / kg (Figure 49B), 0.6 mg / kg (Figure 49C), or 0.2 mg / kg (Figure 49D) one day before infection with the LD90 (90% lethal dose) of IBV B / Brisbane / 60 / 2008 (Victoria). Body weights were also measured in mice treated with vehicle control (left graph in each figure). [Figure 49D] Figures 49A-49D show body weight measurements over 15 days in DBA / 2 mice pretreated with FNI3 or FNI9 and then infected with IBV B / Brisbane / 60 / 2008 (Victoria). Antibodies were administered at 6 mg / kg (Figure 49A), 2 mg / kg (Figure 49B), 0.6 mg / kg (Figure 49C), or 0.2 mg / kg (Figure 49D) one day before infection with the LD90 (90% lethal dose) of IBV B / Brisbane / 60 / 2008 (Victoria). Body weights were also measured in mice treated with vehicle control (left graph in each figure). [Figure 49D-1] Figures 49A-49D show body weight measurements over 15 days in DBA / 2 mice pretreated with FNI3 or FNI9 and then infected with IBV B / Brisbane / 60 / 2008 (Victoria). Antibodies were administered at 6 mg / kg (Figure 49A), 2 mg / kg (Figure 49B), 0.6 mg / kg (Figure 49C), or 0.2 mg / kg (Figure 49D) one day before infection with the LD90 (90% lethal dose) of IBV B / Brisbane / 60 / 2008 (Victoria). Body weights were also measured in mice treated with vehicle control (left graph in each figure).
[0056] [Figure 50A]Figures 50A and 50B show weight loss (reported as change in area under the curve for body weight) from days 4 to 14 post-infection in DBA / 2 mice pre-treated with FNI3 or FNI9 and then infected with B / Victoria / 504 / 2000 (Yamagata) (Figure 50A) or B / Brisbane / 60 / 2008 (Victoria) (Figure 50B). Weight loss was also measured in mice pre-treated with vehicle control. [Figure 50B] Figures 50A and 50B show weight loss (reported as change in area under the curve for body weight) from days 4 to 14 post-infection in DBA / 2 mice pre-treated with FNI3 or FNI9 and then infected with B / Victoria / 504 / 2000 (Yamagata) (Figure 50A) or B / Brisbane / 60 / 2008 (Victoria) (Figure 50B). Weight loss was also measured in mice pre-treated with vehicle control.
[0057] [Figure 51A] Figures 51A and 51B show survival over 15 days in DBA / 2 mice treated with FNI3 or FNI9 and then infected with B / Victoria / 504 / 2000 (Yamagata) (Figure 51A) or B / Brisbane / 60 / 2008 (Victoria) (Figure 51B). Survival was also measured in mice pre-treated with vehicle control. [Figure 51B] Figures 51A and 51B show survival over 15 days in DBA / 2 mice treated with FNI3 or FNI9 and then infected with B / Victoria / 504 / 2000 (Yamagata) (Figure 51A) or B / Brisbane / 60 / 2008 (Victoria) (Figure 51B). Survival was also measured in mice pre-treated with vehicle control.
[0058] [Figure 52A]Figures 52A and 52B show the conservation of the FNI3 epitope in IAV and IBV NA. Figure 52A shows an analysis of N2 NA sequences (n = 65,5262) from H1N2, H2N2, H3N2, and H5N2 IAVs (top) compared with N1 NA sequences (n = 58,954) from H1N1 and H5N1 IAVs (bottom). All sequences were isolated between 2000 and 2020. Acidic amino acids include aspartic acid and glutamic acid; basic amino acids include arginine, histidine, and lysine; hydrophobic amino acids include isoleucine, leucine, tryptophan, valine, alanine, and proline; neutral amino acids include asparagine and glutamine; and polar amino acids include serine, threonine, glycine, and tyrosine. The boxed residues in Figure 52A represent some of the amino acids listed in the lower panel of Figure 52B. The table in Figure 52B shows the key FNI3 interacting residues in the NA of N2 and the corresponding CDRH3 residues of FNI3. [Figure 52B] Figures 52A and 52B show the conservation of the FNI3 epitope in IAV and IBV NA. Figure 52A shows an analysis of N2 NA sequences (n = 65,5262) from H1N2, H2N2, H3N2, and H5N2 IAVs (top) compared with N1 NA sequences (n = 58,954) from H1N1 and H5N1 IAVs (bottom). All sequences were isolated between 2000 and 2020. Acidic amino acids include aspartic acid and glutamic acid; basic amino acids include arginine, histidine, and lysine; hydrophobic amino acids include isoleucine, leucine, tryptophan, valine, alanine, and proline; neutral amino acids include asparagine and glutamine; and polar amino acids include serine, threonine, glycine, and tyrosine. The boxed residues in Figure 52A represent some of the amino acids listed in the lower panel of Figure 52B. The table in Figure 52B shows the key FNI3 interacting residues in the NA of N2 and the corresponding CDRH3 residues of FNI3.
[0059] [Figure 53]Figure 53 shows the conservation of the FNI3 epitope in the NA of IBV. The NA sequence of IBV from B / Brisbane / 60 / 2008 ("FluB Victoria" in the figure; N=7,814; top) was compared with the NA sequence of IBV from B / Victoria / 504 / 2000 ("FluB Yamagata" in the figure; N=13,243; bottom). Acidic amino acids include aspartic acid and glutamic acid; basic amino acids include arginine, histidine, and lysine; hydrophobic amino acids include isoleucine, leucine, tryptophan, valine, alanine, and proline; neutral amino acids include asparagine and glutamine; and polar amino acids include serine, threonine, glycine, and tyrosine. Boxed residues indicate key NA residues that interact with the HCDR3 of FNI3, which are 100% conserved between IAV N1 / N2 and IBV.
[0060] [Figure 54A] Figures 54A and 54B show the in vivo pharmacokinetics over 30 days following administration of FNI antibodies with MLNS Fc mutations (FNI3 ("FNI3-LS"), FNI9 ("FNI9-LS"), FNI17 ("FNI17-LS"), and FNI19 ("FNI19-LS")) and the comparison antibody FM08_MLNS to SCID tg32 mice. The concentration time course (reported as μg / ml) is shown in Figure 54A. The table in Figure 54B shows the half-life (in days), AUC (in days × μg / ml), clearance (in μg / ml), and volume (in ml). [Figure 54B]Figures 54A and 54B show the in vivo pharmacokinetics over 30 days following administration of FNI antibodies with MLNS Fc mutations (FNI3 ("FNI3-LS"), FNI9 ("FNI9-LS"), FNI17 ("FNI17-LS"), and FNI19 ("FNI19-LS")) and the comparison antibody FM08_MLNS to SCID tg32 mice. The concentration time course (reported as μg / ml) is shown in Figure 54A. The table in Figure 54B shows the half-life (in days), AUC (in days × μg / ml), clearance (in μg / ml), and volume (in ml).
[0061] [Figure 55] FIG. 55 shows the lack of polyreactivity in the binding of FNI3, FNI9, FNI17, and FNI19 to human epithelial type 2 (HEP-2) cells.
[0062] [Figure 56A] Figures 56A-56C relate to crystal structure studies of the FNI antibody and show the docking of the antigen-binding fragment (Fab) domain of the FNI antibody with NA. Figure 56A shows the docking of FNI3 onto the NA of N2. Figure 56B shows the superposition of antibodies FNI3, FNI17, and FNI19 docking onto NA. Figure 56C shows the alignment of the amino acid sequences of the VHs of FNI3, FNI9, FNI17, and FNI19 with the unmutated common ancestor "UCA." The CDRH3 interacting with NA is highlighted by a rectangle. [Figure 56B] Figures 56A-56C relate to crystal structure studies of the FNI antibody and show the docking of the antigen-binding fragment (Fab) domain of the FNI antibody with NA. Figure 56A shows the docking of FNI3 onto the NA of N2. Figure 56B shows the superposition of antibodies FNI3, FNI17, and FNI19 docking onto NA. Figure 56C shows the alignment of the amino acid sequences of the VHs of FNI3, FNI9, FNI17, and FNI19 with the unmutated common ancestor "UCA." The CDRH3 interacting with NA is highlighted by a rectangle. [Figure 56C]Figures 56A-56C relate to crystal structure studies of the FNI antibody and show the docking of the antigen-binding fragment (Fab) domain of the FNI antibody with NA. Figure 56A shows the docking of FNI3 onto the NA of N2. Figure 56B shows the superposition of antibodies FNI3, FNI17, and FNI19 docking onto NA. Figure 56C shows the alignment of the amino acid sequences of the VHs of FNI3, FNI9, FNI17, and FNI19 with the unmutated common ancestor "UCA." The CDRH3 interacting with NA is highlighted by a rectangle.
[0063] [Figure 57A] Figure 57A shows the crystal structure of FNI17 in complex with NA of N2, including residues from the light chain CDRs (L-1, L-2, L-3) and heavy chain CDRs (H-1, H-2, H-3). The interaction of NA of N2 with H-CDR3 is shown at increased resolution in the right panel. The percentage values indicate the contribution of each residue to the calculated binding energy. [Figure 57B] Alignment of the amino acid sequences of VH of FNI3, FNI9, FNI17, and FNI19 with the unmutated common ancestor "UCA" is shown. VH residues D107 and R106, which interact with NA, are highlighted by a rectangle.
[0064] [Figure 58] Figure 58 shows the conservation of the top five interacting residues among the FNI NA epitope among group I IAV, group II IAV, and IBV from 2009 to 2019.
[0065] [Figure 59] Figure 59 shows the in vitro neutralization activity of FNI9, oseltamivir (OSE), and the comparative antibody "FM08" against H3N2 A / Hong Kong / 8 / 68 virus as measured by nucleoprotein (NP) staining. The calculated IC50 (in nM), IC80 (in nM), and maximum inhibition (reported as %) are shown below the graph.
[0066] [Figure 60] Figure 60 shows the in vitro inhibition of sialidase activity of NAs of group I (H1N1) IAV, group II (H3N2) IAV, Victoria lineage IBV, and Yamagata lineage IBV by the FNI17 variant FNI17-v19 (VH: SEQ ID NO: 199; VL: SEQ ID NO: 201) and the FNI19 variant FNI19-v3 (VH: SEQ ID NO: 203; VL: SEQ ID NO: 205) measured by ViroSpot microneutralization assay. The rectangle indicates NAs with glycosylation at position 245. Neutralization by the comparative antibody FM08_LS was also measured. Neutralization is reported as IC50 (units: μg / ml).
[0067] [Figure 61] Figure 61 shows antibody activation of FcγRIIIa (F158 allele) and FcγRIIa (H131 allele) by a "GAALIE" Fc variant antibody (containing G236A / A330L / I332E mutations in the Fc). Activation was measured using an NFAT-mediated luciferase reporter in engineered Jurkat cells. Activation was assessed after incubation with A549 cells infected with H1N1 influenza strain A / Puerto Rico / 8 / 34 at a multiplicity of infection (MOI) of 6. Antibodies FNI3, FNI9, FNI17, and FNI19 with the GAALIE mutation (suffix "-GAALIE") were tested, as well as FNI3, FNI9, FNI17, and FNI19. A comparison antibody, "FM08_LS," and a negative control antibody (FY1-GRLR) were also tested.
[0068] [Figure 62]Figure 62 shows the design of an intra-experimental in vivo study to compare the prophylactic activity of FM08_LS with FNI3_LS and FNI9_LS in BALB / c mice infected with IAV A / Puerto Rico / 8 / 34 or A / Hong Kong / 8 / 68. The table shows the doses and virus strains used in the study. The timeline and endpoints of the study are the same as those shown in Figure 28B. Body weight data from Experiment A ("Exp-A") are shown in Figures 29A-29D (FNI3-LS, A / Puerto Rico / 8 / 34), Figures 30A-30D (FNI9-LS, A / Puerto Rico / 8 / 34), Figures 31A-31D (FNI3-LS, A / Hong Kong / 8 / 68), and Figures 32A-32D (FNI9-LS, A / Hong Kong / 8 / 68). Body weight data from Experiment B ("Exp-B") are shown in Figures 63A-63D (FM08_LS, A / Puerto Rico / 8 / 34) and Figures 64A-64D (FM08_LS, A / Hong Kong / 8 / 68).
[0069] [Figure 63A] Figures 63A-63D show body weight measurements over 15 days in BALB / c mice pretreated with FM08_LS and then infected with H1N1 A / Puerto Rico / 8 / 34. Antibody was administered at 6 mg / kg (Figure 63A), 2 mg / kg (Figure 63B), 0.6 mg / kg (Figure 63C), or 0.2 mg / kg (Figure 63D) one day before infection with the LD90 (90% lethal dose) of A / Puerto Rico / 8 / 34. Body weights were also measured in mice treated with vehicle control (left graph in each figure). [Figure 63B]Figures 63A-63D show body weight measurements over 15 days in BALB / c mice pretreated with FM08_LS and then infected with H1N1 A / Puerto Rico / 8 / 34. Antibody was administered at 6 mg / kg (Figure 63A), 2 mg / kg (Figure 63B), 0.6 mg / kg (Figure 63C), or 0.2 mg / kg (Figure 63D) one day before infection with the LD90 (90% lethal dose) of A / Puerto Rico / 8 / 34. Body weights were also measured in mice treated with vehicle control (left graph in each figure). [Figure 63C] Figures 63A-63D show body weight measurements over 15 days in BALB / c mice pretreated with FM08_LS and then infected with H1N1 A / Puerto Rico / 8 / 34. Antibody was administered at 6 mg / kg (Figure 63A), 2 mg / kg (Figure 63B), 0.6 mg / kg (Figure 63C), or 0.2 mg / kg (Figure 63D) one day before infection with the LD90 (90% lethal dose) of A / Puerto Rico / 8 / 34. Body weights were also measured in mice treated with vehicle control (left graph in each figure). [Figure 63D] Figures 63A-63D show body weight measurements over 15 days in BALB / c mice pretreated with FM08_LS and then infected with H1N1 A / Puerto Rico / 8 / 34. Antibody was administered at 6 mg / kg (Figure 63A), 2 mg / kg (Figure 63B), 0.6 mg / kg (Figure 63C), or 0.2 mg / kg (Figure 63D) one day before infection with the LD90 (90% lethal dose) of A / Puerto Rico / 8 / 34. Body weights were also measured in mice treated with vehicle control (left graph in each figure).
[0070] [Figure 64A]Figures 64A-64D show body weight measurements over 15 days in BALB / c mice pretreated with FM08_LS and then infected with H3N2 A / Hong Kong / 8 / 68. Antibody was administered at 6 mg / kg (Figure 64A), 2 mg / kg (Figure 64B), 0.6 mg / kg (Figure 64C), or 0.2 mg / kg (Figure 64D) one day before infection with the LD90 (90% lethal dose) of A / Hong Kong / 8 / 68. Body weights were also measured in mice treated with vehicle control (left graph in each figure). [Figure 64B] Figures 64A-64D show body weight measurements over 15 days in BALB / c mice pretreated with FM08_LS and then infected with H3N2 A / Hong Kong / 8 / 68. Antibody was administered at 6 mg / kg (Figure 64A), 2 mg / kg (Figure 64B), 0.6 mg / kg (Figure 64C), or 0.2 mg / kg (Figure 64D) one day before infection with the LD90 (90% lethal dose) of A / Hong Kong / 8 / 68. Body weights were also measured in mice treated with vehicle control (left graph in each figure). [Figure 64C] Figures 64A-64D show body weight measurements over 15 days in BALB / c mice pretreated with FM08_LS and then infected with H3N2 A / Hong Kong / 8 / 68. Antibody was administered at 6 mg / kg (Figure 64A), 2 mg / kg (Figure 64B), 0.6 mg / kg (Figure 64C), or 0.2 mg / kg (Figure 64D) one day before infection with the LD90 (90% lethal dose) of A / Hong Kong / 8 / 68. Body weights were also measured in mice treated with vehicle control (left graph in each figure). [Figure 64D] Figures 64A-64D show body weight measurements over 15 days in BALB / c mice pretreated with FM08_LS and then infected with H3N2 A / Hong Kong / 8 / 68. Antibody was administered at 6 mg / kg (Figure 64A), 2 mg / kg (Figure 64B), 0.6 mg / kg (Figure 64C), or 0.2 mg / kg (Figure 64D) one day before infection with the LD90 (90% lethal dose) of A / Hong Kong / 8 / 68. Body weights were also measured in mice treated with vehicle control (left graph in each figure).
[0071] [Figure 65] FIG. 65 shows the doses used in the design of an in vivo study to compare the prophylactic activity of FNI17-LS and FM08_LS in BALB / c mice infected with IAV A / Puerto Rico / 8 / 34.
[0072] [Figure 66A] Figures 66A-66D show body weight measurements over 12 days in BALB / c mice pretreated with FNI17-LS or FM08_LS and then infected with H1N1 A / Puerto Rico / 8 / 34. Antibodies were administered at 1 mg / kg (Figure 66A), 0.5 mg / kg (Figure 66B), 0.25 mg / kg (Figure 66C), or 0.125 mg / kg (Figure 66D) one day before infection with the LD90 (90% lethal dose) of A / Puerto Rico / 8 / 34. [Figure 66B] Figures 66A-66D show body weight measurements over 12 days in BALB / c mice pretreated with FNI17-LS or FM08_LS and then infected with H1N1 A / Puerto Rico / 8 / 34. Antibodies were administered at 1 mg / kg (Figure 66A), 0.5 mg / kg (Figure 66B), 0.25 mg / kg (Figure 66C), or 0.125 mg / kg (Figure 66D) one day before infection with the LD90 (90% lethal dose) of A / Puerto Rico / 8 / 34. [Figure 66C] Figures 66A-66D show body weight measurements over 12 days in BALB / c mice pretreated with FNI17-LS or FM08_LS and then infected with H1N1 A / Puerto Rico / 8 / 34. Antibodies were administered at 1 mg / kg (Figure 66A), 0.5 mg / kg (Figure 66B), 0.25 mg / kg (Figure 66C), or 0.125 mg / kg (Figure 66D) one day before infection with the LD90 (90% lethal dose) of A / Puerto Rico / 8 / 34. [Figure 66D]Figures 66A-66D show body weight measurements over 12 days in BALB / c mice pretreated with FNI17-LS or FM08_LS and then infected with H1N1 A / Puerto Rico / 8 / 34. Antibodies were administered at 1 mg / kg (Figure 66A), 0.5 mg / kg (Figure 66B), 0.25 mg / kg (Figure 66C), or 0.125 mg / kg (Figure 66D) one day before infection with the LD90 (90% lethal dose) of A / Puerto Rico / 8 / 34.
[0073] [Figure 67] Figure 67 shows survival over 12 days in BALB / c mice infected with H1N1 A / Puerto Rico / 8 / 34 after treatment with FNI17-LS or FM08_LS. Survival was also measured in mice pre-treated with vehicle control.
[0074] [Figure 68] Figure 68 shows the design of an in vivo study to evaluate the biological efficacy of oseltamivir (OSE) in female BALB / c mice infected with IAV A / Puerto Rico / 8 / 34. The timeline shows the time of infection, OSE administration, and study endpoints. OSE was administered at 10 mg / kg by oral gavage on day 0, 2 hours before infection with a 10x LD50 (50% lethal dose) of A / Puerto Rico / 8 / 34. OSE was administered at the same dose 6 hours post-infection, and then twice daily until day 6 post-infection.
[0075] [Figure 69] Figure 69 shows the results of measuring body weight over 14 days in BALB / c mice pre-treated with oseltamivir (OSE) and then infected with H1N1 A / Puerto Rico / 8 / 34. Weight loss was also measured in mice pre-treated with vehicle control (HO).
[0076] [Figure 70]Figure 70 shows survival over 14 days in BALB / c mice infected with H1N1 A / Puerto Rico / 8 / 34 after treatment with oseltamivir (OSE). Survival was also measured in mice pre-treated with vehicle control (HO).
[0077] [Figure 71] Figure 71 shows virus titers in lung homogenates from BALB / c mice treated with OSE and infected with H1N1 A / Puerto Rico / 8 / 34. Lung tissue was harvested 2 and 4 days after infection. Titers are reported as 50% tissue culture infectious doses per gram of tissue (TCID50 / g).
[0078] [Figure 72A] Figures 72A-72B show the VH (Figure 72A) and VK (Figure 72B) sequences of FNI3, FNI9, FNI17, and FNI19 aligned with the unmutated common ancestor "UCA." [Figure 72B] Figures 72A-72B show the VH (Figure 72A) and VK (Figure 72B) sequences of FNI3, FNI9, FNI17, and FNI19 aligned with the unmutated common ancestor "UCA."
[0079] [Figure 73A]Figures 73A-73E show the in vitro inhibition (reported as IC50 in μg / ml) of sialidase activity by FNI3 and 11 FNI3 variants (FNI3-v8 to FNI3-v18; see Tables 1 and 2 for amino acid and nucleic acid sequences) against group I (H1N1) IAV NA and IBV NA. The neutralizing activity of FNI3 and FNI3 variants is shown for group I (H1N1) IAV NA1 from H5N1 A / Vietnam / 1203 / 2004 (Figure 73A), NA2 from H3N2 A / Tanzania / 205 / 2010 (Figure 73B), and NA9 from H7N9 A / Hong Kong / 56 / 2015 (Figure 73C). The neutralizing activity of FNI3 and FNI3 variants is shown for BNA2 from B / Malaysia / 2506 / 2004 (Figure 73D) and BNA7 from B / Perth / 211 / 2011 (Figure 73E). [Figure 73B] Figures 73A-73E show the in vitro inhibition (reported as IC50 in μg / ml) of sialidase activity by FNI3 and 11 FNI3 variants (FNI3-v8 to FNI3-v18; see Tables 1 and 2 for amino acid and nucleic acid sequences) against group I (H1N1) IAV NA and IBV NA. The neutralizing activity of FNI3 and FNI3 variants is shown for group I (H1N1) IAV NA1 from H5N1 A / Vietnam / 1203 / 2004 (Figure 73A), NA2 from H3N2 A / Tanzania / 205 / 2010 (Figure 73B), and NA9 from H7N9 A / Hong Kong / 56 / 2015 (Figure 73C). The neutralizing activity of FNI3 and FNI3 variants is shown for BNA2 from B / Malaysia / 2506 / 2004 (Figure 73D) and BNA7 from B / Perth / 211 / 2011 (Figure 73E). [Figure 73C]Figures 73A-73E show the in vitro inhibition (reported as IC50 in μg / ml) of sialidase activity by FNI3 and 11 FNI3 variants (FNI3-v8 to FNI3-v18; see Tables 1 and 2 for amino acid and nucleic acid sequences) against group I (H1N1) IAV NA and IBV NA. The neutralizing activity of FNI3 and FNI3 variants is shown for group I (H1N1) IAV NA1 from H5N1 A / Vietnam / 1203 / 2004 (Figure 73A), NA2 from H3N2 A / Tanzania / 205 / 2010 (Figure 73B), and NA9 from H7N9 A / Hong Kong / 56 / 2015 (Figure 73C). The neutralizing activity of FNI3 and FNI3 variants is shown for BNA2 from B / Malaysia / 2506 / 2004 (Figure 73D) and BNA7 from B / Perth / 211 / 2011 (Figure 73E). [Figure 73D] Figures 73A-73E show the in vitro inhibition (reported as IC50 in μg / ml) of sialidase activity by FNI3 and 11 FNI3 variants (FNI3-v8 to FNI3-v18; see Tables 1 and 2 for amino acid and nucleic acid sequences) against group I (H1N1) IAV NA and IBV NA. The neutralizing activity of FNI3 and FNI3 variants is shown for group I (H1N1) IAV NA1 from H5N1 A / Vietnam / 1203 / 2004 (Figure 73A), NA2 from H3N2 A / Tanzania / 205 / 2010 (Figure 73B), and NA9 from H7N9 A / Hong Kong / 56 / 2015 (Figure 73C). The neutralizing activity of FNI3 and FNI3 variants is shown for BNA2 from B / Malaysia / 2506 / 2004 (Figure 73D) and BNA7 from B / Perth / 211 / 2011 (Figure 73E). [Figure 73E]Figures 73A-73E show the in vitro inhibition (reported as IC50 in μg / ml) of sialidase activity by FNI3 and 11 FNI3 variants (FNI3-v8 to FNI3-v18; see Tables 1 and 2 for amino acid and nucleic acid sequences) against group I (H1N1) IAV NA and IBV NA. The neutralizing activity of FNI3 and FNI3 variants is shown for group I (H1N1) IAV NA1 from H5N1 A / Vietnam / 1203 / 2004 (Figure 73A), NA2 from H3N2 A / Tanzania / 205 / 2010 (Figure 73B), and NA9 from H7N9 A / Hong Kong / 56 / 2015 (Figure 73C). The neutralizing activity of FNI3 and FNI3 variants is shown for BNA2 from B / Malaysia / 2506 / 2004 (Figure 73D) and BNA7 from B / Perth / 211 / 2011 (Figure 73E).
[0080] [Figure 74A] Figures 74A-74E show the in vitro inhibition (reported as IC50 in μg / ml) of sialidase activity by FNI9 and five FNI9 variants (FNI9-v5 through FNI9-v9; see Tables 1 and 2 for amino acid and nucleic acid sequences) against IAV and IBV NAs. The neutralizing activity of FNI9 and FNI9 variants is shown for group I (H1N1) IAVs H5N1 A / Vietnam / 1203 / 2004 (Figure 74A), H3N2 A / Tanzania / 205 / 2010 (Figure 74B), and H7N9 A / Hong Kong / 56 / 2015 (Figure 74C). The neutralizing activity of FNI9 and variants is shown for BNA2 from B / Malaysia / 2506 / 2004 (Figure 74D) and BNA7 from B / Perth / 211 / 2011 (Figure 74E). [Figure 74B]Figures 74A-74E show the in vitro inhibition (reported as IC50 in μg / ml) of sialidase activity by FNI9 and five FNI9 variants (FNI9-v5 through FNI9-v9; see Tables 1 and 2 for amino acid and nucleic acid sequences) against IAV and IBV NAs. The neutralizing activity of FNI9 and FNI9 variants is shown for group I (H1N1) IAVs H5N1 A / Vietnam / 1203 / 2004 (Figure 74A), H3N2 A / Tanzania / 205 / 2010 (Figure 74B), and H7N9 A / Hong Kong / 56 / 2015 (Figure 74C). The neutralizing activity of FNI9 and variants is shown for BNA2 from B / Malaysia / 2506 / 2004 (Figure 74D) and BNA7 from B / Perth / 211 / 2011 (Figure 74E). [Figure 74C] Figures 74A-74E show the in vitro inhibition (reported as IC50 in μg / ml) of sialidase activity by FNI9 and five FNI9 variants (FNI9-v5 through FNI9-v9; see Tables 1 and 2 for amino acid and nucleic acid sequences) against IAV and IBV NAs. The neutralizing activity of FNI9 and FNI9 variants is shown for group I (H1N1) IAVs H5N1 A / Vietnam / 1203 / 2004 (Figure 74A), H3N2 A / Tanzania / 205 / 2010 (Figure 74B), and H7N9 A / Hong Kong / 56 / 2015 (Figure 74C). The neutralizing activity of FNI9 and variants is shown for BNA2 from B / Malaysia / 2506 / 2004 (Figure 74D) and BNA7 from B / Perth / 211 / 2011 (Figure 74E). [Fig. 74D]Figures 74A-74E show the in vitro inhibition (reported as IC50 in μg / ml) of sialidase activity by FNI9 and five FNI9 variants (FNI9-v5 through FNI9-v9; see Tables 1 and 2 for amino acid and nucleic acid sequences) against IAV and IBV NAs. The neutralizing activity of FNI9 and FNI9 variants is shown for group I (H1N1) IAVs H5N1 A / Vietnam / 1203 / 2004 (Figure 74A), H3N2 A / Tanzania / 205 / 2010 (Figure 74B), and H7N9 A / Hong Kong / 56 / 2015 (Figure 74C). The neutralizing activity of FNI9 and variants is shown for BNA2 from B / Malaysia / 2506 / 2004 (Figure 74D) and BNA7 from B / Perth / 211 / 2011 (Figure 74E). [Figure 74E] Figures 74A-74E show the in vitro inhibition (reported as IC50 in μg / ml) of sialidase activity by FNI9 and five FNI9 variants (FNI9-v5 through FNI9-v9; see Tables 1 and 2 for amino acid and nucleic acid sequences) against IAV and IBV NAs. The neutralizing activity of FNI9 and FNI9 variants is shown for group I (H1N1) IAVs H5N1 A / Vietnam / 1203 / 2004 (Figure 74A), H3N2 A / Tanzania / 205 / 2010 (Figure 74B), and H7N9 A / Hong Kong / 56 / 2015 (Figure 74C). The neutralizing activity of FNI9 and variants is shown for BNA2 from B / Malaysia / 2506 / 2004 (Figure 74D) and BNA7 from B / Perth / 211 / 2011 (Figure 74E).
[0081] [Figure 75A]Figures 75A-75E show the in vitro inhibition (reported as IC50 in μg / ml) of sialidase activity by FNI17 and 11 FNI17 variants (FNI17-v6 to FNI17-v16; see Table 2 for amino acid and nucleic acid sequences) against IAV and IBV NAs. The neutralizing activity of FNI17 and FNI17 variants is shown for the following group I (H1N1) IAVs: NA1 from H5N1 A / Vietnam / 1203 / 2004 (Figure 75A), NA2 from H3N2 A / Tanzania / 205 / 2010 (Figure 75B), and NA9 from H7N9 A / Hong Kong / 56 / 2015 (Figure 75C). The neutralizing activity of FNI17 and variants is shown for BNA2 from B / Malaysia / 2506 / 2004 (Figure 75D) and BNA7 from B / Perth / 211 / 2011 (Figure 75E). [Figure 75B] Figures 75A-75E show the in vitro inhibition (reported as IC50 in μg / ml) of sialidase activity by FNI17 and 11 FNI17 variants (FNI17-v6 to FNI17-v16; see Table 2 for amino acid and nucleic acid sequences) against IAV and IBV NAs. The neutralizing activity of FNI17 and FNI17 variants is shown for the following group I (H1N1) IAVs: NA1 from H5N1 A / Vietnam / 1203 / 2004 (Figure 75A), NA2 from H3N2 A / Tanzania / 205 / 2010 (Figure 75B), and NA9 from H7N9 A / Hong Kong / 56 / 2015 (Figure 75C). The neutralizing activity of FNI17 and variants is shown for BNA2 from B / Malaysia / 2506 / 2004 (Figure 75D) and BNA7 from B / Perth / 211 / 2011 (Figure 75E). [Figure 75C]Figures 75A-75E show the in vitro inhibition (reported as IC50 in μg / ml) of sialidase activity by FNI17 and 11 FNI17 variants (FNI17-v6 to FNI17-v16; see Table 2 for amino acid and nucleic acid sequences) against IAV and IBV NAs. The neutralizing activity of FNI17 and FNI17 variants is shown for the following group I (H1N1) IAVs: NA1 from H5N1 A / Vietnam / 1203 / 2004 (Figure 75A), NA2 from H3N2 A / Tanzania / 205 / 2010 (Figure 75B), and NA9 from H7N9 A / Hong Kong / 56 / 2015 (Figure 75C). The neutralizing activity of FNI17 and variants is shown for BNA2 from B / Malaysia / 2506 / 2004 (Figure 75D) and BNA7 from B / Perth / 211 / 2011 (Figure 75E). [Figure 75D] Figures 75A-75E show the in vitro inhibition (reported as IC50 in μg / ml) of sialidase activity by FNI17 and 11 FNI17 variants (FNI17-v6 to FNI17-v16; see Table 2 for amino acid and nucleic acid sequences) against IAV and IBV NAs. The neutralizing activity of FNI17 and FNI17 variants is shown for the following group I (H1N1) IAVs: NA1 from H5N1 A / Vietnam / 1203 / 2004 (Figure 75A), NA2 from H3N2 A / Tanzania / 205 / 2010 (Figure 75B), and NA9 from H7N9 A / Hong Kong / 56 / 2015 (Figure 75C). The neutralizing activity of FNI17 and variants is shown for BNA2 from B / Malaysia / 2506 / 2004 (Figure 75D) and BNA7 from B / Perth / 211 / 2011 (Figure 75E). [Figure 75E]Figures 75A-75E show the in vitro inhibition (reported as IC50 in μg / ml) of sialidase activity by FNI17 and 11 FNI17 variants (FNI17-v6 to FNI17-v16; see Table 2 for amino acid and nucleic acid sequences) against IAV and IBV NAs. The neutralizing activity of FNI17 and FNI17 variants is shown for the following group I (H1N1) IAVs: NA1 from H5N1 A / Vietnam / 1203 / 2004 (Figure 75A), NA2 from H3N2 A / Tanzania / 205 / 2010 (Figure 75B), and NA9 from H7N9 A / Hong Kong / 56 / 2015 (Figure 75C). The neutralizing activity of FNI17 and variants is shown for BNA2 from B / Malaysia / 2506 / 2004 (Figure 75D) and BNA7 from B / Perth / 211 / 2011 (Figure 75E).
[0082] [Figure 76A] Figures 76A-76E show the in vitro inhibition (IC50 in μg / ml) of sialidase activity by FNI19 and five FNI19 variants (FNI19-v1 through FNI19-v5; see Table 2 for amino acid and nucleic acid sequences) against IAV and IBV NAs. The neutralizing activity of FNI19 and FNI19 variants is shown for group I (H1N1) IAVs H5N1 A / Vietnam / 1203 / 2004 (Figure 76A), H3N2 A / Tanzania / 205 / 2010 (Figure 76B), and H7N9 A / Hong Kong / 56 / 2015 (Figure 76C). The neutralizing activity of FNI19 and FNI19 variants is shown for BNA2 from B / Malaysia / 2506 / 2004 (Figure 76D) and BNA7 from B / Perth / 211 / 2011 (Figure 76E). [Figure 76B]Figures 76A-76E show the in vitro inhibition (IC50 in μg / ml) of sialidase activity by FNI19 and five FNI19 variants (FNI19-v1 through FNI19-v5; see Table 2 for amino acid and nucleic acid sequences) against IAV and IBV NAs. The neutralizing activity of FNI19 and FNI19 variants is shown for group I (H1N1) IAVs H5N1 A / Vietnam / 1203 / 2004 (Figure 76A), H3N2 A / Tanzania / 205 / 2010 (Figure 76B), and H7N9 A / Hong Kong / 56 / 2015 (Figure 76C). The neutralizing activity of FNI19 and FNI19 variants is shown for BNA2 from B / Malaysia / 2506 / 2004 (Figure 76D) and BNA7 from B / Perth / 211 / 2011 (Figure 76E). [Figure 76C] Figures 76A-76E show the in vitro inhibition (IC50 in μg / ml) of sialidase activity by FNI19 and five FNI19 variants (FNI19-v1 through FNI19-v5; see Table 2 for amino acid and nucleic acid sequences) against IAV and IBV NAs. The neutralizing activity of FNI19 and FNI19 variants is shown for group I (H1N1) IAVs H5N1 A / Vietnam / 1203 / 2004 (Figure 76A), H3N2 A / Tanzania / 205 / 2010 (Figure 76B), and H7N9 A / Hong Kong / 56 / 2015 (Figure 76C). The neutralizing activity of FNI19 and FNI19 variants is shown for BNA2 from B / Malaysia / 2506 / 2004 (Figure 76D) and BNA7 from B / Perth / 211 / 2011 (Figure 76E). [Figure 76D]Figures 76A-76E show the in vitro inhibition (IC50 in μg / ml) of sialidase activity by FNI19 and five FNI19 variants (FNI19-v1 through FNI19-v5; see Table 2 for amino acid and nucleic acid sequences) against IAV and IBV NAs. The neutralizing activity of FNI19 and FNI19 variants is shown for group I (H1N1) IAVs H5N1 A / Vietnam / 1203 / 2004 (Figure 76A), H3N2 A / Tanzania / 205 / 2010 (Figure 76B), and H7N9 A / Hong Kong / 56 / 2015 (Figure 76C). The neutralizing activity of FNI19 and FNI19 variants is shown for BNA2 from B / Malaysia / 2506 / 2004 (Figure 76D) and BNA7 from B / Perth / 211 / 2011 (Figure 76E). [Figure 76E] Figures 76A-76E show the in vitro inhibition (IC50 in μg / ml) of sialidase activity by FNI19 and five FNI19 variants (FNI19-v1 through FNI19-v5; see Table 2 for amino acid and nucleic acid sequences) against IAV and IBV NAs. The neutralizing activity of FNI19 and FNI19 variants is shown for group I (H1N1) IAVs H5N1 A / Vietnam / 1203 / 2004 (Figure 76A), H3N2 A / Tanzania / 205 / 2010 (Figure 76B), and H7N9 A / Hong Kong / 56 / 2015 (Figure 76C). The neutralizing activity of FNI19 and FNI19 variants is shown for BNA2 from B / Malaysia / 2506 / 2004 (Figure 76D) and BNA7 from B / Perth / 211 / 2011 (Figure 76E).
[0083] [Figure 77A]Figures 77A-77D show the binding of FNI3, FNI9, FNI17, and FNI19 variants to IAV and IBV NAs measured by flow cytometry. Figure 77A shows binding to N1 from A / Stockholm / 18 / 2007, N1 from A / California / 07 / 2009, and N1 from A / California / 07 / 2009 I23R / H275Y. Figure 77B shows binding to N2 from A / South Australia / 34 / 2019, N2 from A / Leningrad / 134 / 17 / 57, and N2 from A / Washington / 01 / 2007. Figure 77C shows binding to N3 from A / Canada / rv504 / 2004, N6 from A / swine / Ontario / 01911 / 1 / 99, and N7 from A / Netherlands / 078 / 03. Figure 77D shows binding to B / Yamanashi / 166 / 1998 (Yamagata), B / Malaysia / 2506 / 2004 (Victoria), and B / Lee / 10 / 1940 (Ancestral). [Figure 77A-1]Figures 77A-77D show the binding of FNI3, FNI9, FNI17, and FNI19 variants to IAV and IBV NAs measured by flow cytometry. Figure 77A shows binding to N1 from A / Stockholm / 18 / 2007, N1 from A / California / 07 / 2009, and N1 from A / California / 07 / 2009 I23R / H275Y. Figure 77B shows binding to N2 from A / South Australia / 34 / 2019, N2 from A / Leningrad / 134 / 17 / 57, and N2 from A / Washington / 01 / 2007. Figure 77C shows binding to N3 from A / Canada / rv504 / 2004, N6 from A / swine / Ontario / 01911 / 1 / 99, and N7 from A / Netherlands / 078 / 03. Figure 77D shows binding to B / Yamanashi / 166 / 1998 (Yamagata), B / Malaysia / 2506 / 2004 (Victoria), and B / Lee / 10 / 1940 (Ancestral). [Figure 77B]Figures 77A-77D show the binding of FNI3, FNI9, FNI17, and FNI19 variants to IAV and IBV NAs measured by flow cytometry. Figure 77A shows binding to N1 from A / Stockholm / 18 / 2007, N1 from A / California / 07 / 2009, and N1 from A / California / 07 / 2009 I23R / H275Y. Figure 77B shows binding to N2 from A / South Australia / 34 / 2019, N2 from A / Leningrad / 134 / 17 / 57, and N2 from A / Washington / 01 / 2007. Figure 77C shows binding to N3 from A / Canada / rv504 / 2004, N6 from A / swine / Ontario / 01911 / 1 / 99, and N7 from A / Netherlands / 078 / 03. Figure 77D shows binding to B / Yamanashi / 166 / 1998 (Yamagata), B / Malaysia / 2506 / 2004 (Victoria), and B / Lee / 10 / 1940 (Ancestral). [Figure 77B-1]Figures 77A-77D show the binding of FNI3, FNI9, FNI17, and FNI19 variants to IAV and IBV NAs measured by flow cytometry. Figure 77A shows binding to N1 from A / Stockholm / 18 / 2007, N1 from A / California / 07 / 2009, and N1 from A / California / 07 / 2009 I23R / H275Y. Figure 77B shows binding to N2 from A / South Australia / 34 / 2019, N2 from A / Leningrad / 134 / 17 / 57, and N2 from A / Washington / 01 / 2007. Figure 77C shows binding to N3 from A / Canada / rv504 / 2004, N6 from A / swine / Ontario / 01911 / 1 / 99, and N7 from A / Netherlands / 078 / 03. Figure 77D shows binding to B / Yamanashi / 166 / 1998 (Yamagata), B / Malaysia / 2506 / 2004 (Victoria), and B / Lee / 10 / 1940 (Ancestral). [Figure 77C]Figures 77A-77D show the binding of FNI3, FNI9, FNI17, and FNI19 variants to IAV and IBV NAs measured by flow cytometry. Figure 77A shows binding to N1 from A / Stockholm / 18 / 2007, N1 from A / California / 07 / 2009, and N1 from A / California / 07 / 2009 I23R / H275Y. Figure 77B shows binding to N2 from A / South Australia / 34 / 2019, N2 from A / Leningrad / 134 / 17 / 57, and N2 from A / Washington / 01 / 2007. Figure 77C shows binding to N3 from A / Canada / rv504 / 2004, N6 from A / swine / Ontario / 01911 / 1 / 99, and N7 from A / Netherlands / 078 / 03. Figure 77D shows binding to B / Yamanashi / 166 / 1998 (Yamagata), B / Malaysia / 2506 / 2004 (Victoria), and B / Lee / 10 / 1940 (Ancestral). [Figure 77C-1]Figures 77A-77D show the binding of FNI3, FNI9, FNI17, and FNI19 variants to IAV and IBV NAs measured by flow cytometry. Figure 77A shows binding to N1 from A / Stockholm / 18 / 2007, N1 from A / California / 07 / 2009, and N1 from A / California / 07 / 2009 I23R / H275Y. Figure 77B shows binding to N2 from A / South Australia / 34 / 2019, N2 from A / Leningrad / 134 / 17 / 57, and N2 from A / Washington / 01 / 2007. Figure 77C shows binding to N3 from A / Canada / rv504 / 2004, N6 from A / swine / Ontario / 01911 / 1 / 99, and N7 from A / Netherlands / 078 / 03. Figure 77D shows binding to B / Yamanashi / 166 / 1998 (Yamagata), B / Malaysia / 2506 / 2004 (Victoria), and B / Lee / 10 / 1940 (Ancestral). [Figure 77D]Figures 77A-77D show the binding of FNI3, FNI9, FNI17, and FNI19 variants to IAV and IBV NAs measured by flow cytometry. Figure 77A shows binding to N1 from A / Stockholm / 18 / 2007, N1 from A / California / 07 / 2009, and N1 from A / California / 07 / 2009 I23R / H275Y. Figure 77B shows binding to N2 from A / South Australia / 34 / 2019, N2 from A / Leningrad / 134 / 17 / 57, and N2 from A / Washington / 01 / 2007. Figure 77C shows binding to N3 from A / Canada / rv504 / 2004, N6 from A / swine / Ontario / 01911 / 1 / 99, and N7 from A / Netherlands / 078 / 03. Figure 77D shows binding to B / Yamanashi / 166 / 1998 (Yamagata), B / Malaysia / 2506 / 2004 (Victoria), and B / Lee / 10 / 1940 (Ancestral). [Figure 77D-1]Figures 77A-77D show the binding of FNI3, FNI9, FNI17, and FNI19 variants to IAV and IBV NAs measured by flow cytometry. Figure 77A shows binding to N1 from A / Stockholm / 18 / 2007, N1 from A / California / 07 / 2009, and N1 from A / California / 07 / 2009 I23R / H275Y. Figure 77B shows binding to N2 from A / South Australia / 34 / 2019, N2 from A / Leningrad / 134 / 17 / 57, and N2 from A / Washington / 01 / 2007. Figure 77C shows binding to N3 from A / Canada / rv504 / 2004, N6 from A / swine / Ontario / 01911 / 1 / 99, and N7 from A / Netherlands / 078 / 03. Figure 77D shows binding to B / Yamanashi / 166 / 1998 (Yamagata), B / Malaysia / 2506 / 2004 (Victoria), and B / Lee / 10 / 1940 (Ancestral).
[0084] [Figure 78A] Figures 78A-78E show additional features of several FNI antibodies. Figure 78A shows an alignment of the amino acid sequences of the VHs of FNI3, FNI9, FNI17, and FNI19 with the amino acid sequence of the VH of the unmutated common ancestor "UCA," with rectangles indicating the positively charged residues Lys13 and Lys19 in the UCA sequence and the corresponding residues at the same positions in FNI3, FNI9, FNI17, and FNI19. Full-surface charge maps generated using PyMOL are shown for FNI3 (Figure 78B), FNI9 (Figure 78C), FNI17 (Figure 78D), and FNI19 (Figure 78E), along with pK values and resolution (reported in Å). [Figure 78B]Figures 78A-78E show additional features of several FNI antibodies. Figure 78A shows an alignment of the amino acid sequences of the VHs of FNI3, FNI9, FNI17, and FNI19 with the amino acid sequence of the VH of the unmutated common ancestor "UCA," with rectangles indicating the positively charged residues Lys13 and Lys19 in the UCA sequence and the corresponding residues at the same positions in FNI3, FNI9, FNI17, and FNI19. Full-surface charge maps generated using PyMOL are shown for FNI3 (Figure 78B), FNI9 (Figure 78C), FNI17 (Figure 78D), and FNI19 (Figure 78E), along with pK values and resolution (reported in Å). [Figure 78C] Figures 78A-78E show additional features of several FNI antibodies. Figure 78A shows an alignment of the amino acid sequences of the VHs of FNI3, FNI9, FNI17, and FNI19 with the amino acid sequence of the VH of the unmutated common ancestor "UCA," with rectangles indicating the positively charged residues Lys13 and Lys19 in the UCA sequence and the corresponding residues at the same positions in FNI3, FNI9, FNI17, and FNI19. Full-surface charge maps generated using PyMOL are shown for FNI3 (Figure 78B), FNI9 (Figure 78C), FNI17 (Figure 78D), and FNI19 (Figure 78E), along with pK values and resolution (reported in Å). [Figure 78D] Figures 78A-78E show additional features of several FNI antibodies. Figure 78A shows an alignment of the amino acid sequences of the VHs of FNI3, FNI9, FNI17, and FNI19 with the amino acid sequence of the VH of the unmutated common ancestor "UCA," with rectangles indicating the positively charged residues Lys13 and Lys19 in the UCA sequence and the corresponding residues at the same positions in FNI3, FNI9, FNI17, and FNI19. Full-surface charge maps generated using PyMOL are shown for FNI3 (Figure 78B), FNI9 (Figure 78C), FNI17 (Figure 78D), and FNI19 (Figure 78E), along with pK values and resolution (reported in Å). [Figure 78E]Figures 78A-78E show additional features of several FNI antibodies. Figure 78A shows an alignment of the amino acid sequences of the VHs of FNI3, FNI9, FNI17, and FNI19 with the amino acid sequence of the VH of the unmutated common ancestor "UCA," with rectangles indicating the positively charged residues Lys13 and Lys19 in the UCA sequence and the corresponding residues at the same positions in FNI3, FNI9, FNI17, and FNI19. Full-surface charge maps generated using PyMOL are shown for FNI3 (Figure 78B), FNI9 (Figure 78C), FNI17 (Figure 78D), and FNI19 (Figure 78E), along with pK values and resolution (reported in Å).
[0085] [Figure 79A] Figures 79A-79B show pK data for FNI17-LS, FNI19-LS, FNI17-v19-LS, and FNI19-v3-LS in tg32 mice. Mice were intravenously injected with 5 mg / kg of antibody. The table in Figure 79A shows the inter-experiment values for half-life, area under the curve (AUC), steady-state clearance (CLss), and total volume analyzed (volume) for FNI17-LS and FNI19-LS (Experiment 1 "PK1"), and for FNI17-v19-LS and FNI19-v3-LS (Experiment 2 "PK2"). Figure 79B shows the mean half-life (reported in days) and standard error for FNI17-LS, FNI19-LS, FNI17-v19-LS, and FNI19-v3-LS. [Figure 79B]Figures 79A-79B show pK data for FNI17-LS, FNI19-LS, FNI17-v19-LS, and FNI19-v3-LS in tg32 mice. Mice were intravenously injected with 5 mg / kg of antibody. The table in Figure 79A shows the inter-experiment values for half-life, area under the curve (AUC), steady-state clearance (CLss), and total volume analyzed (volume) for FNI17-LS and FNI19-LS (Experiment 1 "PK1"), and for FNI17-v19-LS and FNI19-v3-LS (Experiment 2 "PK2"). Figure 79B shows the mean half-life (reported in days) and standard error for FNI17-LS, FNI19-LS, FNI17-v19-LS, and FNI19-v3-LS.
[0086] [Figure 80] Figure 80 shows the design of an in vivo study to evaluate the prophylactic activity of FNI17-v19-rIgG1-LS compared to oseltamivir (OSE) in BALB / c mice infected with IAV or IBV. Mice were pre-treated with FNI17-v19-rIgG1-LS (9, 3, 0.9, or 0.3 MPK) 24 hours before challenge at the LD90 (90% lethal dose). OSE was administered orally at 10 mg / kg daily from 2 hours before infection until 3 or 4 days after challenge. Mice were challenged with IAV (H1N1 A / Puerto Rico / 8 / 34 or H3N2 A / Hong Kong / 8 / 68) or IBV (B / Victoria / 504 / 2000 (Yamagata)) or B / Brisbane / 60 / 2008 (Victoria)). A version of FNI17-v19 (FNI17-v19-rIgG1-GRLR) containing Fc mutations that abolish FcγR and complement binding was also tested in groups challenged with IAV viruses (H1N1 A / Puerto Rico / 8 / 34 or H3N2 A / Hong Kong / 8 / 68). Lung plaque-forming units (PFU) were assessed in mice euthanized 3 days after infection.
[0087] [Figure 81A]Figures 81A-81D show lung virus titers in BALB / c mice from the in vivo study described in Figure 80 that were euthanized 3 days post-infection. Lung virus titers are shown following infection with H1N1 A / Puerto Rico / 8 / 34 (Figure 81A) or H3N2 A / Hong Kong / 8 / 68 (Figure 81B) and IBV B / Victoria / 504 / 2000 (Yamagata; Figure 81C) or B / Brisbane / 60 / 2008 (Victoria; Figure 81D). [Figure 81B] Figures 81A-81D show lung virus titers in BALB / c mice from the in vivo study described in Figure 80 that were euthanized 3 days post-infection. Lung virus titers are shown following infection with H1N1 A / Puerto Rico / 8 / 34 (Figure 81A) or H3N2 A / Hong Kong / 8 / 68 (Figure 81B) and IBV B / Victoria / 504 / 2000 (Yamagata; Figure 81C) or B / Brisbane / 60 / 2008 (Victoria; Figure 81D). [Figure 81C] Figures 81A-81D show lung virus titers in BALB / c mice from the in vivo study described in Figure 80 that were euthanized 3 days post-infection. Lung virus titers are shown following infection with H1N1 A / Puerto Rico / 8 / 34 (Figure 81A) or H3N2 A / Hong Kong / 8 / 68 (Figure 81B) and IBV B / Victoria / 504 / 2000 (Yamagata; Figure 81C) or B / Brisbane / 60 / 2008 (Victoria; Figure 81D). [Figure 81D] Figures 81A-81D show lung virus titers in BALB / c mice from the in vivo study described in Figure 80 that were euthanized 3 days post-infection. Lung virus titers are shown following infection with H1N1 A / Puerto Rico / 8 / 34 (Figure 81A) or H3N2 A / Hong Kong / 8 / 68 (Figure 81B) and IBV B / Victoria / 504 / 2000 (Yamagata; Figure 81C) or B / Brisbane / 60 / 2008 (Victoria; Figure 81D).
[0088] [Figure 82] Figure 82 shows the design of an in vivo study to evaluate the prophylactic activity of FNI17-v19 in humanized FcγR mice infected with H1N1 A / Puerto Rico / 8 / 34. Mice were dosed with antibody 24 hours prior to infection at 5x LD50 (5x 50% lethal dose).
[0089] [Figure 83A] Figures 83A-83C show body weight measurements over 14 days in humanized FcgR mice pre-treated with FNI17-v19 and then infected with H1N1 A / Puerto Rico / 8 / 34. The antibody was administered at 0.9 mg / kg (Figure 83A), 0.3 mg / kg (Figure 83B), or 0.09 mg / kg (Figure 83C) one day prior to infection with 5x the LD50 of A / Puerto Rico / 8 / 34. Body weights were also measured in mice administered a vehicle control (left graph in each figure). [Figure 83B] Figures 83A-83C show body weight measurements over 14 days in humanized FcgR mice pre-treated with FNI17-v19 and then infected with H1N1 A / Puerto Rico / 8 / 34. The antibody was administered at 0.9 mg / kg (Figure 83A), 0.3 mg / kg (Figure 83B), or 0.09 mg / kg (Figure 83C) one day prior to infection with 5x the LD50 of A / Puerto Rico / 8 / 34. Body weights were also measured in mice administered a vehicle control (left graph in each figure). [Figure 83C] Figures 83A-83C show body weight measurements over 14 days in humanized FcgR mice pre-treated with FNI17-v19 and then infected with H1N1 A / Puerto Rico / 8 / 34. The antibody was administered at 0.9 mg / kg (Figure 83A), 0.3 mg / kg (Figure 83B), or 0.09 mg / kg (Figure 83C) one day prior to infection with 5x the LD50 of A / Puerto Rico / 8 / 34. Body weights were also measured in mice administered a vehicle control (left graph in each figure).
[0090] [Figure 84] Figure 84 shows pre-infection concentrations of human IgG in serum from humanized FcγR mice from the study described in Figure 82 that were pre-treated with FNI17-v19. Serum was collected from mice 2 hours prior to infection with 5x LD50 of H1N1 A / Puerto Rico / 8 / 34.
[0091] [Figure 85] Figure 85 shows the binding energies between the FNI antibodies FNI3, FNI9, FNI17, and FNI19 and highly conserved residues on NA involved in interactions with sialic acid.
[0092] [Figure 86] Figure 86 shows the binding of FNI3, FNI9, FNI17, and FNI19 to NA expressed on the surface of mammalian cells infected with the H1N1 swine Eurasian avian (EA) strain, A / Swine / Jiangsu / J004 / 2018, measured by flow cytometry. Mock antibody staining is shown as a negative control. [Figure 86-1] Figure 86 shows the binding of FNI3, FNI9, FNI17, and FNI19 to NA expressed on the surface of mammalian cells infected with the H1N1 swine Eurasian avian (EA) strain, A / Swine / Jiangsu / J004 / 2018, measured by flow cytometry. Mock antibody staining is shown as a negative control.
[0093] [Figure 87A]Figures 87A-87D show the in vitro inhibition (IC50 in μg / ml) of sialidase activity by FNI17-v19 or OSE against NAs of group II H7N3 A / chicken / Jalisco / PAVX17170 / 2017 IAV (Figure 87A), group II H5N6 A / chicken / Suzhou / j6 / 2019 IAV (Figure 87B), group II H7N7 A / chicken / Netherlands / 621572 / 03 IAV (Figure 87C), and group I H5N8 A / chicken / Russia / 3-29 / 2020 IAV (Figure 87D). [Figure 87B] Figures 87A-87D show the in vitro inhibition (IC50 in μg / ml) of sialidase activity by FNI17-v19 or OSE against NAs of group II H7N3 A / chicken / Jalisco / PAVX17170 / 2017 IAV (Figure 87A), group II H5N6 A / chicken / Suzhou / j6 / 2019 IAV (Figure 87B), group II H7N7 A / chicken / Netherlands / 621572 / 03 IAV (Figure 87C), and group I H5N8 A / chicken / Russia / 3-29 / 2020 IAV (Figure 87D). [Figure 87C] Figures 87A-87D show the in vitro inhibition (IC50 in μg / ml) of sialidase activity by FNI17-v19 or OSE against NAs of group II H7N3 A / chicken / Jalisco / PAVX17170 / 2017 IAV (Figure 87A), group II H5N6 A / chicken / Suzhou / j6 / 2019 IAV (Figure 87B), group II H7N7 A / chicken / Netherlands / 621572 / 03 IAV (Figure 87C), and group I H5N8 A / chicken / Russia / 3-29 / 2020 IAV (Figure 87D). [Figure 87D]Figures 87A-87D show the in vitro inhibition (IC50 in μg / ml) of sialidase activity by FNI17-v19 or OSE against NAs of group II H7N3 A / chicken / Jalisco / PAVX17170 / 2017 IAV (Figure 87A), group II H5N6 A / chicken / Suzhou / j6 / 2019 IAV (Figure 87B), group II H7N7 A / chicken / Netherlands / 621572 / 03 IAV (Figure 87C), and group I H5N8 A / chicken / Russia / 3-29 / 2020 IAV (Figure 87D).
[0094] [Figure 88] Figure 88 shows the binding kinetics of FNI3, FNI9, and FNI17 to the NA of N9 measured by biolayer interferometry (BLI). KD was calculated from the ratio of kdis / kon, where kdis is the dissociation calculated as (1 / sec) and kon is the association calculated as (1 / Msec).
[0095] [Figure 89] Figure 89 shows the in vitro inhibition of sialidase activity (in ng / ml) by FNI3, FNI9, FNI17, FNI17-v19, FNI19, and FNI19-v3 against the NA of group II H7N9 A / Anhui / 1 / 2013 IAV.
[0096] [Figure 90] Figure 90 shows antibody activation of FcγRIIIa (V158 allele) after incubation with group II H7N9 A / Anhui / 1 / 2013 IAV. Activation was measured using an NFAT-mediated luciferase reporter in engineered Jurkat cells after incubation with Expi-CHO cells transiently transfected with a plasmid encoding N9 from A / Anhui / 1 / 2013 IAV. FNI3, FNI9, FNI17, and FNI19 were tested, along with a negative control antibody (FY1-GRLR).
[0097] [Figure 91A] Figures 91A-91B show the proportion of OSE resistance mutations within the FNI NA binding site of group I H1N1 IAV (Figure 91A) and group II H3N2 IAV (Figure 91B) from 2007 to 2019. [Figure 91B] Figures 91A-91B show the proportion of OSE resistance mutations within the FNI NA binding site of group I H1N1 IAV (Figure 91A) and group II H3N2 IAV (Figure 91B) from 2007 to 2019.
[0098] [Figure 92A] Figures 92A-92B show the in vitro neutralization activity of FNI17, FNI19, and oseltamivir (OSE) against group I H1N1 IAV strains (Figure 92A) and group II H3N2 IAV strains (Figure 92B), optionally harboring one or more OSE resistance mutations. Figure 92A shows activity against A / Puerto Rico / 8 / 34 ("PR8" in the figures) and A / California / 07 / 2009 ("Cal / 09" in the figures), as well as A / California / 07 / 2009 engineered by reverse genetics to harbor the OSE resistance mutations H275Y, E119D, or both S247N and H275Y. Figure 92B shows activity against A / Hong Kong / 8 / 68 ("HK / 68" in the figure) and A / Hong Kong / 8 / 68 engineered by reverse genetics to carry the OSE resistance mutations I222V or N294S. [Figure 92B]Figures 92A-92B show the in vitro neutralization activity of FNI17, FNI19, and oseltamivir (OSE) against group I H1N1 IAV strains (Figure 92A) and group II H3N2 IAV strains (Figure 92B), optionally harboring one or more OSE resistance mutations. Figure 92A shows activity against A / Puerto Rico / 8 / 34 ("PR8" in the figures) and A / California / 07 / 2009 ("Cal / 09" in the figures), as well as A / California / 07 / 2009 engineered by reverse genetics to harbor the OSE resistance mutations H275Y, E119D, or both S247N and H275Y. Figure 92B shows activity against A / Hong Kong / 8 / 68 ("HK / 68" in the figure) and A / Hong Kong / 8 / 68 engineered by reverse genetics to carry the OSE resistance mutations I222V or N294S.
[0099] [Figure 93] Figure 93 shows the binding of FNI17-v19 to NAs from N1_Vic_2019, N2_HK_2019, B / Phuket / 3073 / 2013 (Yamagata) ("B / Phuket_2013(Yam)" in the figures), B / Malaysia / 2506 / 2004 (Victoria) ("B / Malaysia_2004(Vic)" in the figures), and B / Washington / 02 / 2019 (Victoria) ("B / Wash_2019(Vic)" in the figures) measured by flow cytometry and reported as mean fluorescence intensity (MFI). Cells were mock stained as a negative control.
[0100] [Figure 94A]Figures 94A-94B show virus titers in lung homogenates from BALB / c mice treated with various doses of FNI17 or OSE and infected with H1N1 A / Puerto Rico / 8 / 34 (Figure 94A) or H3N2 A / Hong Kong / 8 / 68 (Figure 94B). Lung tissue was harvested 4 days (Figure 94A) or 3 days (Figure 94B) post-infection. In Figure 94A, titers are reported as log 50% tissue culture infectious doses per gram of tissue (Log TCID50 / g). In Figure 94B, titers are reported as log plaque-forming units per gram of tissue (Log pfu / g). In Figures 94A and 94B, the dot plots, arranged from left to right in the graphs, correspond to the top-to-bottom orientation in the figure legends. For example, vehicle is the left-most cluster of dots in the graphs, and OSE is the right-most cluster of dots in the graphs. [Figure 94B] Figures 94A-94B show virus titers in lung homogenates from BALB / c mice treated with various doses of FNI17 or OSE and infected with H1N1 A / Puerto Rico / 8 / 34 (Figure 94A) or H3N2 A / Hong Kong / 8 / 68 (Figure 94B). Lung tissue was harvested 4 days (Figure 94A) or 3 days (Figure 94B) post-infection. In Figure 94A, titers are reported as log 50% tissue culture infectious doses per gram of tissue (Log TCID50 / g). In Figure 94B, titers are reported as log plaque-forming units per gram of tissue (Log pfu / g). In Figures 94A and 94B, the dot plots, arranged from left to right in the graphs, correspond to the top-to-bottom orientation in the figure legends. For example, vehicle is the left-most cluster of dots in the graphs, and OSE is the right-most cluster of dots in the graphs.
[0101] [Figure 95A]Figures 95A-95B show weight loss (reported as peak negative area under the curve) from day 0 to day 14 post-infection, derived from an area under the curve analysis of weight loss in BALB / c mice treated with the indicated doses of FNI17 or OSE and then infected with H1N1 A / Puerto Rico / 8 / 34 (Figure 95A) or H3N2A / Hong Kong / 8 / 68 (Figure 95B). In Figures 95A and 95B, the dot plots and bars arranged from left to right in the graphs correspond to the top-to-bottom orientation in the figure legends. For example, vehicle is the left-most cluster of dots (and associated bars) in the graphs, and OSE is the right-most cluster of dots (and associated bars) in the graphs. [Figure 95B] Figures 95A-95B show weight loss (reported as peak negative area under the curve) from day 0 to day 14 post-infection, derived from an area under the curve analysis of weight loss in BALB / c mice treated with the indicated doses of FNI17 or OSE and then infected with H1N1 A / Puerto Rico / 8 / 34 (Figure 95A) or H3N2A / Hong Kong / 8 / 68 (Figure 95B). In Figures 95A and 95B, the dot plots and bars arranged from left to right in the graphs correspond to the top-to-bottom orientation in the figure legends. For example, vehicle is the left-most cluster of dots (and associated bars) in the graphs, and OSE is the right-most cluster of dots (and associated bars) in the graphs.
[0102] [Figure 96A] Figures 96A-96B show the negative area under the curve peak values compared to serum IgG from an area under the curve analysis of weight loss in BALB / c mice treated with FNI17 or OSE and then infected with H1N1 A / Puerto Rico / 8 / 34 (Figure 96A) or H3N2 A / Hong Kong / 8 / 68 (Figure 96B). IC50, IC70, and IC90 are reported in μg / ml. [Figure 96B]Figures 96A-96B show the negative area under the curve peak values compared to serum IgG from an area under the curve analysis of weight loss in BALB / c mice treated with FNI17 or OSE and then infected with H1N1 A / Puerto Rico / 8 / 34 (Figure 96A) or H3N2 A / Hong Kong / 8 / 68 (Figure 96B). IC50, IC70, and IC90 are reported in μg / ml.
[0103] [Figure 97A] Figures 97A-97B show blood oxygen saturation (reported as peripheral capillary oxygen saturation (SpO2)) as measured by pulse oximetry in BALB / c mice treated with FNI17 or OSE and then infected with H1N1 A / Puerto Rico / 8 / 34 (Figure 97A) or H3N2A / Hong Kong / 8 / 68 (Figure 97B). In Figures 97A and 97B, each group of five bars (and associated dot plot clusters) arranged from left to right in the graph corresponds to the top-to-bottom orientation in the figure legend. For example, vehicle is the leftmost bar in each set of bars, and OSE is the rightmost bar in each set of bars. [Figure 97B] Figures 97A-97B show blood oxygen saturation (reported as peripheral capillary oxygen saturation (SpO2)) as measured by pulse oximetry in BALB / c mice treated with FNI17 or OSE and then infected with H1N1 A / Puerto Rico / 8 / 34 (Figure 97A) or H3N2A / Hong Kong / 8 / 68 (Figure 97B). In Figures 97A and 97B, each group of five bars (and associated dot plot clusters) arranged from left to right in the graph corresponds to the top-to-bottom orientation in the figure legend. For example, vehicle is the leftmost bar in each set of bars, and OSE is the rightmost bar in each set of bars.
[0104] [Figure 98A]Figures 98A-98B show the correlation between oxygen saturation (at day 8 post-infection) and viral lung titers (at day 4 post-infection) in BALB / c mice treated with FNI17 and then infected with H1N1 A / Puerto Rico / 8 / 34 (Figure 98A) or H3N2 A / Hong Kong / 8 / 68 (Figure 98B). Pearson correlation was calculated to quantify the correlation. [Figure 98B] Figures 98A-98B show the correlation between oxygen saturation (at day 8 post-infection) and viral lung titers (at day 4 post-infection) in BALB / c mice treated with FNI17 and then infected with H1N1 A / Puerto Rico / 8 / 34 (Figure 98A) or H3N2 A / Hong Kong / 8 / 68 (Figure 98B). Pearson correlation was calculated to quantify the correlation.
[0105] [Figure 99A] Figures 99A-99C show the in vivo pharmacokinetics of FNI17-v19 and FNI19-v3 for three individual mice ("1501"-"1503"; "2501"-"2503"). Data for individual mice over 1500 hours are shown for the FNI17-v19 (Figure 99A) and FNI19v3 (Figure 99B) treatment groups and summarized over 64 days in Figure 99C. [Figure 99B] Figures 99A-99C show the in vivo pharmacokinetics of FNI17-v19 and FNI19-v3 for three individual mice ("1501"-"1503"; "2501"-"2503"). Data for individual mice over 1500 hours are shown for the FNI17-v19 (Figure 99A) and FNI19v3 (Figure 99B) treatment groups and summarized over 64 days in Figure 99C. [Figure 99C] Figures 99A-99C show the in vivo pharmacokinetics of FNI17-v19 and FNI19-v3 for three individual mice ("1501"-"1503"; "2501"-"2503"). Data for individual mice over 1500 hours are shown for the FNI17-v19 (Figure 99A) and FNI19v3 (Figure 99B) treatment groups and summarized over 64 days in Figure 99C.
[0106] [Figure 100] Figure 100 summarizes the in vivo pharmacokinetic properties of FNI17-v19 and FNI19-v3 evaluated in mice. FM08_LS is shown as a comparative antibody.
[0107] [Figure 101A] Figures 101A-101B show the lack of off-target binding by FNI17-v19 (Figure 101A) and FNI19-v3 (Figure 101B) as measured using an array of 6,000 human membrane proteins. [Figure 101B] Figures 101A-101B show the lack of off-target binding by FNI17-v19 (Figure 101A) and FNI19-v3 (Figure 101B) as measured using an array of 6,000 human membrane proteins.
[0108] [Figure 102] Figure 102 shows the lack of specific positive staining by FNI17-v19 and FNI19-v3 in human tissues as measured using non-Good Laboratory Practice Tissue Cross Reactivity Testing (non-GLP-TCR). IgG was examined to assess background staining.
[0109] [Figure 103A]Figures 103A-103C show antibody activation of FcγRIIa (H131 allele) by the "GAALIE" Fc variant antibody (containing G236A / A330L / I332E mutations in the Fc). Activation was measured using an NFAT-mediated luciferase reporter in engineered Jurkat cells after incubation with Expi-CHO cells transiently transfected with plasmids encoding the NAs of different IAVs (H1N1 A / California / 07 / 2009 in Figure 103A; H3N2 A / Hong Kong / 8 / 68 in Figure 103B) and IBVs (B / Malaysia / 2506 / 2004 in Figure 103C). In addition to FNI3, FNI9, FNI17, and FNI19, antibodies FNI3, FNI9, FNI17, and FNI19 with the GAALIE mutation (denoted by the suffix "-GAALIE" in the figures) were tested. The comparative antibody "FM08_LS" and the negative control antibody (FY1-GRLR) were also tested. FM08_LS and FY1-GRLR had the lowest measured values in Figures 103A-103C. [Figure 103B] Figures 103A-103C show antibody activation of FcγRIIa (H131 allele) by the "GAALIE" Fc variant antibody (containing G236A / A330L / I332E mutations in the Fc). Activation was measured using an NFAT-mediated luciferase reporter in engineered Jurkat cells after incubation with Expi-CHO cells transiently transfected with plasmids encoding the NAs of different IAVs (H1N1 A / California / 07 / 2009 in Figure 103A; H3N2 A / Hong Kong / 8 / 68 in Figure 103B) and IBVs (B / Malaysia / 2506 / 2004 in Figure 103C). In addition to FNI3, FNI9, FNI17, and FNI19, antibodies FNI3, FNI9, FNI17, and FNI19 with the GAALIE mutation (denoted by the suffix "-GAALIE" in the figures) were tested. The comparative antibody "FM08_LS" and the negative control antibody (FY1-GRLR) were also tested. FM08_LS and FY1-GRLR had the lowest measured values in Figures 103A-103C. [Figure 103C]Figures 103A-103C show antibody activation of FcγRIIa (H131 allele) by the "GAALIE" Fc variant antibody (containing G236A / A330L / I332E mutations in the Fc). Activation was measured using an NFAT-mediated luciferase reporter in engineered Jurkat cells after incubation with Expi-CHO cells transiently transfected with plasmids encoding the NAs of different IAVs (H1N1 A / California / 07 / 2009 in Figure 103A; H3N2 A / Hong Kong / 8 / 68 in Figure 103B) and IBVs (B / Malaysia / 2506 / 2004 in Figure 103C). In addition to FNI3, FNI9, FNI17, and FNI19, antibodies FNI3, FNI9, FNI17, and FNI19 with the GAALIE mutation (denoted by the suffix "-GAALIE" in the figures) were tested. The comparative antibody "FM08_LS" and the negative control antibody (FY1-GRLR) were also tested. FM08_LS and FY1-GRLR had the lowest measured values in Figures 103A-103C.
[0110] [Figure 104] Figure 104 shows the in vitro inhibition of NA sialidase activity of group I (H1N1) IAV, group II (H3N2) IAV, Victoria lineage IBV, and Yamagata lineage IBV by FNI17-v19 as measured by ViroSpot microneutralization assay. [Figure 104-1] Figure 104 shows the in vitro inhibition of NA sialidase activity of group I (H1N1) IAV, group II (H3N2) IAV, Victoria lineage IBV, and Yamagata lineage IBV by FNI17-v19 as measured by ViroSpot microneutralization assay.
[0111] [Figure 105]Figure 105 shows the in vitro inhibition of sialidase activity of NA of group I (H1N1) IAV, group II (H3N2) IAV, Victoria lineage IBV, and Yamagata lineage IBV by FNI17-v19 as measured by ViroSpot microneutralization assay. B / Brisbane / 2008 is highlighted by a rectangle. [Figure 105-1] Figure 105 shows the in vitro inhibition of sialidase activity of NA of group I (H1N1) IAV, group II (H3N2) IAV, Victoria lineage IBV, and Yamagata lineage IBV by FNI17-v19 as measured by ViroSpot microneutralization assay. B / Brisbane / 2008 is highlighted by a rectangle.
[0112] [Figure 106A] Figures 106A-106B show virus titers in lung homogenates from BALB / c mice treated with various doses of FNI17 or OSE and infected with H3N2 A / Hong Kong / 8 / 68 (Figure 106A) or H1N1 A / Puerto Rico / 8 / 34 (Figure 106B). Lung tissue was harvested 3 days (Figure 106A) or 4 days (Figure 106B) post-infection. In Figure 106A, titers are reported as log plaque-forming units per gram of tissue (Log pfu / g). In Figure 106B, titers are reported as log 50% tissue culture infectious doses per gram of tissue (Log TCID50 / g). The dose of FNI17 (mg / kg) that was able to reduce virus in the lungs similar to OSE is highlighted by an oval. In Figures 106A and 106B, the dot plots arranged left to right in the graphs correspond to the top to bottom orientation in the figure legends, e.g., vehicle is the leftmost cluster of dots in the graphs, and OSE is the rightmost cluster of dots in the graphs. [Figure 106B]Figures 106A-106B show virus titers in lung homogenates from BALB / c mice treated with various doses of FNI17 or OSE and infected with H3N2 A / Hong Kong / 8 / 68 (Figure 106A) or H1N1 A / Puerto Rico / 8 / 34 (Figure 106B). Lung tissue was harvested 3 days (Figure 106A) or 4 days (Figure 106B) post-infection. In Figure 106A, titers are reported as log plaque-forming units per gram of tissue (Log pfu / g). In Figure 106B, titers are reported as log 50% tissue culture infectious doses per gram of tissue (Log TCID50 / g). The dose of FNI17 (mg / kg) that was able to reduce virus in the lungs similar to OSE is highlighted by an oval. In Figures 106A and 106B, the dot plots arranged left to right in the graphs correspond to the top to bottom orientation in the figure legends, e.g., vehicle is the leftmost cluster of dots in the graphs, and OSE is the rightmost cluster of dots in the graphs.
[0113] [Figure 107] Figure 107 shows the "% protection" compared to IgG in the serum of BALB / c mice infected with influenza and treated with FNI17 or OSE. IC50, IC70, and IC90 are reported in μg / ml.
[0114] [Figure 108] Figure 108 shows weight loss (reported as peak negative area under the curve) from day 0 to day 14 after infection in mice pretreated with FNI17 or FM08_LS and then infected with H1N1 A / Puerto Rico / 8 / 3. Weight loss was also measured in mice pretreated with vehicle control. At the 1 mg / kg dose (left-most set of three bars), the order of the bars from left to right corresponds to the top-to-bottom orientation in the figure legend (i.e., vehicle is the left-most bar in the 1 mg / kg compartment; FM08_LS is the right-most bar). At other doses, the left bar represents FNI17 and the right bar represents FM08_LS.
[0115] [Figure 109] Figure 109 shows survival over 13 days in BALB / c mice treated with FNI17 or FM08_LS and then infected with H1N1 A / Puerto Rico / 8 / 34. Survival in mice pre-treated with vehicle control (shortest survival curve) was also measured.
[0116] [Figure 110] Figure 110 shows the antibody titers of several mAbs for FNI3, FNI9, FNI17, or FNI19, including gain / loss compared to wild type for the variants.
[0117] [Figure 111] Figure 111 shows the binding of FNI3 and 11 FNI3 variants (FNI3-v8 to FNI3-v18) to the NA of group I IAV, group II IAV, and IBV as measured by flow cytometry (reported as MFI). MFI values for the variants were normalized to the MFI value for wild-type FNI3. [Figure 111-1] Figure 111 shows the binding of FNI3 and 11 FNI3 variants (FNI3-v8 to FNI3-v18) to the NA of group I IAV, group II IAV, and IBV as measured by flow cytometry (reported as MFI). MFI values for the variants were normalized to the MFI value for wild-type FNI3.
[0118] [Figure 112] Figure 112 shows the binding of FNI9 and five FNI9 variants (FNI9-v5 through FNI9-v9) to the NA of group I IAV, group II IAV, and IBV as measured by flow cytometry (reported as MFI). MFI values for the variants were normalized to the MFI value for wild-type FNI9.
[0119] [Figure 113]Figure 113 shows the binding of FNI17 and 11 FNI17 variants (FNI17-v6 through FNI17-v16) to the NA of group I IAV, group II IAV, and IBV as measured by flow cytometry (reported as MFI). MFI values for the variants were normalized to the MFI value for wild-type FNI7. [Figure 113-1] Figure 113 shows the binding of FNI17 and 11 FNI17 variants (FNI17-v6 through FNI17-v16) to the NA of group I IAV, group II IAV, and IBV as measured by flow cytometry (reported as MFI). MFI values for the variants were normalized to the MFI value for wild-type FNI7.
[0120] [Figure 114] Figure 114 shows the binding of FNI19 and five FNI19 variants (FNI19-v1 through FNI19-v5) to the NA of group I IAV, group II IAV, and IBV as measured by flow cytometry (reported as MFI). MFI values for the variants were normalized to the MFI value for wild-type FNI9.
[0121] [Figure 115A] Figures 115A-115D show the binding kinetics of FNI3-LS, FNI9-LS, FNI17-LS, and FNI19-LS to different FcγRs, as well as the binding kinetics of antibodies FNI3-LS, FNI9-LS, FNI17-LS, and FNI19-LS with the GAALIE mutation (suffixed "-GAALIE" in the figures), measured by biolayer interferometry (BLI). Arrows indicate the curves for FNI17-LS and FNI17-LS-GAALIE. Figure 115A shows binding to FcγRIIA(H), Figure 115B shows binding to FcγRIIA(R), Figure 115C shows binding to FcγRIIIA(F), and Figure 115D shows binding to FcγRIIIA(v). [Figure 115B]Figures 115A-115D show the binding kinetics of FNI3-LS, FNI9-LS, FNI17-LS, and FNI19-LS to different FcγRs, as well as the binding kinetics of antibodies FNI3-LS, FNI9-LS, FNI17-LS, and FNI19-LS with the GAALIE mutation (suffixed "-GAALIE" in the figures), measured by biolayer interferometry (BLI). Arrows indicate the curves for FNI17-LS and FNI17-LS-GAALIE. Figure 115A shows binding to FcγRIIA(H), Figure 115B shows binding to FcγRIIA(R), Figure 115C shows binding to FcγRIIIA(F), and Figure 115D shows binding to FcγRIIIA(v). [Figure 115C] Figures 115A-115D show the binding kinetics of FNI3-LS, FNI9-LS, FNI17-LS, and FNI19-LS to different FcγRs, as well as the binding kinetics of antibodies FNI3-LS, FNI9-LS, FNI17-LS, and FNI19-LS with the GAALIE mutation (suffixed "-GAALIE" in the figures), measured by biolayer interferometry (BLI). Arrows indicate the curves for FNI17-LS and FNI17-LS-GAALIE. Figure 115A shows binding to FcγRIIA(H), Figure 115B shows binding to FcγRIIA(R), Figure 115C shows binding to FcγRIIIA(F), and Figure 115D shows binding to FcγRIIIA(v). [Figure 115D] Figures 115A-115D show the binding kinetics of FNI3-LS, FNI9-LS, FNI17-LS, and FNI19-LS to different FcγRs, as well as the binding kinetics of antibodies FNI3-LS, FNI9-LS, FNI17-LS, and FNI19-LS with the GAALIE mutation (suffixed "-GAALIE" in the figures), measured by biolayer interferometry (BLI). Arrows indicate the curves for FNI17-LS and FNI17-LS-GAALIE. Figure 115A shows binding to FcγRIIA(H), Figure 115B shows binding to FcγRIIA(R), Figure 115C shows binding to FcγRIIIA(F), and Figure 115D shows binding to FcγRIIIA(v). DETAILED DESCRIPTION OF THE INVENTION
[0122] Provided herein are antibodies and antigen-binding fragments that are capable of binding to various influenza viruses (e.g., influenza A virus (IAV) and influenza B virus (IBV)) and potently neutralizing infection by those influenza viruses. Polynucleotides, vectors, host cells, and related compositions encoding the antibodies and antigen-binding fragments are also provided, as are methods of using the antibodies, nucleic acids, vectors, host cells, and related compositions to treat (e.g., reduce, delay, eliminate, or prevent) influenza virus infection in a subject and / or to manufacture a medicament for treating influenza infection in a subject.
[0123] As taught in the Examples herein, a number of clonally related antibodies have been identified that bind to a wide range of IAV and IBV NAs and have neutralizing / inhibitory function against IAV and IBV viruses. Sequence variants of these antibodies have been generated and characterized. Certain disclosed embodiments relate to such antibodies, antigen-binding fragments thereof, and related compositions and uses.
[0124] Before setting forth this disclosure in more detail, it will be helpful to provide definitions of some terms used herein to aid in its understanding. Additional definitions are set forth throughout this disclosure.
[0125] As used herein, any concentration range, percentage range, ratio range, or integer range is understood to include any integer value within the stated range, and fractions thereof, where appropriate (such as 1 / 10 and 1 / 100 of an integer), unless otherwise indicated. Additionally, any numerical ranges described herein with respect to any physical characteristic (such as polymer subunits, size, or thickness) are understood to include any integer within the stated range, unless otherwise indicated. As used herein, the term "about" means ±20% of the stated range, value, or structure, unless otherwise indicated. The terms "a" and "an" are understood herein to mean "one or more" of the listed components. The use of alternatives (e.g., "or") is understood to mean either one, both, or any combination of the alternatives. As used herein, the terms "include," "having," and "comprise" are used synonymously, and it is intended that these terms and variants thereof be interpreted as non-limiting.
[0126] "Optional" or "optionally" means that the element, component, event, or circumstance described thereafter may or may not occur, and the term includes instances where the element, component, event, or circumstance occurs or does not occur.
[0127] Additionally, each individual construct, or group of constructs derived from various combinations of the structures and subunits described herein, should be understood to be disclosed herein to the same extent as if each construct, or group of constructs, were set forth individually, and thus selection of a particular structure or particular subunit is within the scope of this disclosure.
[0128] The phrase "consisting essentially of" is not equivalent to "comprising" and means materials or steps specified in a claim or materials or steps that do not materially affect the essential characteristics of the claimed subject matter. For example, a domain, region, or module (e.g., a binding domain) of a protein or protein "consists primarily of" a particular amino acid sequence if the amino acid sequence of the domain, region, module, or protein contains extensions, deletions, mutations, or combinations thereof (e.g., amino acids located at the amino or carboxy terminus or between domains) that, in combination, contribute to at most 20% (e.g., at most 15%, 10%, 8%, 6%, 5%, 4%, 3%, 2%, or 1%) of the length of the domain, region, module, or protein, but do not substantially affect (i.e., reduce) the activity of the domain, region, module, or protein (e.g., target binding affinity of a binding protein) by more than 50%, e.g., by no more than 40%, 30%, 25%, 20%, 15%, 10%, 5%, or 1%).
[0129] As used herein, "amino acid" refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function in a manner similar to naturally occurring amino acids. Naturally occurring amino acids are those encoded by the genetic code, as well as those amino acids that are later modified (e.g., hydroxypurine, γ-carboxyglutamate, and O-phosphoserine). Amino acid analogs refer to compounds that have the same basic chemical structure as a naturally occurring amino acid (i.e., an α-carbon attached to a hydrogen, a carboxyl group, an amino group, and an R group), such as homoserine, norleucine, methionine sulfoxide, and methionine methylsulfonium. Such analogs have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as a naturally occurring amino acid. Amino acid mimetics refer to compounds that have a structure that is different from the general chemical structure of an amino acid, but that function in a manner similar to a naturally occurring amino acid.
[0130] As used herein, "mutation" means that the sequence of a nucleic acid molecule or polypeptide molecule is altered compared to a reference or wild-type nucleic acid molecule or polypeptide molecule, respectively. A mutation can result in several different types of changes in the sequence, including nucleotide or amino acid substitutions, insertions, or deletions.
[0131] "Conservative substitution" refers to an amino acid substitution that does not significantly affect or change the binding characteristics of a particular protein. Generally, a conservative substitution is one in which the substituted amino acid residue is replaced with an amino acid residue having a similar side chain. Conservative substitutions include those found in one of the following groups: Group 1: alanine (Ala or A), glycine (Gly or G), serine (Ser or S), threonine (Thr or T); Group 2: aspartic acid (Asp or D), glutamic acid (Glu or Z); Group 3: asparagine (Asn or N), glutamine (Gln or Q); Group 4: arginine (Arg or R), lysine (Lys or K), histidine (His or H); Group 5: isoleucine (Ile or I), leucine (Leu or L), methionine (Met or M), valine (Val or V); and Group 6: phenylalanine (Phe or F), tyrosine (Tyr or Y), tryptophan (Trp or W). Additionally or alternatively, amino acids can be grouped into multiple conservative substitution groups by similarity in function, chemical structure, or composition (e.g., acidic, basic, aliphatic, aromatic, or sulfur-containing). For example, aliphatic groups may include, for substitution purposes, Gly, Ala, Val, Leu, and Ile. Other conservative substitution groups include sulfur-containing: Met and cysteine (Cys or C); acidic: Asp, Glu, Asn, and Gln; small aliphatic nonpolar or slightly polar residues: Ala, Ser, Thr, Pro, and Gly; polar negatively charged residues: Asp, Asn, Glu, and Gln; polar positively charged residues: His, Arg, and Lys; large aliphatic nonpolar residues: Met, Leu, Ile, Val, and Cys; and large aromatic residues: Phe, Tyr, and Trp. Additional information can be found in Creighton (1984) Proteins, WH Freeman and Company.
[0132] As used herein, "protein" or "polypeptide" refers to a polymer of amino acid residues. Protein refers to naturally occurring amino acid polymers, as well as amino acid polymers in which one or more amino acid residues are artificial chemical mimetics of corresponding naturally occurring amino acids, and to unnatural amino acid polymers. Variants of the proteins, peptides, and polypeptides of the present disclosure are also contemplated. In certain embodiments, variant proteins, peptides, and polypeptides comprise or consist of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 99.9% identical to the amino acid sequence of a defined or reference amino acid sequence described herein.
[0133] "Nucleic acid molecule" or "polynucleotide" or "polynucleic acid" refers to a polymeric compound containing covalently linked nucleotides, which may be composed of natural subunits (e.g., purine or pyrimidine bases) or non-natural subunits (e.g., morpholine rings). Purine bases include adenine, guanine, hypoxanthine, and xanthine, while pyrimidine bases include uracil, thymine, and cytosine. Nucleic acid molecules include polyribonucleic acid (RNA) (including mRNA, microRNA, siRNA, viral genomic RNA, and synthetic RNA) and polydeoxyribonucleic acid (DNA) (including cDNA, genomic DNA, and synthetic DNA), both of which can be single-stranded or double-stranded. If single-stranded, a nucleic acid molecule can be the coding strand or the non-coding (antisense) strand. A nucleic acid molecule encoding a given amino acid sequence includes all nucleotide sequences that encode the same amino acid sequence. Some versions of a nucleotide sequence may also contain introns, which may be removed through co-transcriptional or post-transcriptional mechanisms. In other words, different nucleotide sequences may encode the same amino acid sequence as a result of redundancy or degeneracy in the genetic code, or due to splicing.
[0134] In some embodiments, the polynucleotide comprises a modified nucleoside, a Cap-1 structure, a Cap-2 structure, or any combination thereof. In certain embodiments, the polynucleotide comprises pseudouridine, N6-methyladenosine, 5-methylcytidine, 2-thiouridine, or any combination thereof. In some embodiments, the pseudouridine comprises N1-methylpseudouridine. These features are known in the art and have been described, for example, in Zhang et al. Front. Immunol., DOI=10.3389 / fimmu.2019.00594(2019); Eyler et al. PNAS 116(46): 23068-23071; DOI: 10.1073 / pnas.1821754116(2019); Nance and Meier, ACS Cent. Sci. 2021, 7, 5, 748-756; doi.org / 10.1021 / acscentsci.1c00197(2021), and van Hoecke and Roose, J. Translational Med 17:54(2019); https: / / doi.org / 10.1186 / s12967-019-1804-8 (the modified nucleosides and mRNA features therein are incorporated herein by reference). Variants of the nucleic acid molecules of the present disclosure are also contemplated. Variant nucleic acid molecules are at least 70%, 75%, 80%, 85%, 90%, and preferably 95%, 96%, 97%, 98%, 99%, or 99.9% identical to or hybridize to a polynucleotide under stringent hybridization conditions of 0.015 M sodium chloride, 0.0015 M sodium citrate at about 65-68°C, or 0.015 M sodium chloride, 0.0015 M sodium citrate, and 50% formamide at about 42°C. Nucleic acid molecule variants retain the ability to encode their binding domains that have the functions (e.g., binding to a target molecule) described herein.
[0135] "Percent sequence identity" refers to the relationship between two or more sequences as determined by comparing the sequences. Preferred methods for determining sequence identity are designed to obtain the best match between the sequences being compared. For example, sequences are aligned for optimal comparison (e.g., gaps can be introduced in one or both of the first and second amino acid or nucleic acid sequences for optimal alignment). Furthermore, non-homologous sequences can be disregarded for comparison purposes. Percent sequence identity referred to herein is calculated over the length of the reference sequence, unless otherwise indicated. Methods for determining sequence identity and similarity can be found in publicly available computer programs. Sequence alignment and percent identity calculations can be performed using BLAST programs (e.g., BLAST 2.0, BLASTP, BLASTN, or BLASTX). The mathematical algorithm used in BLAST programs can be found in Altschul et al., Nucleic Acids Res. 25:3389-3402, 1997. In the context of the present disclosure, when sequence analysis software is used for an analysis, it will be understood that the results of the analysis will be based on the "default values" of the referenced program, which refers to any set of values or parameters that originally load into the software when it is first initialized.
[0136] The term "isolated" means that a material is removed from its original environment (e.g., the natural environment if the material is naturally occurring). For example, a naturally occurring nucleic acid or polypeptide present in a living animal is not isolated, but the same nucleic acid or polypeptide separated from some or all of the coexisting materials in the natural system is isolated. Such a nucleic acid can be part of a vector, and / or such a nucleic acid or polypeptide can be part of a composition (e.g., a cell lysate), and such a vector or composition is still isolated in the sense that it is not part of the natural environment for the nucleic acid or polypeptide. "Isolated" also describes, in some embodiments, an antibody, antigen-binding fragment, polynucleotide, vector, host cell, or composition that is outside the human body.
[0137] The term "gene" refers to a segment of DNA or RNA involved in producing a polypeptide chain; in some contexts, it includes the regions preceding and following the coding segment (e.g., the 5' untranslated region (UTR) and the 3' UTR), as well as intervening sequences (introns) between individual coding segments (exons).
[0138] "Functional variant" means a polypeptide or polynucleotide that is similar or substantially similar in structure to a parent or reference compound of the present disclosure, but differs in composition slightly (e.g., a single base, atom, or functional group is different, added, or removed), such that the polypeptide, or the encoded polypeptide, is capable of performing at least one function of the parent polypeptide with at least 50% efficiency, preferably at least 55%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% of the activity of the parent polypeptide. In other words, a polypeptide of the present disclosure or a functional variant of the encoded polypeptide has "similar binding," "similar affinity," or "similar activity" in a selected assay (e.g., an assay for measuring binding affinity, e.g., an association constant (Ka) or dissociation constant (K DA functional variant is one that exhibits no more than a 50% decrease in performance compared to the parent or reference polypeptide in a method such as Biacore® or tetramer staining, which measures the activity of the functional variant.
[0139] As used herein, a "functional portion" or "functional fragment" refers to a polypeptide or polynucleotide that comprises only a domain, portion, or fragment of a parent or reference compound, where the polypeptide or encoded polypeptide retains at least 50% of the activity associated with that domain, portion, or fragment of the parent or reference compound, preferably at least 55%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% of the activity of the parent polypeptide, or provides a biological benefit (e.g., effector function). A "functional portion" or "functional fragment" of a polypeptide or encoded polypeptide of the present disclosure has "similar binding" or "similar activity" if it exhibits no more than a 50% decrease in performance in a selected assay compared to the parent or reference polypeptide (preferably no more than a 20% or 10% decrease in affinity compared to the parent or reference, or no more than an order of magnitude difference).
[0140] As used herein, the terms "engineered," "recombinant," or "non-naturally occurring" refer to an organism, microorganism, cell, nucleic acid molecule, or vector that contains at least one genetic change or that has been modified by the introduction of a foreign or heterologous nucleic acid molecule, where such change or modification is introduced by genetic manipulation (i.e., human intervention). Genetic changes include, for example, modifications that introduce expressible nucleic acid molecules that encode functional RNA, proteins, fusion proteins, or enzymes, or the addition, deletion, substitution, or other functional disruption of other nucleic acid molecules in the genetic material of a cell. Additional modifications include, for example, non-coding regulatory regions in which the modification alters expression of a polynucleotide, gene, or operon.
[0141] As used herein, "heterologous" or "non-endogenous" or "exogenous" refers to any gene, protein, compound, nucleic acid molecule, or activity that is not native to a host cell or subject, or any gene, protein, compound, nucleic acid molecule, or activity that is native to a host cell or subject that has been altered. Included in heterologous, non-endogenous, or exogenous is a gene, protein, compound, or nucleic acid molecule that has been mutated or otherwise altered such that one or both of its structure and activity differ between its native state and the altered gene, protein, compound, or nucleic acid molecule. In certain embodiments, a heterologous, non-endogenous, or exogenous gene, protein, or nucleic acid molecule (e.g., a receptor, ligand, etc.) may not be endogenous to a host cell or subject; instead, a nucleic acid encoding such a gene, protein, or nucleic acid molecule can be added to a host cell by conjugation, transformation, transfection, electroporation, etc., and the added nucleic acid molecule can be integrated into the genome of the host cell or can exist as extrachromosomal genetic material (e.g., a plasmid or other self-replicating vector, etc.). The terms "homologous" or "homolog" refer to a gene, protein, compound, nucleic acid molecule, or activity found in or derived from a host cell, species, or strain. For example, a heterologous or foreign polynucleotide or gene encoding a polypeptide may be homologous to a naturally occurring polynucleotide or gene and may encode a homologous polypeptide or activity, but the polynucleotide or polypeptide may be altered in structure, sequence, expression level, or any combination thereof. The non-endogenous polynucleotide or gene, as well as the encoded polypeptide or activity, may be derived from the same species, a different species, or a combination thereof.
[0142] In certain embodiments, a nucleic acid molecule or portion thereof native to a host cell is considered heterologous to the host cell if it is altered or mutated; a nucleic acid molecule native to a host cell can be considered heterologous if it has been altered with heterologous expression control sequences or if it has been altered with endogenous expression control sequences not normally associated with the nucleic acid molecule native to the host cell. In addition, the term "heterologous" can refer to a different, altered, or biological activity not endogenous to the host cell. As described herein, two or more heterologous nucleic acid molecules can be introduced into a host cell as separate nucleic acid molecules, as multiple, individually regulated genes, as a polycistronic nucleic acid molecule, as a single nucleic acid molecule encoding a fusion protein, or any combination thereof.
[0143] As used herein, the term "endogenous" or "native" refers to a polynucleotide, gene, protein, compound, molecule, or activity that is normally present in a host cell or subject.
[0144] The term "expression," as used herein, refers to the process by which a polypeptide is produced based on a coding sequence of a nucleic acid molecule (such as a gene). This process can include transcription, post-transcriptional control, post-transcriptional modification, translation, post-translational control, post-translational modification, or any combination thereof. An expressed nucleic acid molecule is typically operably linked to an expression control sequence (e.g., a promoter).
[0145] The phrase "operably linked" refers to the association of two or more nucleic acid molecules on a single nucleic acid fragment so that the function of one is affected by the other. For example, a promoter is operably linked to a coding sequence when it is capable of affecting the expression of that coding sequence (i.e., the coding sequence is under the transcriptional control of the promoter). "Unlinked" means that the associated genetic elements are not closely related to each other so that the function of one does not affect the function of the other.
[0146] As used herein, two or more heterologous nucleic acid molecules can be introduced into a host cell as separate nucleic acid molecules, as multiple individually regulated genes, as a polycistronic nucleic acid molecule, as a single nucleic acid molecule encoding a protein (e.g., the heavy chain of an antibody), or any combination thereof. It is understood that when two or more heterologous nucleic acid molecules are introduced into a host cell, the two or more heterologous nucleic acid molecules can be introduced as a single nucleic acid molecule (e.g., on a single vector), introduced on separate vectors, integrated into a host chromosome at a single site or multiple sites, or any combination thereof. The number of heterologous nucleic acid molecules or protein activities referred to refers to the number of encoding nucleic acid molecules or protein activities, not the number of separate nucleic acid molecules introduced into the host cell.
[0147] The term "construct" refers to any polynucleotide containing a recombinant nucleic acid molecule (or, when the context clearly indicates, a fusion protein of the present disclosure). A (polynucleotide) construct can be present in a vector (e.g., a bacterial vector, a viral vector) or can be integrated into a genome. A "vector" is a nucleic acid molecule capable of transporting another nucleic acid molecule. A vector can be, for example, a plasmid, cosmid, virus, RNA vector, or linear or circular DNA or RNA molecule, which can contain chromosomal, non-chromosomal, semisynthetic, or synthetic nucleic acid molecules. Vectors of the present disclosure also include transposon-based vectors (e.g., Sleeping Beauty; see, e.g., Geurts et al., Mol. Ther. 8:108, 2003; Mates et al., Nat. Genet. 41:753, 2009). Exemplary vectors are those capable of autonomous replication (episomal vectors), those capable of delivering polynucleotides into a cellular genome (e.g., viral vectors), or those capable of expressing linked nucleic acid molecules (expression vectors).
[0148] As used herein, "expression vector" or "vector" refers to a DNA construct containing a nucleic acid molecule operably linked to suitable control sequences capable of effecting expression of the nucleic acid molecule in a suitable host. Included in such control sequences are a promoter to effect transcription, an optional operator sequence to control such transcription, a sequence encoding suitable mRNA ribosomal binding sites, and sequences that control the termination of transcription and translation. A vector can be a plasmid, a phage particle, a virus, or simply a potential genomic insert. Once introduced into a suitable host for transformation, a vector can replicate and function independently of the host genome; in some cases, it can integrate into the genome itself or deliver a polynucleotide contained in the vector into the genome free of vector sequences. As used herein, the terms "plasmid," "expression plasmid," "virus," and "vector" are often used interchangeably.
[0149] The term "introduced" in the context of inserting a nucleic acid molecule into a cell means "transfection," "transformation," or "transduction," and includes reference to the incorporation of a nucleic acid molecule into a eukaryotic or prokaryotic cell, where the nucleic acid molecule may be integrated into the cell's genome (e.g., chromosome, plasmid, plastid, or mitochondrial DNA), converted into an autonomous replicon, or transiently expressed (e.g., transfected mRNA).
[0150] In certain embodiments, the polynucleotides of the present disclosure can be operably linked to certain elements of a vector. For example, polynucleotide sequences necessary for the expression and processing of the linked coding sequence can be operably linked. Expression control sequences can include appropriate transcription initiation, termination, promoter, and enhancer sequences; signals for efficient RNA processing (such as splicing and polyadenylation signals); sequences that stabilize cytoplasmic mRNA; sequences that enhance translation efficiency (i.e., Kozak consensus sequences); sequences that enhance protein stability; and possibly sequences that enhance protein secretion. Expression control sequences can be operably linked when they are contiguous with a gene of interest and expression control sequences that act in trans or at a distance to regulate the gene of interest.
[0151] In some embodiments, the vector includes a plasmid vector or a viral vector (e.g., a lentiviral vector or a gamma-retroviral vector). Viral vectors include retroviruses, adenoviruses, parvoviruses (e.g., adeno-associated viruses), coronaviruses, negative-strand RNA viruses (e.g., orthomyxoviruses (e.g., influenza viruses), rhabdoviruses (e.g., rabies and vesicular stomatitis viruses), and paramyxoviruses (e.g., measles and Sendai viruses)), positive-strand RNA viruses (e.g., picornaviruses and alphaviruses), and double-stranded DNA viruses (e.g., adenoviruses, herpesviruses (e.g., herpes simplex virus types 1 and 2, Epstein-Barr virus, and cytomegalovirus), and poxviruses (e.g., cowpox, fowlpox, and canarypox). Other viruses include, for example, Norwalk virus, togaviruses, flaviviruses, reoviruses, papovaviruses, hepadnaviruses, and hepatitis viruses. Examples of retroviruses include avian leukosis-sarcoma viruses, mammalian type C, type B, and type D viruses, the HTLV-BLV group, lentiviruses, and spumaviruses (Coffin, JM, Retroviridae: The viruses and their replication, in Fundamental Virology, Third Edition, BN Fields et al., Eds., Lippincott-Raven Publishers, Philadelphia, 1996).
[0152] A "retrovirus" is a virus with an RNA genome that is reverse transcribed into DNA using reverse transcriptase, and the reverse-transcribed DNA is then integrated into the genome of the host cell. "Gammaretrovirus" refers to a genus in the Retroviridae family. Examples of gammaretroviruses include murine stem cell virus, murine leukemia virus, feline leukemia virus, feline sarcoma virus, and avian reticuloendotheliosis virus.
[0153] "Lentiviral vectors" include HIV-based lentiviral vectors for gene delivery, which can be integrating or non-integrating, have relatively large packaging capacities, and are capable of transforming a range of different cell types. Lentiviral vectors are typically generated after transient transfection of three or more plasmids (packaging, envelope, and transfer) into producer cells. Like HIV, lentiviral vectors enter target cells through the interaction of viral surface glycoproteins with cell surface receptors. Once inside, viral RNA undergoes reverse transcription mediated by the viral reverse transcriptase complex. The product of reverse transcription is double-stranded linear viral DNA, which is the substrate for viral integration into the DNA of infected cells.
[0154] In certain embodiments, the viral vector can be a vector derived from a gammaretrovirus, such as Moloney murine leukemia (MLV). In other embodiments, the viral vector can be a vector derived from a more complex retrovirus, such as a lentivirus. HIV-1-derived vectors fall into this category. Other examples include lentiviral vectors derived from HIV-2, FIV, equine infectious anemia, SIV, and Maedi-Visna virus (ovine lentivirus). Methods for packaging mammalian host cells with retroviral and lentiviral vectors for transduction of the cells with transgene-containing viral particles are known in the art and have been previously described (e.g., U.S. Pat. No. 8,119,772; Walchli et al., PLoS One 6:327930, 2011; Zhao et al., J. Immunol. 174:4415, 2005; Engels et al., Hum. Gene Ther. 14:1155, 2003; Frecha et al., Mol. Ther. 18:1748, 2010; and Verhoeyen et al., Methods Mol. Biol. 506:97, 2009). Retroviral and lentiviral vector constructs and expression systems are also commercially available. Other viral vectors can also be used to deliver polynucleotides, including DNA viral vectors (e.g., adenovirus-based vectors and adeno-associated virus (AAV)-based vectors); herpes simplex virus (HSV)-derived vectors, including amplicon vectors, replication-deficient HSV, and attenuated HSV (Krisky et al., Gene Ther. 5:1517, 1998).
[0155] Other vectors that can be used in the compositions and methods of the present disclosure include vectors derived from baculoviruses and alpha-viruses (Jolly, D J. 1999. Emerging Viral Vectors. pp 209-40 in Friedmann T. ed. The Development of Human Gene Therapy. New York: Cold Spring Harbor Lab), or plasmid vectors (such as Sleeping Beauty or other transposon vectors).
[0156] When the genome of a viral vector contains multiple polynucleotides to be expressed in a host cell as separate transcripts, the viral vector can also contain additional sequences between the two (or more) transcripts that allow for bicistronic or polycistronic expression. Examples of such sequences used in viral vectors include an internal ribosome entry site (IRES), a furin cleavage site, a viral 2A peptide, or any combination thereof.
[0157] Plasmid vectors for direct administration to a subject, including plasmid vectors encoding DNA-based antibodies or antigen-binding fragments, are further described herein.
[0158] As used herein, the term "host" refers to a cell or microorganism that is the target of genetic modification with a heterologous nucleic acid molecule to produce a polypeptide of interest (e.g., an antibody of the present disclosure).
[0159] A host cell can be any individual cell or cell culture capable of accepting a vector or nucleic acid integration or expressing a protein. The term also encompasses the progeny of the host cell, whether of the same or different genotype or phenotype. Suitable host cells can vary depending on the vector and can include mammalian cells, animal cells, human cells, simian cells, insect cells, yeast cells, and bacterial cells. These cells can be induced to integrate vectors or other materials using viral vectors, transformation by calcium phosphate precipitation, DEAE-dextran, electroporation, microinjection, or other methods. See, e.g., Sambrook et al., Molecular Cloning: A Laboratory Manual, 2d ed. (Cold Spring Harbor Laboratory, 1989).
[0160] In the context of influenza infection, "host" means a cell or subject infected with influenza.
[0161] "Antigen" or "Ag," as used herein, refers to an immunogenic molecule that elicits an immune response. This immune response may include antibody production, activation of specific immunocompetent cells, complement activation, antibody-dependent cellular cytotoxicity, or any combination thereof. Antigens (immunogenic molecules) can be, for example, peptides, glycopeptides, polypeptides, glycopolypeptides, polynucleotides, polysaccharides, lipids, and the like. It is understood that antigens can be synthetic, recombinantly produced, or derived from biological samples. Exemplary biological samples that can contain one or more antigens include tissue samples, stool samples, cells, body fluids, or combinations thereof. Antigens can be produced by cells modified or genetically engineered to express the antigen. Antigens can also be present in influenza NA antigens (such as those present in virions) or expressed or present on the surface of influenza-infected cells.
[0162] The term "epitope" or "antigenic epitope" includes any molecule, structure, amino acid sequence, or protein determinant that is recognized by and specifically bound by a cognate binding molecule (such as an immunoglobulin or other binding molecule, domain, or protein). Epitopic determinants generally contain chemically active surface groupings of molecules (such as amino acids or sugar side chains) and can have specific three-dimensional structural characteristics, as well as specific charge characteristics. When the antigen is or comprises a peptide or protein, the epitope can consist of contiguous amino acids (e.g., a linear epitope), or can consist of amino acids from different portions or regions of the protein that are brought into proximity by protein folding (e.g., a discontinuous or conformational epitope), or can consist of non-contiguous amino acids that remain in proximity regardless of protein folding.
[0163] Antibodies, antigen-binding fragments, and compositions
[0164] In one aspect, the present disclosure provides an isolated antibody or antigen-binding fragment thereof capable of binding to neuraminidase (NA) from (i) influenza A virus (IAV), including group 1 IAV, group 2 IAV, or both, and (ii) influenza B virus (IBV).
[0165] In certain embodiments, the antibodies or antigen-binding fragments of the present disclosure associate with or associate with NA, while not significantly associating with or associating with any other molecules or components in the sample.
[0166] In one embodiment, the antibody or antigen-binding fragment of the present disclosure specifically binds to the NA of an IAV. As used herein, "specifically binds" refers to an antibody or antigen-binding fragment that specifically binds to an antigen. 5 M -1 or greater affinity or K a (i.e., the equilibrium association constant (units 1 / M) of a specific binding interaction) ais the off-rate of this association reaction [K off ] to the on-rate [K on ] while not significantly associating or combining with any other molecules or components in the sample. Alternatively, affinity can be measured by the equilibrium dissociation constant (K d ) (The unit is M, e.g., 10 -5 M~10 -13 Antibodies can be classified as "high affinity" or "low affinity" antibodies. "High affinity" antibodies have a K a is at least 10 7 M -1 , at least 10 8 M -1 , at least 10 9 M -1 , at least 10 10 M -1 , at least 10 11 M -1 , at least 10 12 M -1 , or at least 10 13 M -1 A "low affinity" antibody refers to an antibody that has a K a is 10 7 M -1 Up to 10 6 M -1 Up to 10 5 M -1 Alternatively, affinity refers to the equilibrium dissociation constant (K) of a particular binding interaction. d ) (The unit is M, e.g., 10 -5 M~10 -13 M).
[0167] A variety of assays are known for identifying antibodies of the disclosure that bind to a particular target, as well as for determining the affinity of a binding domain or binding protein, including Western blots, ELISAs (e.g., direct, indirect, or sandwich), analytical ultracentrifugation, spectroscopy, and surface plasmon resonance (Biacore®) analysis (see, e.g., Scatchard et al., Ann. NY Acad. Sci. 51:660, 1949; Wilson, Science 295:2103, 2002; Wolff et al., Cancer Res. 53:2560, 1993; and U.S. Patent Nos. 5,283,173, 5,468,614, or equivalents). Assays for assessing affinity, apparent affinity, or relative affinity are also known.
[0168] In some instances, binding can be demonstrated by recombinantly expressing influenza NA antigen in host cells (e.g., by transfection), immunostaining the host cells (e.g., fixed or fixed and permeabilized) with the antibody, and analyzing binding by flow cytometry (e.g., using a ZE5 Cell Analyzer (BioRad®) and FlowJo software (TreeStar)). In some embodiments, positive binding can be determined by differential antibody staining of influenza NA-expressing cells versus control (e.g., mock) cells.
[0169] In some embodiments, the antibodies or antigen-binding fragments of the present disclosure bind to the NA protein of influenza as measured using biolayer interferometry or by surface plasmon resonance.
[0170] Certain characteristics of the antibodies or antigen-binding fragments of the present disclosure can be described using IC50 or EC50 values. In certain embodiments, IC50 is the concentration of a composition (e.g., an antibody) that inhibits a given biological or biochemical function, activity, or response by half-maximal amounts. In certain embodiments, EC50 is the concentration of a composition that provides a half-maximal response in an assay. In some embodiments, IC50 and EC50 are used interchangeably to describe, for example, the ability of an antibody or antigen-binding fragment of the present disclosure to neutralize infection by influenza.
[0171] In some embodiments, the antibodies of the present disclosure are capable of neutralizing influenza infection. As used herein, a "neutralizing antibody" is an antibody that can neutralize, i.e., prevent, inhibit, reduce, block, or interfere with, the ability of a pathogen to initiate and / or sustain infection in a host. The terms "neutralizing antibody" and "neutralizing antibody" or "neutralizing antibodies" are used interchangeably herein. In any embodiment of the present disclosure, the antibody or antigen-binding fragment can prevent and / or neutralize influenza infection in an in vitro model of infection, and / or an in vivo animal model of infection, and / or in humans.
[0172] In certain embodiments, the antibody or antigen-binding fragment thereof is human, humanized, or chimeric.
[0173] In one embodiment, (i) the NA of group 1 IAV includes N1, N4, N5, and / or N8; and / or (ii) the NA of group 2 IAV includes N2, N3, N6, N7, and / or N9. In some embodiments, (i) the N1 is selected from the group consisting of A / California / 07 / 2009, A / California / 07 / 2009 I223R / H275Y, A / Swine / Jiangsu / J004 / 2018, A / Stockholm / 18 / 2007, A / Brisbane / 02 / 2018, A / Michigan / 45 / 2015, A / Mississippi / 3 / 2001, A / Netherlands / 603 / 2009, A / Netherlands / 602 / 2009, A / Vietnam / 1203 / 2004, A / G4 / SW / Shangdong / 1207 / 2016, A / G4 / SW / Henan / SN13 / 2018, and A / New (ii) N1 derived from any one or more of A / mallard duck / Netherlands / 30 / 2011; (iii) N5 derived from A / aquatic bird / Korea / CN5 / 2009; (iv) N8 derived from A / harbor seal / New Hampshire / 179629 / 2011;(v) The above N2 is A / Washington / 01 / 2007, A / HongKong / 68, A / South Australia / 34 / 2019, A / Switzerland / 8060 / 2017, A / Singapore / INFIMH-16-0019 / 2016, A / Switzerland / 9715293 / 2013, A / Leningrad / 134 / 17 / 57, A / Florida / 4 / 2006, A / Netherlan ds / 823 / 1992, A / Norway / 466 / 2014, A / Switzerland / 8060 / 2017, A / Texas / 50 / 2012, A / Vic toria / 361 / 2011, A / HongKong / 2671 / 2019, A / SW / Mexico / SG1444 / 2011, A / Tanzania / 205 / 2 (vi) the N3 is derived from A / Canada / rv504 / 2004; (v) the N6 is derived from A / swine / Ontario / 01911 / 1 / 99; (vi) the N7 is derived from A / Netherlands / 078 / 03; and / or (vii) the N9 is derived from any one or more of A / Anhui / 2013 and A / Hong Kong / 56 / 2015. In some embodiments, the NA of the IBV is B / Lee / 10 / 1940(Ancestral);B / Brisbane / 60 / 2008(Victoria);B / Malaysia / 2506 / 2004(Victoria);B / Malaysia / 3120318925 / 2013(Yamagata);B / Wisconsin / 1 / 2010(Yamagata);B / Yamanashi / 166 / 1998(Yamagata);B / Brisbane / 33 / 2008;B / Colorado / 06 / 2017;B / Hubei-wujiang / 158 / 2009;B / Massachusetts / 02 / 2012;B / Netherlands / 234 / 2011;NA from any one or more of B / Perth / 211 / 2001; B / Phuket / 3073 / 2013; B / Texas / 06 / 2011 (Yamagata); B / Perth / 211 / 2011; B / Hong Kong / 05 / 1972; B / Harbin / 7 / 1994 (Victoria); and B / Washington / 02 / 2019 (Victoria).
[0174] In one embodiment, the antibody or antigen-binding fragment is capable of binding to each of (i) the NA of group 1 IAV; (ii) the NA of group 2 IAV; and (iii) the NA of IBV, and is 50 is in the range of about 0.1 μg / mL to about 50 μg / mL, or in the range of about 0.1 μg / mL to about 2 μg / mL, or in the range of 0.1 μg / mL to about 10 μg / mL, or in the range of 2 μg / mL to about 10 μg / mL, or in the range of about 0.4 μg / mL to about 50 μg / mL, or in the range of about 0.4 μg / mL to about 2 μg / mL, or in the range of 0.4 μg / mL to about 10 μg / mL, or in the range of 2 μg / mL to about 10 μg / mL, or in the range of 0.4 μg / mL to about 1 μg / mL, or 0.4 μg / mL or less.
[0175] In one embodiment, the antibody or antigen-binding fragment (i) is capable of binding to the NA of the group 1 IAV and is 50 (ii) is capable of binding to the NA of the Group 2 IAV and is in the range of about 0.4 μg / mL to about 50 μg / mL, about 0.4 μg / mL to about 10 μg / mL, about 0.4 μg / mL to about 2 μg / mL, about 2 μg / mL to about 50 μg / mL, about 2 μg / mL to about 10 μg / mL, or about 10 μg / mL to about 50 μg / mL; (ii) is capable of binding to the NA of the Group 2 IAV and is in the range of about 0.4 μg / mL to about 50 μg / mL, about 0.4 μg / mL to about 10 μg / mL, about 0.4 μg / mL to about 2 μg / mL, about 2 μg / mL to about 50 μg / mL, about 2 μg / mL to about 10 μg / mL, or about 10 μg / 50 is in the range of about 0.4 μg / mL to about 50 μg / mL, or about 0.4 μg / mL to about 10 μg / mL, or about 0.4 μg / mL to about 2 μg / mL, or about 2 μg / mL to about 50 μg / mL, or about 2 μg / mL to about 10 μg / mL, or about 10 μg / mL to about 50 μg / mL; and / or (iii) is capable of binding to the NA of said IBV and is capable of inhibiting EC 50In further embodiments, the antibody or antigen-binding fragment (i) is capable of binding to N1 and has an EC of about 0.4 μg / mL, or in the range of about 0.1 μg / mL to about 1.9 μg / mL, or about 0.1 μg / mL to about 1.5 μg / mL, or about 0.1 μg / mL to about 1.0 μg / mL, or about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, or 1.0 μg / mL. 50 is about 0.4 μg / mL, or in the range of about 0.4 μg / mL to about 50 μg / mL, or in the range of about 0.1 μg / mL to about 1.9 μg / mL, or in the range of about 0.1 μg / mL to about 1.5 μg / mL, or in the range of about 0.1 μg / mL to about 1.0 μg / mL, or about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, or 1.0 μg / mL; (ii) capable of binding to N4 and having an EC 50 is in the range of about 0.4 μg / mL, or about 0.1 μg / mL to about 1.9 μg / mL, or about 0.1 μg / mL to about 1.5 μg / mL, or about 0.1 μg / mL to about 1.0 μg / mL, or about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, or 1.0 μg / mL; (iii) capable of binding to N5, and EC 50 (iv) can bind to N8 and has an EC 50 (v) can bind to N2 and has an EC 50 is in the range of about 0.4 μg / mL to about 20 μg / mL, or about 0.4 μg / mL to about 10 μg / mL, or about 0.4 μg / mL to about 2 μg / mL, about 1 μg / mL to about 10 μg / mL, or about 1 μg / mL to about 20 μg / mL, or about 1 μg / mL to about 5 μg / mL, or about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, or 20 μg / mL; (vi) capable of binding to N3, and EC 50is in the range of about 0.4 μg / mL, or about 0.1 μg / mL to about 1.9 μg / mL, or about 0.1 μg / mL to about 1.5 μg / mL, or about 0.1 μg / mL to about 1.0 μg / mL, or about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, or 1.0 μg / mL; (vii) capable of binding to N6, and EC 50 is in the range of about 0.4 μg / mL, or about 0.1 μg / mL to about 1.9 μg / mL, or about 0.1 μg / mL to about 1.5 μg / mL, or about 0.1 μg / mL to about 1.0 μg / mL, or about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, or 1.0 μg / mL; (viii) capable of binding to N7, and EC 50 (ix) is capable of binding to N9 and has an EC 50 is in the range of about 0.4 μg / mL, or about 0.1 μg / mL to about 1.9 μg / mL, or about 0.1 μg / mL to about 1.5 μg / mL, or about 0.1 μg / mL to about 1.0 μg / mL, or about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, or 1.0 μg / mL; and / or (xi) is capable of binding to the NA of IBV and has an EC 50 is about 0.4 μg / mL, or about 0.1 μg / mL to about 1.9 μg / mL, or about 0.1 μg / mL to about 1.5 μg / mL, or in the range of about 0.1 μg / mL to about 1.0 μg / mL, or about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, or 1.0 μg / mL.
[0176] In one embodiment, the antibody or antigen-binding fragment is selected from the group consisting of: (i) N1 A / California / 07 / 2009, N1 A / California / 07 / 2009 I223R / H275Y, N1 A / Stockholm / 18 / 2007, N1 A / Swine / Jiangsu / J004 / 2008, N4 A / mallard duck / Netherlands / 30 / 2011, N5 A / aquatic bird / Korea / CN5 / 2009, N2 A / Hong Kong / 68, N2 A / Leningrad / 134 / 17 / 57, N3 A / Canada / rv504 / 2004, N6 A / Swine / Ontario / 01911 / 1 / 99, and N9 Able to bind to one or more of A / Anhui / 1 / 2013, B / Lee / 10 / 1940 (Ancestral), B / Brisbane / 60 / 2008 (Victoria), B / Malaysia / 2506 / 2004 (Victoria), B / Malaysia / 3120318925 / 2013 (Yamagata), B / Wisconsin / 1 / 2010 (Yamagata), and B / Yamanashi / 166 / 1998 (Yamagata), and EC 50 is in the range of about 0.4 μg / mL, or about 0.1 μg / mL to about 1.9 μg / mL, or about 0.1 μg / mL to about 1.5 μg / mL, or about 0.1 μg / mL to about 1.0 μg / mL, or about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, or 1.0 μg / mL; (ii) capable of binding to N5 A / aquatic bird / Korea / CN5 / 2009, and EC 50 (iii) is capable of binding to N8 A / harbor seal / New Hampshire / 179629 / 2011 and is in the range of about 2 μg / mL to about 10 μg / mL; 50 (iv) can bind to N2 A / Washington / 01 / 2007 and EC 50 (v) capable of binding to N7 A / Netherlands / 078 / 03, and EC 50(vi) capable of binding to N2 A / South Australia / 34 / 2019; and (vi) capable of binding to EC 50 (vii) capable of binding to N2 A / Switzerland / 8060 / 2017; and (vii) capable of binding to EC 50 (viii) can bind to N2 A / Singapore / INFIMH-16-0019 / 2016 and EC 50 (iv) can bind to N2 A / Switzerland / 9715293 / 2013 and can bind to EC 50 (v) is in the range of about 1.6 μg / mL to about 1.2 μg / mL; and / or (v) is capable of binding to N1 A / Swine / Jiangsu / J004 / 2018, and EC 50 is in the range of about 0.4 μg / mL to about 50 μg / mL, or about 0.4, about 2, about 10, or about 50 μg / mL.
[0177] In one embodiment, the NA therein is expressed on the surface of a host cell (e.g., a CHO cell), and binding to the NA is measured by flow cytometry.
[0178] In one embodiment, the antibody or antigen-binding fragment is capable of binding to NA, with a KD of less than 1.0E-12 M, less than 1.0E-11 M, 1.0E-11 M, or 1.0E-12 M or less, 1.0E-11 M or less, or 1.0E-10 or less, or a KD between 1.0E-10 and 1.0E-13, or a KD between 1.0E-11 and 1.0E-13, optionally wherein the binding is assessed by biolayer interferometry (BLI).
[0179] In one embodiment, the NA is N1, N2, and / or N9.
[0180] In some embodiments, the antibody or antigen-binding fragment can bind to (1) an NA epitope comprising any one or more of the following amino acids (N1 NA numbering): R368, R293, E228, E344, S247, D198, D151, R118; and / or (2) an NA epitope comprising any one or more of the following amino acids (N2 NA numbering): R371, R292, E227, E344, S247, D198, D151, R118. It will be understood that the antibody and antigen-binding fragment can also bind to influenza neuraminidases that may not follow the N1 or N2 amino acid numbering convention; the amino acids of these epitopes may correspond to the N1 or N2 amino acid residues set forth herein by being the same amino acid residues at equivalent but differently numbered positions in the NA (e.g., by alignment, 3D structure, conservation, or a combination thereof). Thus, reference to N1 or N2 numbering will be understood to mean that the amino acid corresponds to the numbered amino acid.
[0181] An example showing a comparison of the numbering of N1 and N2 positions (using H1N1_California.07.2009 and H3N2_NewYork.392.2004) is provided in Table 3.
[0182] In one embodiment, the antibody or antigen-binding fragment can bind to (1) an NA epitope comprising amino acids R368, R293, E228, D151, and R118 (N1 NA numbering); and / or (2) an NA epitope comprising amino acids R371, R292, E227, D151, and R118 (N2 NA numbering).
[0183] In some embodiments, the antibody or antigen-binding fragment can bind to an epitope contained in or comprising an NA active site (as described herein, the NA active site includes functional amino acids that form the catalytic core and directly contact sialic acid, as well as structural amino acids that form the active site framework), optionally comprising the following amino acids (N2 numbering): R118, D151, R152, R224, E276, R292, R371, Y406, E119, R156, W178, S179, D / N198, I222, E227, H274, E277, D293, E425. In some embodiments, R118, D151, R152, R224, E276, R292, R371, and Y406 form the catalytic core and directly contact sialic acid. In one embodiment, E119, R156, W178, S179, D / N198, I222, E227, H274, E277, D293, and E425 form the active site framework.
[0184] In certain embodiments, the epitope comprises or further comprises any one or more of the following NA amino acids (N2 numbering): E344, E227, S247, and D198.
[0185] In certain embodiments, the antibody or antigen-binding fragment is capable of binding to an NA comprising an S245N amino acid mutation and / or an E221D amino acid mutation (N2 numbering).
[0186] In some embodiments, the NA comprises an IBV NA. In some embodiments, the antibody or antigen-binding fragment can bind to an IBV NA epitope that includes any one or more of the following amino acids (IBV numbering; e.g., for FluB Victoria and FluB Yamagata): R116, D149, E226, R292, and R374. In some embodiments, the epitope includes amino acids R116, D149, E226, R292, and R374.
[0187] In one embodiment, the antibody or antigen-binding fragment is capable of inhibiting the sialidase activity of (i) IAV NA, including Group 1 IAV NA, Group 2 IAV NA, or both, and / or (ii) IBV NA in an in vitro model of infection, an in vivo animal model of infection, and / or in humans. In further embodiments, (i) the NA of said group 1 IAV comprises H1N1 and / or H5N1; (ii) the NA of said group 2 IAV comprises H3N2 and / or H7N9; and / or (iii) the NA of said IBV comprises B / Lee / 10 / 1940 (Ancestral); B / HongKong / 05 / 1972; B / Taiwan / 2 / 1962 (Ancestral); B / Brisbane / 33 / 2008 (Victoria); B / Brisbane / 60 / 2008 (Victoria); B / Malaysia / 2506 / 2004 (Victoria); B / New York / 1056 / 2003(Victoria);B / Florida / 4 / 2006(Yamagata);B / Jiangsu / 10 / 2003(Yamagata);B / Texas / 06 / 201 1(Yamagata);B / Perth / 211 / 2011;B / Harbin / 7 / 1994(Victoria);B / Colorado / 06 / 2017(Victoria);B / Washingt on / 02 / 2019 (Victoria); B / Perth / 211 / 2001 (Yamagata); B / Hubei-wujiagang / 158 / 2009 (Yamagata); B / Wisconsin / 01 / 2010 (Yamagata); B / Massachusetts / 02 / 2012 (Yamagata); and B / Phuket / 3073 / 2013 (Yamagata).
[0188] In some embodiments, the antibody or antigen-binding fragment is capable of inhibiting the sialidase activity of Group 1 IAV NA; Group 2 IAV NA; and / or IBV NA, with an IC50 of about 0.0008 μg / mL to about 4 μg / mL, about 0.0008 μg / mL to about 3 μg / mL, about 0.0008 μg / mL to about 2 μg / mL, about 0.0008 μg / mL to about 1 μg / mL, about 0.0008 μg / mL to about 0.9 μg / mL, about 0.0008 μg / mL to about 0.8 μg / mL, about 0.0008 μg / mL to about 0.7 μg / mL, about 0.0008 μg / mL to about 0.6 μg / mL, or about 0.0008 μg / mL to about 0. .5μg / mL, about 0.0008μg / mL to about 0.4μg / mL, about 0.0008μg / mL to about 0.3μg / mL, about 0.0008μg / mL to about 0.2μg / mL, about 0.0008μg / mL to about 0.1μg / mL, about 0.0008μg / mL to about 0.09μ g / mL, approximately 0.0008μg / mL to approximately 0.08μg / mL, approximately 0.0008μg / mL to approximately 0.07μg / mL, approximately 0.0008μg / mL to approximately 0.06μg / mL, approximately 0.0008μg / mL to approximately 0.05μg / mL, approximately 0.0008μg / mL to approximately 0.04μ g / mL, approximately 0.0008μg / mL to approximately 0.03μg / mL, approximately 0.0008μg / mL to approximately 0.02μg / mL, approximately 0.0008μg / mL to approximately 0.01μg / mL, 0.002μg / mL to approximately 4μg / mL, approximately 0.001μg / mL to 50μg / mL, approximately 0. 1μg / mL to about 30μg / mL, about 0.1μg / mL to about 20μg / mL, about 0.1μg / mL to about 10μg / mL, about 0.1μg / mL to about 9μg / mL, about 0.1μg / mL to about 8μg / mL, about 0.1μg / mL to about 7μg / mL, about 0.1μg / mL to about 6 μg / mL, approximately 0.1 μg / mL to approximately 5 μg / mL, approximately 0.1 μg / mL to approximately 4 μg / mL, approximately 0.1 μg / mL to approximately 3 μg / mL, approximately 0.1 μg / mL to approximately 2 μg / mL, approximately 0.1 μg / mL to approximately 1 μg / mL, approximately 0.1 μg / mL to approximately 0.9 μg / mL, approximately 0. 1μg / mL to approximately 0.8μg / mL, approximately 0.1μg / mL to approximately 0.7μg / mL, approximately 0.1μg / mL to approximately 0.6μg / mL, approximately 0.1μg / mL to approximately 0.5μg / mL, approximately 0.1μg / mL to approximately 0.4μg / mL, approximately 0.1μg / mL to approximately 0.3μg / mL, approximately 0.1μg / mL to approx. 0.2μg / mL, approx. 0.8μg / mL to approx. 30μg / mL, approx. 0.8μg / mL to approx. 20μg / mL, approx. 0.8μg / mL to approx. 10μg / mL, approx. 0.8μ g / mL~about 9μg / mL, about 0.8μg / mL~about 8μg / mL, about 0.8μg / mL~about 7μg / mL, about 0.8μg / mL~about 6μg / mL, about 0.8μg / mL~about 5 μg / mL, about 0.8 μg / mL to about 4 μg / mL, about 0.8 μg / mL to about 3 μg / mL, about 0.8 μg / mL to about 2 μg / mL, about 0.8 μg / mL to about 1 μg / mL, or about 0.1 μg / mL, about 0.2 μg / mL, about 0.3 μg / mL, about 0.4 μg / mL, about 0.5 μg / mL, about 0.6 μg / mL, about 0.7 μg / mL, about 0.8μg / mL, approximately 0.9μg / mL, approximately 1.0μg / mL, approximately 1.5μg / mL, approximately 2.0μg / mL, approximately 2.5μg / mL, approximately 3.0μg / mL, approximately 3.5μg / mL, Approximately 4.0μg / mL, approximately 4.5μg / mL, approximately 5.0μg / mL, approximately 5.5μg / mL, approximately 6.0μg / mL, approximately 6.5μg / mL, approximately 7.0μg / mL, approximately 7.5μg / mL , about 8.0 μg / mL, about 8.5 μg / mL, about 9.0 μg / mL, about 10 μg / mL, about 11 μg / mL, about 12 μg / mL, about 13 μg / mL, about 14 μg / mL, about 15 μg / mL, about 16 μg / mL, about 17 μg / mL, about 18 μg / mL, about 19 μg / mL, about 20 μg / mL, about 25 μg / mL, and / or about 30 μg / mL. In further embodiments, the antibody or antigen-binding fragment is capable of inhibiting the NA sialidase activity of one or more Group 1 and / or Group 2 IAVs, and / or one or more IBVs, with an IC50 of about 0.00001 μg / ml to about 25 μg / ml, or about 0.0001 μg / ml to about 10 μg / ml, or about 0.0001 μg / ml to about 1 μg / ml, or about 0.0001 μg / ml ml to about 0.1 μg / ml, or about 0.0001 μg / ml to about 0.01 μg / ml, or about 0.0001 μg / ml to about 001 μg / ml, or about 0.0001 μg / ml to about 0001 μg / ml, or about 0001 μg / ml to about 25 μg / ml, or about 0001 μg / ml to about 10 μg / ml, or about 0001 μg / ml to about 1 μg / ml, or about 0001 μg / ml to about 0.1 μg / ml, or about 0.001 μg / ml to about 0.01 μg / ml, or about 0.001 μg / ml to about 25 μg / ml, or about 0.01 μg / ml to about 10 μg / ml, or about 0.01 μg / ml to about 1 μg / ml, or about 0.01 μg / ml to about 0.1 μg / ml, or about 0.01 μg / ml to about 25 μg / ml, or about 0.1 μg / ml to about 10 μg / ml, or about 0.1 μg / ml The concentration ranges from about 1 μg / ml to about 1 μg / ml, or from about 0.1 μg / ml to about 0.1 μg / ml, or from about 1 μg / ml to about 25 μg / ml, or from about 1 μg / ml to about 10 μg / ml, or about 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, 12, 12.5, 13, 13.5, 14, 14.5, or 15 μg / ml.
[0189] In one embodiment, the antibody or antigen-binding fragment is capable of activating human FcγRIIIa. In a further embodiment, activation is determined after incubating the antibody or antigen-binding fragment with target cells (e.g., A549 cells) infected with IAV (e.g., for 23 hours) using host cells (optionally Jurkat cells) comprising (i) human FcγRIIIa (optionally the F158 allele) and (ii) an NFAT expression control sequence operably linked to a sequence encoding a reporter (e.g., a luciferase reporter). In yet another embodiment, activation is determined after incubating the antibody or antigen-binding fragment with target cells infected with H1N1 IAV (optionally for about 23 hours), wherein optionally the H1N1 IAV is A / PR8 / 34 and / or optionally the infection is at a multiplicity of infection (MOI) of 6.
[0190] In one embodiment, the antibody or antigen-binding fragment is capable of neutralizing infection by IAV and / or IBV. In one embodiment, the IAV and / or IBV is resistant to an antiviral agent, and optionally the antiviral agent is oseltamivir.
[0191] In one embodiment, the IAV comprises an N1 NA comprising the amino acid mutations: H275Y; E119D+H275Y; S247N+H275Y; I222V; and / or N294S, and optionally the IAV comprises CA09 or A / Aichi. In one embodiment, the IAV comprises an N2 NA comprising the amino acid mutations E119V, Q136K, and / or R292K.
[0192] In certain embodiments, the antibody or antigen-binding fragment is capable of treating and / or preventing (i) an IAV infection and / or (ii) an IBV infection in a subject.
[0193] In certain embodiments, the antibody or antigen-binding fragment is capable of treating and / or ameliorating infection by (i) an H1N1 virus (optionally including A / PR8 / 34); and / or (ii) an H3N2 virus (optionally including A / Hong Kong / 68).
[0194] In some embodiments, the antibody or antigen-binding fragment can prevent weight loss in a subject infected with the IAV and / or IBV, optionally for (i) up to 15 days, or (ii) more than 15 days, after administration of an effective amount of the antibody or antigen-binding fragment.
[0195] In one embodiment, the antibody or antigen-binding fragment is capable of preventing weight loss in a subject infected with IAV and / or IBV by more than 10% as measured relative to the subject's weight immediately prior to infection with the IAV and / or IBV.
[0196] In one embodiment, the antibody or antigen-binding fragment is capable of prolonging survival of a subject infected with IAV and / or IBV.
[0197] In certain embodiments, the antibody or antigen-binding fragment is administered in a mouse (e.g., a tg32 mouse) for (i) about 10 days to about 14 days, about 10.2 days to about 13.8 days, about 10.5 days to about 13.5 days, about 11 days to about 13 days, about 11.5 days to about 12.5 days, between 10 and 14 days, or between 10.5 and 13.5 days, or between 11 and 13 days, or about 10.0, 10.1, 10.2, 10.3, 10.4, 10.5, 10.6, 10.7, 10.8, 10.9, 11.1, 11.2, 11.3, 11.4, 11.5, 11.5, 11.6, 11.7, 11.8, 11.9 ... 1, 10.2, 10.3, 10.4, 10.5, 10.6, 10.7, 10.8, 10.9, 11.0, 11.1, 11.2, 11.3, 11.4, 11.5, 11.6, 11.7, 11.8, 11.9, 12.0, 12.1, 12.2, 12.3, 12.4, 12.5, 12.6, 12.7, 12.8, 12.9, 13.0, 13.1, 13.2, 13.3, 13.4, 13.5, 13.6, 13.7 , 13.8, 13.9, or 14.0 days; or (ii) an in vivo half-life of about 12 days to about 16 days, about 12.5 days to 15.5 days, about 13 days to 15 days, about 13.5 days to about 14.5 days, or between 12 days and 16 days, or between 13 days and 15 days, or between 13.5 days and 14.5 days, or about 12.0, 12.1, 12.2, 12.3, 12.4, 12.5, 12.6, 12.7 , 12.8, 12.9, 13.0, 13.1, 13.2, 13.3, 13.4, 13.5, 1.36, 13.7, 13.8, 13.9, 14.0, 14.1, 14.2, 14.3, 14.4, 14.5, 14.6, 14.7, 14.8, 14.9, 15.0, 15.1, 15.2, 15.3, 15.4, 15.5, 1.56, 15.7, 15.8, 15.9, or 16.0 days.
[0198] Terms understood by those skilled in the antibody arts are given their art-acquired meanings unless expressly defined otherwise herein. For example, the term "antibody" refers to an intact antibody comprising at least two heavy (H) chains and two light (L) chains connected to each other by disulfide bonds, as well as fragments of any antigen-binding portion of an intact antibody (e.g., scFv, Fab, or Fab'2 fragments) that are capable of binding to the antigen target molecule recognized by the intact antibody. Thus, the term "antibody" is used in the broadest sense herein to encompass polyclonal and monoclonal antibodies, including intact antibodies and functional (antigen-binding) antibody fragments thereof, including fragment antigen-binding (Fab) fragments, F(ab')2 fragments, Fab' fragments, Fv fragments, recombinant IgG (rIgG) fragments, single-chain antibody fragments (including single-chain variable fragments (scFv)), and single-domain antibody (e.g., sdAb, sdFv, nanobody) fragments. The term encompasses genetically engineered and / or otherwise modified forms of immunoglobulins (such as intrabodies, peptibodies, chimeric antibodies, fully human antibodies, humanized antibodies, and heteroconjugate antibodies), multispecific (e.g., bispecific) antibodies, diabodies, triabodies, tetrabodies, tandem di-scFvs, and tandem tri-scFvs. Unless otherwise specified, the term "antibody" should be understood to include functional antibody fragments thereof. The term also encompasses intact, i.e., full-length, antibodies of any class or subclass, including IgG and its subclasses (IgG1, IgG2, IgG3, IgG4), IgM, IgE, IgA, and IgD.
[0199] "V L " or "VL" and "V HThe terms "VH" and "VH" refer to the variable binding regions from antibody light chains and heavy chains, respectively. In one embodiment, the VL is of the kappa (κ) class (also referred to herein as "VK"). In one embodiment, the VL is of the lambda (λ) class. The variable binding regions comprise discrete, well-defined subregions known as "complementarity-determining regions" (CDRs) and "framework regions" (FRs). The terms "complementarity-determining regions" and "CDRs" are synonyms for "hypervariable regions" or "HVRs" and refer to the sequences of amino acids within antibody variable regions that generally confers antigen specificity and / or binding affinity to the antibody. Contiguous CDRs in an antibody (i.e., CDR1 and CDR2, and CDR2 and CDR3) are separated from each other by framework regions in the primary structure. There are three CDRs in each variable region (HCDR1, HCDR2, HCDR3; LCDR1, LCDR2, LCDR3; also referred to as CDRH and CDRL, respectively). In one embodiment, an antibody VH comprises four FRs and three CDRs in the following order: FR1-HCDR1-FR2-HCDR2-FR3-HCDR3-FR4; and an antibody VL comprises four FRs and three CDRs in the following order: FR1-LCDR1-FR2-LCDR2-FR3-LCDR3-FR4. Generally, the VH and VL combine through their respective CDRs to form an antigen-binding site. In one embodiment, one or more CDRs do not contact the antigen and / or do not contribute energetically to antigen binding.
[0200] As used herein, a "variant" of a CDR refers to a functional variant of the CDR sequence having up to 1 to 3 amino acid substitutions (e.g., conservative or non-conservative substitutions), deletions, or a combination thereof.
[0201] Numbering of the CDRs and framework regions can follow any known method or scheme, such as the Kabat, Chothia, EU, IMGT, Contact, North, Martin, and AHo numbering schemes (e.g., Kabat et al., Sequences of Proteins of Immunological Interest, US Dept. Health and Human Services, Public Health Service National Institutes of Health, 1991, 5 thed.; Chothia and Lesk, J. Mol. Biol. 196:901-917 (1987); Lefranc et al., Dev. Comp. Immunol. 27:55, 2003; Honegger and Pluckthun, J. Mol. Bio. 309:657-670(2001); North et al. J Mol Biol.(2011) 406:228-56; doi:10.1016 / j.jmb.2010.10.030; Abhinandan and Martin, Mol Immunol.(2008) 45:3832-9. 10.1016 / j.molimm.2008.05.022). The antibody and CDR numbering systems of these references are incorporated herein by reference. Equivalent residue positions can be annotated, and different molecules can be compared using the Antigen Receptor Numbering And Receptor Classification (ANARCI) software tool (2016, Bioinformatics 15:298-300). Therefore, identifying the CDRs of one representative variable domain (VH or VL) sequence presented herein according to one numbering scheme does not exclude antibodies containing the CDRs of the same variable domain determined using a different numbering scheme. In one embodiment, the CDRs of SEQ ID NOS: 2, 14, 26, 171, 38, 50, 62, 74, 86, 183, 98, 110, 122, 134, 146, 158, 199, 203, 207, 216, and 228 are identified as CDRs of any known variable domain, including Kabat, Chothia, EU, IMGT, Martin (enhanced Chothia), Contact, and AHo numbering systems. and a VL sequence according to any one of SEQ ID NOs: 26, 36, 46, 56, 66, 76, 86, 96, 8, 20, 32, 44, 56, 68, 80, 92, 104, 116, 128, 140, 152, 174, 177, 180, 186, 189, 192, 164, 201, 205, 209, 217, and 230.In some embodiments, the CDRs follow the IMGT numbering system. In some embodiments, the CDRs follow the antibody numbering system developed by the Chemical Computing Group (CCG), for example, using Molecular Operating Environment (MOE) software (www.chemcomp.com).
[0202] In one embodiment, an antibody or antigen-binding fragment of the present disclosure comprises CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3, where each CDR is independently selected from the corresponding CDR of an NA-specific antibody presented in Table 1 and / or Table 2. That is, all combinations of CDRs from the NA-specific antibodies presented in Table 1 and / or Table 2 are contemplated.
[0203] In some embodiments, the CDRs follow the IMGT numbering system.
[0204] In an embodiment, the present disclosure provides an antibody or antigen-binding fragment thereof comprising a heavy chain variable domain (VH) comprising complementarity determining regions (CDRs) H1, CDRH2, and CDRH3, and a light chain variable domain (VL) comprising CDRL1, CDRL2, and CDRL3, (i) optionally, the CDRH1 comprises or consists of an amino acid sequence set forth in any one of SEQ ID NOs: 3, 15, 27, 39, 51, 63, 75, 87, 99, 111, 123, 135, 147, 159, and 231, or a functional variant thereof, containing one, two, or three amino acid substitutions, one or more of which are optionally conservative and / or to a germline-encoded amino acid; (ii) Optionally, the CDRH2 comprises or consists of an amino acid sequence set forth in any one of SEQ ID NOs: 4, 16, 28, 40, 52, 64, 76, 88, 100, 112, 124, 136, 148, 160, and 232, or a functional variant thereof, comprising one, two, or three amino acid substitutions, one or more of which are optionally conservative substitutions and / or substitutions to a germline-encoded amino acid; ) the CDRH3 comprises or consists of an amino acid sequence set forth in any one of SEQ ID NOs: 5, 17, 29, 172, 41, 53, 65, 77, 89, 184, 101, 113, 125, 137, 149, 161, and 233, or a functional variant thereof, containing one, two, or three amino acid substitutions, one or more of which are optionally conservative substitutions and / or substitutions to a germline-encoded amino acid; (iv) optionally, said CDRL1 comprises or consists of an amino acid sequence set forth in any one of SEQ ID NOs: 9, 21, 33, 45, 57, 69, 81, 93, 105, 117, 129, 141, 153, 165, and 234, or a functional variant thereof, comprising one, two, or three amino acid substitutions, wherein one or more of the substitutions are, optionally, conservative and / or to a germline-encoded amino acid;(v) optionally, said CDRL2 comprises or consists of the amino acid sequence set forth in any one of SEQ ID NOs: 10, 22, 34, 46, 58, 70, 82, 94, 106, 118, 130, 142, 154, 166, and 235, or a functional variant thereof, containing one, two, or three amino acid substitutions, one or more of which are optionally conservative substitutions and / or to a germline-encoded amino acid; and / or (vi) optionally, said CDRL3 is , SEQ ID NOs: 11, 23, 35, 175, 178, 181, 47, 59, 71, 83, 95, 187, 193, 107, 119, 131, 143, 155, 190, 167, and 236, or a functional variant thereof, comprising one, two, or three amino acid substitutions, one or more of which are optionally conservative substitutions and / or substitutions to a germline-encoded amino acid;
[0205] In further embodiments, CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3 are selected from the group consisting of (i) SEQ ID NOs: 3-5 and 9-11, respectively; (ii) SEQ ID NOs: 15-17 and 21-23, respectively; (iii) SEQ ID NOs: 27-29 and 33-35, respectively; (iv) SEQ ID NOs: 27, 28, 172, and 33-35, respectively; (v) SEQ ID NOs: 27-29, 33, 34, and 175, respectively; (vi) SEQ ID NOs: 27-29, 33, 34, and 178, respectively; (vii) SEQ ID NOs: 27-29, 33, 34, and 181, respectively; (viii) SEQ ID NOs: 27, 28, 172, 33, 34, and 175, respectively; (ix) SEQ ID NOs: 27, 28, (x) SEQ ID NOs: 27, 28, 172, 33, 34, and 178, respectively; (xi) SEQ ID NOs: 39-41 and 45-47, respectively; (xii) SEQ ID NOs: 51-53 and 57-59, respectively; (xiii) SEQ ID NOs: 63-65 and 69-71, respectively; (xiv) SEQ ID NOs: 75-77 and 81-83, respectively; (xv) SEQ ID NOs: 87-89 and 93-95, respectively; (xvi) SEQ ID NOs: 87, 88, 184, and 93-95, respectively; (xvii) SEQ ID NOs: 87-89, 93, 94, and 187, respectively; (xviii) SEQ ID NOs: 87-89, 93, 94, and 190, respectively; (xix) SEQ ID NOs: 87-89 (xx) SEQ ID NOs: 87, 88, 184, 93, 94, and 187; (xxi) SEQ ID NOs: 87, 88, 184, 93, 94, and 190; (xxii) SEQ ID NOs: 87, 88, 184, 93, 94, and 193; (xxiii) SEQ ID NOs: 87-89, 141, 142, and 131; (xxiv) SEQ ID NO: (xxv) SEQ ID NOs: 111-113 and 117-119, respectively; (xxvi) SEQ ID NOs: 123-125 and 129-131, respectively; (xxvii) SEQ ID NOs: 135-137 and 141-143, respectively; (xxviii) SEQ ID NOs: 147-149 and 153-155, respectively; (xxix) SEQ ID NOs: 159-161 and 165-167, respectively;or (xxx) comprising or consisting of the amino acid sequences set forth in SEQ ID NOs: 231 to 233 and 234 to 236, respectively;
[0206] The term "CL" refers to an "immunoglobulin light chain constant region" or "light chain constant region," i.e., the constant region from an antibody light chain. The term "CH" refers to an "immunoglobulin heavy chain constant region" or "heavy chain constant region," which can be further divided into CH1, CH2, and CH3 domains (IgA, IgD, IgG) or CH1, CH2, CH3, and CH4 domains (IgE, IgM), depending on the antibody isotype. The Fc region of an antibody heavy chain is further described herein. In any embodiment of the present disclosure, an antibody or antigen-binding fragment of the present disclosure can comprise any one or more of CL, CH1, CH2, and CH3. In any embodiment of the present disclosure, an antibody or antigen-binding fragment of the present disclosure can comprise any one or more of CL, CH1, CH2, and CH3. In some embodiments, CL comprises an amino acid sequence that is 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 211. In some embodiments, CH1-CH2-CH3 comprises an amino acid sequence that is 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 210 or SEQ ID NO: 215. It will be appreciated that one or more C-terminal lysines of an antibody heavy chain may be removed, for example, for production in a mammalian cell system (see, e.g., Liu et al. mAbs 6(5):1145-1154 (2014)). Thus, antibodies or antigen-binding fragments of the present disclosure can include heavy chain, CH1-CH3, CH3, or Fc polypeptides in which a C-terminal lysine residue is present or absent; in other words, embodiments in which the C-terminal residue of a heavy chain, CH1-CH3, or Fc polypeptide is not lysine and embodiments in which lysine is the C-terminal residue are encompassed. In one embodiment, a composition comprises a plurality of an antibody and / or antigen-binding fragment of the present disclosure, wherein one or more of the antibodies or antigen-binding fragments do not include a lysine residue at the C-terminus of the heavy chain, CH1-CH3, or Fc polypeptide, and one or more of the antibodies or antigen-binding fragments include a lysine residue at the C-terminus of the heavy chain, CH1-CH3, or Fc polypeptide.
[0207] "Fab" (Fragment Antigen Binding) is the antigen-binding portion of an antibody and comprises the variable region and CH1 of the heavy chain linked to the light chain by an interchain disulfide bond. Each Fab fragment is monovalent with respect to antigen binding (i.e., has a single antigen-binding site). Pepsin treatment of an antibody generates a single large F(ab')2 fragment, which roughly corresponds to two disulfide-linked Fab fragments with bivalent antigen-binding activity and is still capable of cross-linking antigen. Both Fab and F(ab')2 are examples of "antigen-binding fragments." Fab' fragments differ from Fab fragments by having several additional residues at the carboxy terminus of the CH1 domain, including one or more cysteines from the antibody hinge region. Fab'-SH, as used herein, refers to Fab' in which the cysteine residues in the constant domains bear free thiol groups. F(ab')2 antibody fragments are originally produced as pairs of Fab' fragments, with hinge cysteines between them. Other chemical couplings of antibody fragments are also known.
[0208] Fab fragments can be joined, for example, by a peptide linker to form a single-chain Fab (also referred to herein as an "scFab"). In these embodiments, the intrachain disulfide bonds present in native Fabs may be absent, and the linker serves, in whole or in part, to link or connect the Fab fragments in a single polypeptide chain. Fab fragments derived from the heavy chain (e.g., Fab fragments comprising, consisting of, or primarily consisting of VH+CH1 or "Fd") and Fab fragments derived from the light chain (e.g., Fab fragments comprising, consisting of, or primarily consisting of VL+CL) can be linked in any configuration to form an scFab. For example, scFabs can be arranged from N-terminus to C-terminus in the following order: (heavy chain Fab fragment-linker-light chain Fab fragment) or (light chain Fab fragment-linker-heavy chain Fab fragment). Peptide linkers and representative linker sequences for use in scFabs are described in further detail herein.
[0209] An "Fv" is a small antibody fragment that contains a complete antigen-recognition and antigen-binding site. This fragment generally consists of a dimer of one heavy- and one light-chain variable domain in tight, noncovalent association. However, even a single variable domain (i.e., half of an Fv, containing only three CDRs specific for an antigen) can recognize and bind to an antigen, although typically with lower affinity than the entire binding site.
[0210] "Single-chain Fv" (also abbreviated as "sFv" or "scFv") is a V H Antibody domains and V L In some embodiments, an scFv polypeptide is an antibody fragment in which antibody domains are joined together into a single polypeptide chain. H Domains and V LThe scFv comprises a polypeptide linker disposed between the domains, which allows the scFv to maintain or form the desired structure for antigen binding. Such peptide linkers can be incorporated into the fusion polypeptide using standard techniques in the art. For a review of scFvs, see Pluckthun, pp. 269-315, in The Pharmacology of Monoclonal Antibodies, vol. 113, Rosenburg and Moore eds., Springer-Verlag, New York (1994); Borrebaeck 1995, infra. In certain embodiments, the antibody or antigen-binding fragment comprises an scFv comprising a VH domain, a VL domain, and a peptide linker connecting the VH domain to the VL domain. In particular embodiments, the scFv comprises a VH domain connected to the VL domain by a peptide linker, and can be in a VH-linker-VL orientation or a VL-linker-VH orientation. Any scFv of the disclosure can be engineered so that the C-terminus of the VL domain is linked to the N-terminus of the VH domain by a short peptide sequence, or vice versa (i.e., (N)VL(C)-linker-(N)VH(C) or (N)VH(C)-linker-(N)VL(C). Alternatively, in some embodiments, a linker can be linked to the N-terminal portion or N-terminus of the VH domain, VL domain, or both.
[0211] The peptide linker sequence can be selected based on, for example, (1) its ability to adopt a flexible, extended conformation; (2) its inability or lack of ability to adopt secondary structures that may interact with functional epitopes on the first and second polypeptides and / or target molecules; and / or (3) its lack or relative paucity of hydrophobic or charged residues that may interact with the polypeptides and / or target molecules. Other considerations for linker design (e.g., length) may include the conformation or range of conformations that allow the VH and VL to form a functional antigen-binding site. In certain embodiments, the peptide linker sequence contains residues such as Gly, Asn, and Ser. Other near-neutral amino acids (e.g., Thr and Ala) can also be included in the linker sequence. Other amino acid sequences that may be useful as linkers include those disclosed in Maratea et al., Gene 40:39 46 (1985); Murphy et al., Proc. Natl. Acad. Sci. USA 83:8258 8262 (1986); U.S. Patent No. 4,935,233, and U.S. Patent No. 4,751,180. Other illustrative, non-limiting examples of linkers can include, for example, Glu-Gly-Lys-Ser-Ser-Gly-Ser-Gly-Ser-Glu-Ser-Lys-Val-Asp (Chaudhary et al., Proc. Natl. Acad. Sci. USA 87:1066-1070(1990)) and Lys-Glu-Ser-Gly-Ser-Val-Ser-Ser-Glu-Gln-Leu-Ala-Gln-Phe-Arg-Ser-Leu-Asp (Bird et al., Science 242:423-426(1988)), and the pentamer Gly-Gly-Gly-Gly-Ser when present only once or in 1 to 5 or more repeats.Any suitable linker can be used, and generally can be about 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 15, 23, 24, 25, 26, 27, 28, 29, 30, 40, 50, 60, 70, 80, 90, 100 amino acids in length, or less than about 200 amino acids in length, preferably comprises a flexible structure (capable of providing flexibility and space for conformational movement between the two regions, domains, motifs, fragments, or modules connected by the linker), and preferably is biologically inactive in the human body and / or has a low risk of immunogenicity. ScFvs can be constructed using any combination of VH and VL sequences, or any combination of CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3 sequences disclosed herein. In some embodiments, a linker sequence is not required, for example, when the first and second polypeptides have non-essential N-terminal amino acid regions that can be used to separate the functional domains and prevent steric hindrance.
[0212] During antibody development, DNA within germline variable (V), joining (J), and diversity (D) loci can be rearranged, resulting in the insertion and / or deletion of nucleotides within the coding sequence. Somatic mutations can be encoded by the resulting sequence and can be identified by reference to the corresponding known germline sequence of nucleotides. In some contexts, somatic mutations that are not essential for a desired antibody property (e.g., binding to an influenza NA antigen) or that confer undesirable antibody properties (e.g., increased risk of immunogenicity in a subject receiving the antibody), or both, can be substituted with the corresponding germline-encoded amino acid or with a different amino acid, thereby improving or maintaining the desired antibody property and reducing or eliminating the undesirable antibody property. Thus, in some embodiments, an antibody or antigen-binding fragment of the present disclosure comprises at least one or more germline-encoded amino acids in the variable region compared to a parent antibody or antigen-binding fragment that comprises one or more somatic mutations. The amino acid sequences of the variable regions and CDRs of representative anti-NA antibodies of the present disclosure are provided in Table 1 herein.
[0213] In some embodiments, the VH is encoded by or derived from human IGHV1-69*01F or IGHV1-69D*01F, IGHJ4*02F, and IGHD1-26*01F, and / or the VL is encoded by or derived from human IGKV3D-15*01 F and Homsap IGKJ2*02(F), the polynucleotide sequences and other information for which and related human IG alleles are available, for example, at IMGT.org (see, e.g., www.imgt.org / IMGT_vquest / analysis).
[0214] In certain embodiments, the antibody or antigen-binding fragment comprises amino acid modifications (eg, substitution mutations) to eliminate the undesirable risks of oxidation, deamidation, and / or isomerization.
[0215] Also provided herein are variant antibodies that contain one or more amino acid changes in the variable regions (e.g., VH, VL, framework, or CDR) compared to a ("parent") antibody of the present disclosure, which variant antibodies are capable of binding to the NA antigen.
[0216] In one embodiment, (i) the VH comprises or consists of an amino acid sequence at least 80% identical (e.g., 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to the amino acid sequence set forth in any one of SEQ ID NOs: 2, 14, 26, 171, 38, 50, 62, 74, 86, 183, 98, 110, 122, 134, 146, 158, 199, 203, 207, 216, and 228, wherein sequence variation is optionally limited to one or more framework regions, and / or wherein sequence variation includes one or more substitutions to germline-encoded amino acids; and / or ii) the VL comprises or consists of an amino acid sequence at least 80% identical (e.g., 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to the amino acid sequence set forth in any one of SEQ ID NOs: 8, 20, 32, 44, 56, 68, 80, 92, 104, 116, 128, 140, 152, 174, 177, 180, 186, 189, 192, 164, 201, 205, 209, 217, and 230, wherein sequence variation therein is optionally limited to one or more framework regions and / or wherein sequence variation includes one or more substitutions to germline-encoded amino acids.
[0217] In some embodiments, the VH and the VL are selected from (i) SEQ ID NOs: 2 and 8, respectively; (ii) SEQ ID NOs: 14 and 20, respectively; (iii) SEQ ID NOs: 26 and 32, respectively; (iv) SEQ ID NOs: 26 and 174, respectively; (v) SEQ ID NOs: 26 and 177, respectively; (vi) SEQ ID NOs: 26 and 180, respectively; (vii) SEQ ID NOs: 171 and 32, respectively; (viii) SEQ ID NOs: 171 and 174, respectively; (ix) SEQ ID NOs: 171 and 177, respectively; (x) SEQ ID NOs: 171 and 180, respectively. (xi) SEQ ID NOs: 38 and 44, respectively; (xii) SEQ ID NOs: 50 and 56, respectively; (xiii) SEQ ID NOs: 62 and 68, respectively; (xiv) SEQ ID NOs: 74 and 80, respectively; (xv) SEQ ID NOs: 86 and 92, respectively; (xvi) SEQ ID NOs: 86 and 186, respectively; (xvii) SEQ ID NOs: 86 and 189, respectively; (xviii) SEQ ID NOs: 86 and 192, respectively; (xix) SEQ ID NOs: 183 and 92, respectively; (xx) SEQ ID NOs: 183 and 186, respectively; (xxi) SEQ ID NOs: (xxii) SEQ ID NOs: 183 and 189, respectively; (xxii) SEQ ID NOs: 183 and 192, respectively; (xxiii) SEQ ID NOs: 98 and 104, respectively; (xxiv) SEQ ID NOs: 110 and 116, respectively; (xxv) SEQ ID NOs: 122 and 128, respectively; (xxvi) SEQ ID NOs: 134 and 140, respectively; (xxvii) SEQ ID NOs: 146 and 152, respectively; (xxviii) SEQ ID NOs: 158 and 164, respectively; (xxix) SEQ ID NOs: 199 and 201, respectively; (xxx) SEQ ID NOs: 203 and 205 (xxxi) each of SEQ ID NOs: 207 and 209; (xxxii) each of SEQ ID NOs: 216 and 217; or (xxxiii) each of SEQ ID NOs: 228 and 230, comprising or consisting of an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to each of SEQ ID NOs: 228 and 230, respectively.
[0218] In one embodiment, the VH comprises or consists of any VH amino acid sequence shown in Table 1 and / or Table 2, and the VL comprises or consists of any VL amino acid sequence shown in Table 1 and / or Table 2.
[0219] In some embodiments, the VH and the VL are selected from the group consisting of (i) SEQ ID NOs: 2 and 8, respectively; (ii) SEQ ID NOs: 14 and 20, respectively; (iii) SEQ ID NOs: 26 and 32, respectively; (iv) SEQ ID NOs: 26 and 174, respectively; (v) SEQ ID NOs: 26 and 177, respectively; (vi) SEQ ID NOs: 26 and 180, respectively; (vii) SEQ ID NOs: 171 and 32, respectively; (viii) SEQ ID NOs: 171 and 174, respectively; (ix) SEQ ID NO: 1 (x) SEQ ID NOs: 171 and 180, respectively; (xi) SEQ ID NOs: 38 and 44, respectively; (xii) SEQ ID NOs: 50 and 56, respectively; (xiii) SEQ ID NOs: 62 and 68, respectively; (xiv) SEQ ID NOs: 74 and 80, respectively; (xv) SEQ ID NOs: 86 and 92, respectively; (xvi) SEQ ID NOs: 86 and 186, respectively; (xvii) SEQ ID NOs: 86 and 189, respectively; (xviii) SEQ ID NOs: 86 and 19 (xxviii) SEQ ID NOs: 158 and 164; (xxix) SEQ ID NOs: 199 and 201; (xxx) SEQ ID NOs: 203 and 205; (xxxi) SEQ ID NOs: 207 and 209; (xxxii) SEQ ID NOs: 216 and 217; or (xxxiii) SEQ ID NOs: 228 and 230, respectively.
[0220] Also provided herein is a polypeptide comprising an amino acid sequence according to SEQ ID NO: 219, which is capable of binding to influenza virus neuraminidase (NA). As demonstrated in the Examples herein, CDRH3 by the exemplified clonally related antibodies binds within the active site cavity (i.e., the enzymatic pocket) within NA.
[0221] In some embodiments, the polypeptide comprises an antibody heavy chain variable domain (VH) or fragment thereof, wherein the VH or fragment thereof optionally comprises an amino acid sequence according to SEQ ID NO: 219. In further embodiments, the amino acid sequence according to SEQ ID NO: 219 comprises any one of SEQ ID NOs: 149, 5, 17, 29, 172, 41, 53, 65, 77, 89, 184, 101, 113, 125, 137, and 161. In certain embodiments, the polypeptide or VH further comprises (i) an amino acid sequence according to SEQ ID NO: 220; and / or (ii) an amino acid sequence according to SEQ ID NO: 221.
[0222] In one embodiment, the polypeptide further comprises an antibody light chain variable domain (VL), optionally comprising: (i) an amino acid sequence according to SEQ ID NO: 222; (ii) an amino acid sequence according to SEQ ID NO: 223; and / or (iii) an amino acid sequence according to SEQ ID NO: 224.
[0223] In one embodiment, the VH comprises or consists of an amino acid sequence that is at least 90%, at least 92%, at least 95%, at least 97%, or at least 99% identical to the amino acid sequence of any one of SEQ ID NOs: 199, 2, 14, 26, 171, 38, 50, 62, 74, 86, 183, 98, 110, 122, 134, 146, 158, 203, 207, 216, and 228.
[0224] In some embodiments, the VL comprises or consists of an amino acid sequence that is at least 90%, at least 92%, at least 95%, at least 97%, or at least 99% identical to the amino acid sequence of any one of SEQ ID NOs: 201, 8, 20, 32, 44, 56, 68, 80, 92, 104, 116, 128, 140, 152, 174, 177, 180, 186, 189, 192, 164, 205, 209, 217, and 230.
[0225] In one embodiment, the VH comprises or consists of an amino acid sequence that is at least 90%, at least 92%, at least 95%, at least 97%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 199, and the VL comprises or consists of an amino acid sequence that is at least 90%, at least 92%, at least 95%, at least 97%, or at least 99% identical to the amino acid sequence of any one of SEQ ID NOs: 201.
[0226] In certain embodiments, the polypeptide comprises an antibody or an antibody-binding fragment thereof.
[0227] The antibody comprises an amino acid sequence of a heavy chain variable domain (VH) and an amino acid sequence of a light chain variable domain (VL), wherein the VH comprises or consists of an amino acid sequence that is at least 90%, at least 92%, at least 95%, at least 97%, or at least 99% identical to the amino acid sequence of any one of SEQ ID NOs: 199, 2, 14, 26, 171, 38, 50, 62, 74, 86, 183, 98, 110, 122, 134, 146, 158, 203, 207, 216, and 228. Also provided is an antibody or antibody-binding fragment thereof, wherein the VL comprises or consists of an amino acid sequence that is at least 90%, at least 92%, at least 95%, at least 97%, or at least 99% identical to the amino acid sequence of any one of SEQ ID NOs: 201, 8, 20, 32, 44, 56, 68, 80, 92, 104, 116, 128, 140, 152, 174, 177, 180, 186, 189, 192, 164, 205, 209, 217, and 230, and which is capable of binding to neuraminidase (NA) from (i) influenza A virus (IAV), including group 1 IAV, group 2 IAV, or both, and / or (ii) influenza B virus (IBV).
[0228] Also provided are antibodies or antigen-binding fragments thereof comprising a VH and a VL, wherein the VH comprises any combination of VH amino acid residues shown in Figures 2A, 56C, 57B, and 72A, and the VL comprises any combination of VL amino acid residues shown in Figure 72B. Briefly, the clonally related FNI antibodies shown in these figures all recognize NA. Some of these FNI antibodies contain different amino acids at one or more VH or VL positions than other FNI antibodies. Thus, disclosed embodiments include antibodies and antigen-binding fragments comprising a consensus VH amino acid sequence encompassing all variations and combinations of VH amino acid residues shown in the figures, and a VL amino acid sequence encompassing all variations and combinations of VL amino acid residues shown in the figures. Also provided are antibodies or antibody-binding fragments thereof capable of binding to (i) an NA epitope comprising any one or more of the following amino acids (N1 NA numbering): R368, R293, E228, E344, S247, D198, D151, R118; and / or (ii) an NA epitope comprising any one or more of the following amino acids (N2 NA numbering): R371, R292, E227, E344, S247, D198, D151, R118.
[0229] Also provided are antibodies or antibody-binding fragments thereof capable of binding to (i) an NA epitope comprising amino acids R368, R293, E228, D151, and R118 (N1 NA numbering); and / or (ii) an NA epitope comprising amino acids R371, R292, E227, D151, and R118 (N2 NA numbering).
[0230] Also provided are antibodies or antigen-binding fragments thereof capable of binding to an epitope contained in or comprising an NA active site, optionally comprising the following amino acids (N2 numbering): R118, D151, R152, R224, E276, R292, R371, Y406, E119, R156, W178, S179, D / N198, I222, E227, H274, E277, D293, E425. In some embodiments, the epitope further comprises any one or more of the following NA amino acids (N2 numbering): E344, E227, S247, and D198. In some embodiments, the antibody or antigen-binding fragment is capable of binding to an NA comprising an S245N amino acid mutation and / or an E221D amino acid mutation.
[0231] Also provided is an antibody or antigen-binding fragment thereof capable of binding to an NA epitope of IBV that includes any one or more of the following amino acids: R116, D149, E226, R292, and R374.
[0232] Also provided is an antibody or antigen-binding fragment thereof capable of binding to an NA epitope of IBV comprising amino acids R116, D149, E226, R292, and R374.
[0233] In some embodiments, the influenza comprises an influenza A virus, an influenza B virus, or both.
[0234] In some embodiments, the antibodies or antigen-binding fragments of the present disclosure are monospecific (e.g., bind to a single epitope) or multispecific (e.g., bind to multiple epitopes and / or target molecules). Antibodies and antigen-binding fragments can be configured in a variety of formats. Exemplary antibody formats are disclosed in Spiess et al., Mol. Immunol. 67(2):95(2015) and Brinkmann and Kontermann, mAbs 9(2):182-212(2017).These formats and methods for making them are incorporated herein by reference (formats include, for example, Bispecific T Cell Engagers (BiTEs), DARTs, Knobs-Into-Holes (KIH) assemblies, scFv-CH3-KIH assemblies, KIH common light chain antibodies, TandAbs, triple bodies, TriBi minibodies, Fab-scFv, scFv-CH-CL-scFv, F(ab')2-scFv2, tetravalent HCabs, intrabodies, CrossMAbs, dual acting Fabs (DAFs) (two-in-one or one-in-one). four-in-one functions), DutaMab, DT-IgG, charge pair, Fab arm exchange, SEED body, triomab, LUZ-Y assembly, Fcab, κλ-body, orthogonal Fab, DVD-Ig (see e.g., U.S. Patent No. 8,258,268, which formats are incorporated herein by reference in their entirety), IgG(H)-scFv, scFv-(H)IgG, IgG(L)-scFv, scFv-(L)IgG, IgG(L,H)-Fv, IgG(H)-V, V(H)-IgG, IgG(L)-V, V(L)-IgG, KIH IgG-scFab, 2scFv-IgG, IgG-2scFv, scFv4-Ig, Zy-body, and DVI-IgG (four-in-one), as well as the so-called FIT-Ig (e.g., PCT Publication No. WO2015 / 103072, these formats are incorporated herein by reference in their entirety), the so-called WuxiBody format (e.g., PCT Publication No. WO2019 / 057122, these formats are incorporated herein by reference in their entirety), and the so-called In-Elbow-Insert Ig format (IEI-Ig; e.g., PCT Publication Nos. WO2019 / 024979 and WO2019 / 025391, these formats are incorporated herein by reference in their entirety).
[0235] In certain embodiments, the antibody or antigen-binding fragment comprises two or more VH domains, two or more VL domains, or both (i.e., two or more VH domains and two or more VL domains). In particular embodiments, the antigen-binding fragment comprises (from N- to C-terminus) the format VH-linker-VL-linker-VH-linker-VL (wherein the two VH sequences may be the same or different, and the two VL sequences may be the same or different). Such linked scFvs can comprise any combination of VH and VL domains configured to bind a given target, and formats comprising two or more VHs and / or two or more VLs can bind one, two, or more different epitopes or antigens. It will be appreciated that formats incorporating multiple antigen-binding domains can comprise VH and / or VL sequences in any combination or orientation. For example, the antigen-binding fragment can comprise the format VL-linker-VH-linker-VL-linker-VH, VH-linker-VL-linker-VL-linker-VH, or VL-linker-VH-linker-VH-linker-VH-linker-VL.
[0236] Constructed monospecific or multispecific antibodies or antigen-binding fragments of the present disclosure can include any combination of VH and VL sequences, and / or any combination of CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3 sequences disclosed herein. Bispecific or multispecific antibodies or antigen-binding fragments, in some embodiments, can include one, two, or more antigen-binding domains (e.g., VH and VL) of the present disclosure. There can be two or more binding domains that bind to the same or different NA epitopes, and the bispecific or multispecific antibodies or antigen-binding fragments provided herein, in some embodiments, can include additional NA-specific binding domains and / or can include binding domains that bind to different antigens or pathogens altogether.
[0237] In any embodiment of the present disclosure, the antibody or antigen-binding fragment can be multispecific (multiple specificities; e.g., bispecific, trispecific, etc.).
[0238] In one embodiment, the antibody or antigen-binding fragment comprises an Fc polypeptide or fragment thereof. This "Fc" fragment or Fc polypeptide comprises the carboxy-terminal portions of both antibody heavy chains (i.e., the CH2 and CH3 domains of IgG) held together by disulfides. The Fc can comprise a dimer of two Fc polypeptides (i.e., two CH2-CH3 polypeptides). Antibody "effector functions" refer to the biological activities attributable to the Fc region of an antibody (a native-sequence Fc region or an amino acid sequence variant Fc region) and vary depending on the antibody isotype. Examples of antibody effector functions include C1q binding and complement-dependent cytotoxicity; Fc receptor binding; anti-dependent cellular cytotoxicity (ADCC); phagocytosis; down-regulation of cell surface receptors (e.g., B cell receptors); and B cell activation. As discussed herein, Fc-containing polypeptides (e.g., antibodies of the present disclosure) can be modified (e.g., by amino acid substitution) to alter (e.g., improve, reduce, or eliminate) one or more functions. Such functions include, for example, Fc receptor (FcR) binding, modification of antibody half-life (eg, by binding to FcRn), ADCC function, protein A binding, protein G binding, and complement fixation.Amino acid modifications that alter (e.g., improve, reduce, or eliminate) Fc function include, for example, T250Q / M428L, M252Y / S254T / T256E, H433K / N434F, M428L / N434S, E233P / L234V / L235A / G236+A327G / A330S / P3 31S, E333A, S239D / A330L / I332E, P257I / Q311, K326W / E333S, S239D / I332E / G236A, N297Q, K322A, S228P, L235E+E318A / K320A / K322A, L234A / L235A (also referred to herein as "LALA"), and and L234A / L235A / P329G mutations, which are summarized and annotated in "Engineered Fc Regions" published by InvivoGen (2011), available online at invivogen.com / PDF / review / review-Engineered-Fc-Regions-invivogen.pdf?utm_source=review&utm_medium=pdf&utm_campaign=review&utm_content=Engineered-Fc-Regions (incorporated herein by reference).
[0239] For example, to activate the complement cascade, the C1q protein complex can bind to at least two IgG1 molecules or one IgM molecule when the immunoglobulin molecule is attached to an antigenic target (Ward, ES, and Ghetie, V., Ther. Immunol. 2(1995)77-94). Burton, DR (Mol. Immunol. 22(1985)161-206) described that the heavy chain region containing amino acid residues 318-337 is involved in complement fixation. Duncan, AR, and Winter, G. (Nature 332(1988)738-740) used site-directed mutagenesis to report that Glu318, Lys320, and Lys322 form the binding site for C1q. The role of residues Glu318, Lys320, and Lys 322 in C1q binding was confirmed by the ability of short synthetic peptides containing these residues to inhibit complement-mediated lysis.
[0240] For example, binding to FcRs can be mediated by the interaction of the Fc portion (of an antibody) with specialized cell surface receptors on cells (including hematopoietic cells), called Fc receptors (FcRs). Fc receptors belong to the immunoglobulin superfamily and have been shown to mediate both the removal of antibody-coated pathogens by phagocytosis of immune complexes and the lysis of corresponding antibody-coated red blood cells and various other cellular targets (e.g., tumor cells) through antibody-dependent cellular cytotoxicity (ADCC; Van de Winkel, JG, and Anderson, CL, J. Leukoc. Biol. 49 (1991) 511-524). FcRs are defined by their specificity for each class of immunoglobulin; Fc receptors for IgG antibodies are called FcγR, those for IgE are called FcεR, those for IgA are called FcαR, and neonatal Fc receptors are called FcRn. Binding to Fc receptors is described, for example, in Ravetch, JV, and Kinet, JP, Annu. Rev. Immunol. 9(1991)457-492; Capel, PJ, et al., Immunomethods 4(1994)25-34; de Haas, M., et al., J Lab. Clin. Med. 126(1995)330-341, and Gessner, JE, et al., Ann. Hematol. 76(1998)231-248.
[0241] Cross-linking of receptors (FcγRs) by the Fc domain of native IgG antibodies initiates a variety of effector functions (including phagocytosis, antibody-dependent cellular cytotoxicity, and release of inflammatory mediators), as well as immune complex clearance and modulation of antibody production. The Fc moiety that provides cross-linking to receptors (e.g., FcγRs) is considered herein. In humans, three classes of FcγRs have been characterized to date: (i) FcγRI (CD64), which binds monomeric IgG with high affinity and is expressed on the surface of macrophages, monocytes, neutrophils, and eosinophils; (ii) FcγRII (CD32), which binds IgG with intermediate to low affinity in complexes, is widely expressed (especially on the surface of leukocytes), and is thought to play a central role in antibody-mediated immunity and can be classified as FcγRIIA, FcγRIIB, and FcγRIIC. (These receptors serve various functions in the immune system but bind IgG-Fc with similar low affinity, and the ectodomains of these receptors share a high degree of homology); and (iii) FcγRIII (CD16), which binds IgG with moderate to low affinity and exists in two forms: FcγRIIIA, which is found on the surface of NK cells, macrophages, eosinophils, and some monocytes and T cells and is thought to mediate ADCC; and FcγRIIIB, which is highly expressed on the surface of neutrophils.
[0242] FcγRIIA is found on the surface of many cells involved in killing (e.g., macrophages, monocytes, and neutrophils) and appears to be able to activate the killing process. FcγRIIB appears to play a role in inhibitory processes and is found on the surface of B cells, macrophages, mast cells, and eosinophils. Importantly, 75% of all FcγRIIB has been shown to be found in the liver (Ganesan, LP et al., 2012: "FcγRIIb on liver sinusoidal endothelium clears small immune complexes," Journal of Immunology 189: 4981-4988). FcγRIIB is abundantly expressed on the surface of liver sinusoidal endothelial cells (LSECs) and Kupffer cells in the liver, which are the primary site of clearance of small immune complexes (Ganesan, LP et al., 2012: FcγRIIb on liver sinusoidal endothelium clears small immune complexes. Journal of Immunology 189: 4981-4988).
[0243] In some embodiments, the antibodies and antigen-binding fragments thereof disclosed herein comprise an Fc polypeptide or fragment thereof (e.g., an IgG-type antibody) to bind to FcγRIIb (particularly the Fc region). Furthermore, the Fc portion can be engineered to enhance binding to FcγRIIb by introducing the mutations S267E and L328F, as described by Chu, SY et al., 2008: Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and FcgammaRIIb with Fc-engineered antibodies. Molecular Immunology 45, 3926-3933. Doing so can enhance the clearance of immune complexes (Chu, S., et al., 2014: Accelerated Clearance of IgE In Chimpanzees Is Mediated By Xmab7195, An Fc-Engineered Antibody With Enhanced Affinity For Inhibitory Receptor FcγRIIb. Am J Respir Crit, American Thoracic Society International Conference Abstracts). In some embodiments, the antibody or antigen-binding fragment thereof of the present disclosure comprises an engineered Fc portion with the mutations S267E and L328F, particularly as described by Chu, SY et al., 2008: Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and FcγRIIb with Fc-engineered antibody. Molecular Immunology 45, 3926-3933.
[0244] On the surface of B cells, FcγRIIB may function to suppress further immunoglobulin production and isotype switching, for example to IgE classes. On the surface of macrophages, FcγRIIB is thought to inhibit phagocytosis through FcγRIIA. On the surface of eosinophils and mast cells, the B forms may help suppress activation of these cells through IgE binding to their corresponding alternative receptors.
[0245] With respect to binding to FcγRI, modifications of at least one of E233-G236, P238, D265, N297, A327, and P329 in native IgG reduce binding to FcγRI. Substitution of IgG2 residues at positions 233-236 with those at the corresponding positions of IgG1 and IgG4 reduces binding of IgG1 and IgG4 to FcγRI by 10. 3 2-fold decrease and abolishment of human monocyte responses to antibody-sensitized red blood cells (Armour, KL, et al. Eur. J. Immunol. 29(1999)2613-2624).
[0246] With respect to binding to FcγRII, reduced binding to FcγRIIA is seen with at least one IgG mutation, e.g., E233 to G236, P238, D265, N297, A327, P329, D270, Q295, A327, R292, and K414.
[0247] The two allelic forms of human FcγRIIA are the "H131" variant, which binds IgG1 Fc with greater affinity, and the "R131" variant, which binds IgG1 Fc with lower affinity. See, e.g., Bruhns et al., Blood 113:3716-3725 (2009).
[0248] With respect to FcγRIII binding, reduced binding to FcγRIIIA is observed with mutations, for example, at least one of E233-G236, P238, D265, N297, A327, P329, D270, Q295, A327, S239, E269, E293, Y296, V303, A327, K338, and D376. Mapping of the binding site on human IgG1 for Fc receptors, the mutation sites described above, and methods for measuring binding to FcγRI and FcγRIIA are described in Shields, R.L., et al., J. Biol. Chem. 276(2001)6591-6604.
[0249] The two allelic forms of human FcγRIIIA are the "F158" variant, which binds IgG1 Fc with lower affinity, and the "V158" variant, which binds IgG1 Fc with greater affinity. See, e.g., Bruhns et al., Blood 113:3716-3725 (2009).
[0250] With regard to binding to FcγRII, two regions of native IgG Fc appear to be involved in the interaction between FcγRII and IgG: (i) the lower hinge region of IgG Fc, specifically amino acid residues L, L, G, G (234-237, EU numbering); and (ii) adjacent regions of the CH2 domain of IgG Fc, specifically loops and chains in the upper CH2 domain adjacent to the lower hinge region, e.g., in the region of P331 (Wines, BD, et al., J. Immunol. 2000; 164: 5313-5318). Furthermore, FcγRI appears to bind to the same site on IgG Fc, whereas FcRn and protein A bind to different sites on IgG Fc that appear to be located at the CH2-CH3 interface (Wines, BD, et al., J. Immunol. 2000; 164: 5313-5318).
[0251] Mutations that increase the binding affinity of an Fc polypeptide or fragment thereof of the present disclosure to one (i.e., one or more) Fcγ receptor (e.g., compared to a reference Fc polypeptide or fragment thereof, or the same containing no mutations) are also contemplated. See, e.g., Delillo and Ravetch, Cell 161(5):1035-1045 (2015) and Ahmed et al., J. Struc. Biol. 194(1):78 (2016), the Fc mutations and Fc mutation techniques of which are incorporated herein by reference.
[0252] In any embodiment disclosed herein, the antibody or antigen-binding fragment may comprise an Fc polypeptide or fragment thereof comprising one mutation selected from G236A; S239D; A330L; and I332E; or a combination comprising any two or more thereof; e.g., S239D / I332E; S239D / A330L / I332E; G236A / S239D / I332E; G236A / A330L / I332E (also referred to herein as "GAALIE"); or G236A / S239D / A330L / I332E. In some embodiments, the Fc polypeptide or fragment thereof does not comprise S239D. In some embodiments, the Fc polypeptide or fragment thereof comprises an S at position 239 (EU numbering).
[0253] In some embodiments, the Fc polypeptide or fragment thereof can comprise or consist of at least a portion of an Fc polypeptide or fragment thereof involved in binding to FcRn. In some embodiments, the Fc polypeptide or fragment thereof comprises one or more amino acid modifications that improve binding affinity (e.g., enhance binding) to FcRn (e.g., at a pH of about 6.0), thereby extending the in vivo half-life of a molecule comprising the Fc polypeptide or fragment thereof (e.g., compared to a reference Fc polypeptide or fragment thereof, or an otherwise identical antibody that does not comprise the modifications). In some embodiments, the Fc polypeptide or fragment thereof comprises or is derived from an IgG Fc, and the half-life-extending mutations include any one or more of M428L; N434S; N434H; N434A; N434S; M252Y; S254T; T256E; T250Q; P257I Q311I; D376V; T307A; E380A (EU numbering). In some embodiments, the half-life extending mutations include M428L / N434S (also referred to herein as "MLNS," "LS," "_LS," and "-LS"). In some embodiments, the half-life extending mutations include M252Y / S254T / T256E. In some embodiments, the half-life extending mutations include T250Q / M428L. In some embodiments, the half-life extending mutations include P257I / Q311I. In some embodiments, the half-life extending mutations include P257I / N434H. In some embodiments, the half-life extending mutations include D376V / N434H. In some embodiments, the half-life extending mutations include T307A / E380A / N434A.
[0254] In some embodiments, the antibody or antigen-binding fragment comprises an Fc portion comprising the substitution mutations M428L / N434S. In some embodiments, the antibody or antigen-binding fragment comprises an Fc polypeptide or fragment thereof comprising the substitution mutations G236A / A330L / I332E. In certain embodiments, the antibody or antigen-binding fragment comprises an Fc portion (e.g., an IgG) comprising the G236A, A330L, and I332E mutations (GAALIE), but not the S239D mutation (e.g., comprising a natural S at position 239). In particular embodiments, the antibody or antigen-binding fragment comprises an Fc polypeptide or fragment thereof comprising the substitution mutations M428L / N434S and G236A / A330L / I332E, optionally excluding S239D (e.g., comprising an S at position 239). In certain embodiments, the antibody or antigen-binding fragment comprises an Fc polypeptide or fragment thereof comprising the substitution mutations M428L / N434S and G236A / S239D / A330L / I332E.
[0255] In some embodiments, the antibody or antigen-binding fragment comprises a mutation that alters glycosylation (including N297A, N297Q, or N297G), and / or the antibody or antigen-binding fragment is partially or completely deglycosylated and / or partially or completely defucosylated. Host cell lines and methods for producing partially or completely deglycosylated or partially or completely defucosylated antibodies and antigen-binding fragments are known (see, e.g., PCT Publication No. WO2016 / 181357; Suzuki et al. Clin. Cancer Res. 13(6):1875-82(2007); Huang et al. MAbs 6:1-12(2018)).
[0256] In some embodiments, the antibody or antigen-binding fragment can induce continued protection in a subject even when detectable levels of the antibody or antigen-binding fragment are no longer found in the subject (i.e., when the antibody or antigen-binding fragment is excreted from the subject after administration). Such protection is referred to herein as a vaccine effect. Without wishing to be bound by theory, it is believed that dendritic cells can induce or contribute to an endogenous immune response to the antigen after internalizing the antibody-antigen complex. In some embodiments, the antibody or antigen-binding fragment contains one or more modifications (e.g., mutations in Fc including G236A, A330L, and I332E) that can activate dendritic cells, which may induce T cell immunity against the antigen, for example.
[0257] In any embodiment of the present disclosure, the antibody or antigen-binding fragment comprises an Fc polypeptide or fragment thereof, including a CH2 (or fragment thereof), a CH3 (or fragment thereof), or a CH2 and a CH3, wherein the CH2, CH3, or both can be of any isotype and can contain amino acid substitutions or other modifications compared to the corresponding wild-type CH2 or CH3, respectively. In one embodiment, an Fc polypeptide of the present disclosure comprises two CH2-CH3 polypeptides that associate to form a dimer.
[0258] In any embodiment of the present disclosure, the antibody or antigen-binding fragment can be monoclonal. The term "monoclonal antibody" (mAb) is used herein to refer to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for natural mutations that may be present in some cases at minor levels. Monoclonal antibodies are highly specific, being directed against a single antigenic site. Furthermore, unlike polyclonal antibody preparations, which include different antibodies directed against different epitopes, each monoclonal antibody is directed against a single epitope on the antigen. In addition to their specificity, monoclonal antibodies are advantageous in that they may be synthesized uncontaminated by other antibodies. The term "monoclonal" should not be construed as requiring production of the antibody by any particular method. For example, monoclonal antibodies useful in the present invention can be prepared by the hybridoma method first described by Kohler et al., Nature 256:495 (1975), or can be made in bacterial, eukaryotic, or plant cells using recombinant DNA methodologies (see, e.g., U.S. Pat. No. 4,816,567). Monoclonal antibodies can also be isolated from phage antibody libraries using the techniques described, for example, in Clackson et al., Nature, 352:624-628 (1991) and Marks et al., J. Mol. Biol., 222:581-597 (1991). Monoclonal antibodies can also be obtained using the methods disclosed in PCT Publication No. WO2004 / 076677A2.
[0259] The antibodies and antigen-binding fragments of the present disclosure include "chimeric antibodies" (in which a portion of the heavy and / or light chain is identical to or homologous to corresponding sequences in antibodies from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain is identical to or homologous to corresponding sequences in antibodies from another species or belonging to another antibody class or subclass), as well as fragments of such antibodies, provided they exhibit the desired biological activity (see U.S. Patent Nos. 4,816,567; 5,530,101; and 7,498,415; Morrison et al., Proc. Natl. Acad. Sci. USA, 81:6851-6855 (1984)). For example, chimeric antibodies may contain human and non-human residues. Furthermore, chimeric antibodies may contain residues that are not found in the recipient antibody or in the donor antibody. These modifications may be made to further refine antibody performance. For more details, see Jones et al., Nature 321:522-525 (1986); Riechmann et al., Nature 332:323-329 (1988); and Presta, Curr. Op. Struct. Biol. 2:593-596 (1992). Chimeric antibodies also include primatized and humanized antibodies.
[0260] A "humanized antibody" is generally considered to be a human antibody with one or more amino acid residues introduced from a non-human source. These non-human amino acid residues are typically taken from the variable domain. Humanization can be performed by substituting non-human variable sequences for the corresponding sequences of a human antibody according to the method of Winter and coworkers (Jones et al., Nature, 321:522-525 (1986); Reichmann et al., Nature, 332:323-327 (1988); Verhoeyen et al., Science, 239:1534-1536 (1988)). Such "humanized" antibodies are thus chimeric antibodies in which substantially less intact human variable domains have been substituted with the corresponding sequences from a non-human species (U.S. Patent Nos. 4,816,567; 5,530,101; and 7,498,415). In some cases, a "humanized" antibody is an antibody produced by a non-human cell or animal and contains human sequences, e.g., H C Includes the domain.
[0261] A "human antibody" is an antibody that contains only sequences present in antibodies produced by humans (i.e., sequences encoded by genes encoding human antibodies). However, as used herein, human antibodies may contain residues or modifications (including modified and variant sequences described herein) that are not found in naturally occurring human antibodies (e.g., antibodies isolated from humans). These are typically made to refine or enhance antibody performance. In some cases, human antibodies are produced by transgenic animals. See, e.g., U.S. Patent Nos. 5,770,429; 6,596,541; and 7,049,426.
[0262] In certain embodiments, the antibodies or antigen-binding fragments of the present disclosure are chimeric, humanized, or human.
[0263] In some embodiments, various pharmacokinetic ("PK") parameters are used to describe or characterize the antibodies or antigen-binding fragments presented herein. Details regarding collection of antibody serum concentrations for the purposes of assessing PK parameters are provided in connection with the Examples herein. 1 / 2 The term "C" or "half-life" refers to the elimination half-life of an antibody or antigen-binding fragment contained in a pharmaceutical composition administered to a subject. last " generally refers to a final measurable plasma concentration (i.e., the substance is no longer present in the plasma in measurable concentrations).
[0264] In any embodiment of the present disclosure, the antibody or antigen-binding fragment can comprise the CH1-CH3 amino acid sequence set forth in SEQ ID NO:210 and / or the CH1-CH3 amino acid sequence set forth in SEQ ID NO:215.
[0265] In any embodiment of the present disclosure, the antibody or antigen-binding fragment can comprise the CL amino acid sequence shown in SEQ ID NO:211.
[0266] In some embodiments, the heavy chain amino acid sequence shown in SEQ ID NO: 212: QVQLVQSGAEVKEPGSSVTVSCKASGGTFSNNVISWVRQAPGQGLEWMGGIIPTSGIANYAQKFQGRVAIIADKSTSTVYMALSSLRSEDSAVYFCARARSDYFNRDLGWEDYYFENWG QGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPP An antibody comprising CPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEALHSHYTQKSLSLSPGK (SEQ ID NO: 212) is provided.
[0267] In one embodiment, the antibody further comprises the light chain amino acid sequence set forth in SEQ ID NO: 214: EIVMTQSPATLSVSPGERATLSCRASQSVGSSLAWYQQKPGQAPRLLIYGASTRATGVPARFSGSGSGTEFTLTISSLQSEDFAVYYCQHYNNWPPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 214).
[0268] In some embodiments, the heavy chain amino acid sequence shown in SEQ ID NO: 213: QVQLVQSGAEVKEPGSSVTVSCKASGGTFSNNVISWVRQAPGQGLEWMGGIIPTSGIANYAQKFQGRVAIIADKSTSTVYMALSSLRSEDSAVYFCARARSDYFNRDLGWEDYYFENWG QGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPP An antibody comprising CPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEALHSHYTQKSLSLSPG (SEQ ID NO: 213) is provided.
[0269] In one embodiment, the antibody further comprises the light chain amino acid sequence set forth in SEQ ID NO: 214: EIVMTQSPATLSVSPGERATLSCRASQSVGSSLAWYQQKPGQAPRLLIYGASTRATGVPARFSGSGSGTEFTLTISSLQSEDFAVYYCQHYNNWPPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 214).
[0270] In some embodiments, an antibody is provided that comprises: (1) two heavy chains, each comprising the amino acid sequence set forth in SEQ ID NO: 212, and (2) two light chains, each comprising the amino acid sequence set forth in SEQ ID NO: 214.
[0271] In some embodiments, an antibody is provided that comprises: (1) two heavy chains, each comprising the amino acid sequence set forth in SEQ ID NO: 213, and (2) two light chains, each comprising the amino acid sequence set forth in SEQ ID NO: 214.
[0272] Polynucleotides, Vectors, and Host Cells
[0273] In another aspect, the present disclosure provides isolated polynucleotides encoding any of the antibodies or antigen-binding fragments thereof (e.g., CDRs, VH, VL, heavy chain, or light chain, or heavy and light chains) of the present disclosure, or encoding a polypeptide of the present disclosure.
[0274] In one embodiment, the polynucleotide comprises deoxyribonucleic acid (DNA) or ribonucleic acid (RNA), which RNA optionally comprises messenger RNA (mRNA).
[0275] In some embodiments, the polynucleotide comprises a modified nucleoside, a Cap-1 structure, a Cap-2 structure, or any combination thereof. In certain embodiments, the polynucleotide comprises pseudouridine, N6-methyladenosine, 5-methylcytidine, 2-thiouridine, or any combination thereof. In some embodiments, the pseudouridine comprises N1-methylpseudouridine.
[0276] In certain embodiments, the polynucleotide is selected from the group consisting of SEQ ID NOs: 198, 200, 1, 13, 25, 170, 37, 49, 61, 73, 85, 182, 97, 109, 121, 133, 145, 157, 6, 18, 30, 42, 54, 66, 78, 90, 102, 114, 126, 138, 150, 162, 7, 19, 31, 173, 176, 179, 43, 55, 67, 79, 91, 185, 188, 191, 103, 115, 127, 139, 151, 163, 12, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 78, 90, 102, 114, 126, 138, 150, 162, 173, 176, 179, 43, 55, 67, 79, 91, 1 4, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 202, 206, 204, 208, 227, and 229.
[0277] In one embodiment, the polynucleotide is codon-optimized for expression in a host cell (e.g., a human cell or a CHO cell). Once the coding sequence is known or identified, codon optimization can be performed using known techniques and tools (e.g., the GenScript® OptimiumGene™ tool, etc.). Codon-optimized sequences include partially codon-optimized sequences (i.e., sequences in which one or more codons have been optimized for expression in a host cell) and fully codon-optimized sequences.
[0278] In particular embodiments, the polynucleotide comprises the polynucleotide sequence of SEQ ID NO:198 and the polynucleotide sequence of SEQ ID NO:200.
[0279] It will also be recognized that polynucleotides encoding the antibodies and antigen-binding fragments of the present disclosure may have different polynucleotide sequences and still encode the same antibody or antigen-binding fragment due to, for example, degeneracy of the genetic code, splicing, etc.
[0280] In any embodiment of the present disclosure, the polynucleotide can comprise deoxyribonucleic acid (DNA) or ribonucleic acid (RNA). In some embodiments, the RNA comprises messenger RNA (mRNA).
[0281] Vectors are also provided. The vectors comprise or contain the polynucleotides disclosed herein (e.g., polynucleotides encoding antibodies, antigen-binding fragments, or polypeptides that bind to the NA of IAV). The vectors can comprise any one or more of the vectors disclosed herein. In specific embodiments, vectors are provided that comprise DNA plasmid constructs encoding antibodies or antigen-binding fragments, or portions thereof (e.g., so-called "DMAbs"; see, e.g., Muthumani et al., J Infect Dis. 214(3):369-378(2016); Muthumani et al., Hum Vaccin Immunother 9:2253-2262(2013)); Flingai et al., Sci Rep. 5:12616(2015); and Elliott et al., NPJ Vaccines 18(2017); the DNA constructs encoding the antibodies and related methods of use, including administration thereof, are incorporated herein by reference). In certain embodiments, the DNA plasmid construct comprises a single open reading frame encoding the heavy and light chains (or VH and VL) of the antibody or antigen-binding fragment, wherein the heavy chain-encoding sequence and the light chain-encoding sequence are optionally separated by a polynucleotide encoding a protease cleavage site and / or a polynucleotide encoding a self-cleaving peptide. In some embodiments, the replacement components of the antibody or antigen-binding fragment are encoded by polynucleotides contained in a single plasmid. In other embodiments, the replacement components of the antibody or antigen-binding fragment are encoded by polynucleotides contained in two or more plasmids (e.g., a first plasmid contains polynucleotides encoding the heavy chain, VH, or VH+CH, and a second plasmid contains polynucleotides encoding the cognate light chain, VL, or VL+CL). In certain embodiments, a single plasmid contains polynucleotides encoding the heavy and / or light chains from two or more antibodies or antigen-binding fragments of the present disclosure. One exemplary expression vector is pVax1, available from Invitrogen®.The DNA plasmids of the present disclosure can be delivered to a subject, for example, by electroporation (e.g., intramuscular electroporation) or with an appropriate formulation (e.g., hyaluronidase).
[0282] In some embodiments, methods are provided that include administering to a subject a first polynucleotide (e.g., mRNA) encoding an antibody heavy chain, VH, or Fd (VH+CH1), and administering to the subject a second polynucleotide (e.g., mRNA) encoding a cognate antibody light chain, VL, or VL+CL.
[0283] In some embodiments, polynucleotides (e.g., mRNA) encoding heavy and light chains of an antibody or antigen-binding fragment thereof are provided. In some embodiments, polynucleotides (e.g., mRNA) encoding two heavy and two light chains of an antibody or antigen-binding fragment thereof are provided. See, for example, Li, JQ., Zhang, ZR., Zhang, HQ. et al. Intranasal delivery of replicating mRNA encoding neutralizing antibody against SARS-CoV-2 infection in mice. Sig Transduct Target Ther 6, 369(2021). https: / / doi.org / 10.1038 / s41392-021-00783-1 (antibody-encoding mRNA constructs, vectors, and related technology are incorporated herein by reference). In some embodiments, the polynucleotide is delivered to a subject using an alphavirus replicon particle (VRP) delivery system. In some embodiments, the replicon comprises a modified VEEV replicon comprising two subgenomic promoters. In some embodiments, the polynucleotide or replicon is capable of co-translating the heavy chain (or VH, or VH+1) and the light chain (or VL, or VL+CL) of an antibody or antigen-binding fragment thereof. In some embodiments, methods are provided that include delivering such a polynucleotide or replicon to a subject.
[0284] In a further aspect, the present disclosure also provides a host cell that expresses an antibody or antigen-binding fragment according to the disclosure, or that comprises or contains a vector or polynucleotide according to the disclosure.
[0285] Non-limiting examples of such cells include eukaryotic cells (e.g., yeast cells, animal cells, insect cells, plant cells) and prokaryotic cells (including E. coli). In some embodiments, the cell is a mammalian cell (such as a human B cell). In some such embodiments, the cells are mammalian cell lines, such as CHO cells (e.g., DHFR-CHO cells (Urlaub et al., PNAS 77:4216 (1980)), human embryonic kidney cells (e.g., HEK293T cells), PER.C6 cells, YO cells, Sp2 / 0 cells, NS0 cells, human hepatocytes (e.g., Hepa RG cells), myeloma cells, or hybridoma cells. Other examples of mammalian host cell lines include mouse Sertoli cells (e.g., TM4 cells); SV40-transformed monkey kidney CV1 line (COS-7); baby hamster kidney cells (BHK); African green monkey kidney cells (VERO-76); monkey kidney cells (CV1); human cervical carcinoma cells (HELA); human lung cells (W138); human hepatocytes (Hep G2); canine kidney cells (MDCK); buffalo rat liver cells (BRL 3A); mouse mammary carcinoma cells (MMT 060562); TRI cells; MRC 5 cells; and FS4 cells. Suitable mammalian host cell lines for antibody production also include those described, for example, in Yazaki and Wu, Methods in Molecular Biology, Vol. 248 (BKC Lo, ed., Humana Press, Totowa, NJ), pp. 255-268 (2003).
[0286] In one embodiment, the host cell is a prokaryotic cell (e.g., E. coli). Expression of peptides in prokaryotic cells (e.g., E. coli) is well established (see, e.g., Pluckthun, A. Bio / Technology 9: 545-551 (1991)). For example, antibodies can be produced in bacteria, particularly when glycosylation and Fc effector functions are required. For expression of antibody fragments and polypeptides in bacteria, see, e.g., U.S. Patent Nos. 5,648,237; 5,789,199; and 5,840,523.
[0287] In particular embodiments, a vector of the present disclosure carrying an expression vector can be transfected into a cell. The term "transfection" refers to the introduction of a nucleic acid molecule (such as a DNA or RNA (e.g., mRNA) molecule) into a cell (such as a eukaryotic cell). In the context of this specification, the term "transfection" encompasses any method known to those skilled in the art for introducing a nucleic acid molecule into a cell (such as a eukaryotic cell, including a mammalian cell). Such methods include, for example, electroporation, lipofection (e.g., based on cationic lipids and / or liposomes), calcium phosphate precipitation, nanoparticle-based transfection, virus-based transfection, or cationic polymer (such as DEAE-dextran or polyethyleneimine)-based transfection. In certain embodiments, the introduction is non-viral.
[0288] Additionally, host cells of the present disclosure can be stably or transiently transfected with vectors according to the present disclosure, for example, to express an antibody or antigen-binding fragment thereof according to the present disclosure. In such embodiments, the cells can be stably transfected with a vector described herein. Alternatively, the cells can be transiently transfected with a vector according to the present disclosure encoding an antibody or antigen-binding fragment disclosed herein. In any embodiment of the present disclosure, the polynucleotide can be heterologous to the host cell.
[0289] Accordingly, the present disclosure also provides recombinant host cells that heterologously express an antibody or antigen-binding fragment of the present disclosure. For example, the cell can be of a species different from the species from which all or part of the antibody was obtained (e.g., a CHO cell expressing a human antibody or an engineered human antibody). In some embodiments, the host cell's cell type does not naturally express the antibody or antigen-binding fragment. Furthermore, the host cell can impart post-translational modifications (PTMs; e.g., glycosylation or fucosylation) to the antibody or antigen-binding fragment that are not present in the native state of the antibody or antigen-binding fragment (or the native parent antibody from which the antibody or antigen-binding fragment was engineered or derived). Such PTMs can result in different function (e.g., reduced immunogenicity). Thus, the antibody or antigen-binding fragment of the present disclosure produced by a host cell of the present disclosure can contain one or more post-translational modifications that differ from the native state of the antibody (or parent antibody) (e.g., a human antibody produced by a CHO cell can contain more post-translational modifications that differ from the antibody when isolated from a human and / or when produced by natural human B cells or plasma cells).
[0290] Insect cells useful for expressing the binding proteins of the present disclosure are known in the art and include, for example, Fall Armyworm Sf9 cells, Common Looper BTI-TN5B1-4 cells, and Fall Armyworm SfSWT01 "Mimic™" cells. See, e.g., Palmberger et al., J. Biotechnol. 153(3-4):160-166 (2011). Numerous baculovirus strains have been identified that can be used in combination with insect cells, particularly for transfection of Fall Armyworm cells.
[0291] Eukaryotic microbes, such as filamentous fungi or yeast, are also suitable hosts for cloning or expressing protein-encoding vectors. Included among these are fungal and yeast strains with "humanized" glycosylation pathways, which produce antibodies with partially or fully human glycosylation patterns. See Gerngross, Nat. Biotech. 22:1409-1414 (2004); Li et al., Nat. Biotech. 24:210-215 (2006).
[0292] Plant cells can also be used as hosts for expressing the binding proteins of the present disclosure, for example, by producing antibodies in transgenic plants using PL Antibody™ technology (e.g., as described in U.S. Patent Nos. 5,959,177; 6,040,498; 6,420,548; 7,125,978; and 6,417,429).
[0293] In certain embodiments, the host cell comprises a mammalian cell. In particular embodiments, the host cell is a CHO cell, a HEK293 cell, a PER.C6 cell, a Y0 cell, a Sp2 / 0 cell, an NS0 cell, a human hepatocyte, a myeloma cell, or a hybridoma cell.
[0294] In a related aspect, the present disclosure provides a method for producing an antibody or antigen-binding fragment. The method includes culturing a host cell of the present disclosure under conditions and for a time sufficient to produce the antibody or antigen-binding fragment. A useful method for isolating and purifying a recombinantly produced antibody can include, for example, obtaining a supernatant from a suitable host cell / vector system that secretes the recombinant antibody into the culture medium, followed by concentrating the culture medium using a commercially available filter. After concentration, the concentrate can be applied to a suitable purification matrix or a series of suitable matrices, such as an affinity matrix or ion exchange resin. One or more reverse-phase HPLC steps can be used to further purify the recombinant polypeptide. These purification methods can also be used when isolating an immunogen from its native environment. Large-scale production of one or more of the isolated / recombinant antibodies described herein can include batch cell cultures that are monitored and controlled to maintain appropriate culture conditions. Purification of soluble antibodies can be carried out according to methods described herein and known in the art and consistent with the laws and guidelines of domestic and international regulatory authorities.
[0295] composition
[0296] Also provided herein are compositions comprising the antibodies, antigen-binding fragments, polypeptides, polynucleotides, vectors, or host cells of the present disclosure, alone or in any combination, and which can further comprise a pharmaceutically acceptable carrier, excipient, or diluent. Such compositions, as well as carriers, excipients, and diluents, are discussed in more detail herein.
[0297] In some embodiments, the composition comprises a first vector containing a first plasmid and a second vector containing a second plasmid, wherein the first plasmid contains a polynucleotide encoding the heavy chain, VH, or VH+CH, of the antibody or antigen-binding fragment thereof, and the second plasmid contains a polynucleotide encoding the cognate light chain, VL, or VL+CL. In some embodiments, the composition comprises a polynucleotide (e.g., mRNA) coupled to a suitable delivery vehicle or carrier. Exemplary vehicles or carriers suitable for administration to human subjects include lipid or lipid-derived delivery vehicles, such as liposomes, solid lipid nanoparticles, oil suspensions, submicron lipid emulsions, lipid microbubbles, reversed-phase lipid micelles, cochlear liposomes, lipid microtubules, lipid microcylinders, or lipid nanoparticles (LNPs), or nanoscale platforms (see, e.g., Li et al. Wilery Interdiscip Rev. Nanomed Nanobiotechnol. 11(2):e1530(2019)). The principles, reagents, and techniques for designing appropriate mRNAs, formulating mRNA-LNPs, and delivering them have been described, for example, by Pardi et al. (J Control Release 217345-351(2015)); Thess et al. (Mol Ther 23: 1456-1464(2015)); Thran et al. (EMBO Mol Med 9(10):1434-1448(2017); Kose et al. (Sci. Immunol. 4 eaaw6647(2019); and Sabnis et al. (Mol. Ther. 26:1509-1519 (2018)), which techniques include capping, codon optimization, nucleoside modification, mRNA purification, incorporation of mRNA into stable lipid nanoparticles (e.g., ionizable cationic lipid / phosphatidylcholine / cholesterol / PEG-lipid; ionizable lipid:distearoyl PC:cholesterol:polyethylene glycol lipid), and its administration subcutaneously, intramuscularly, intradermally, intravenously, intraperitoneally, and intrathecally, which techniques are incorporated herein by reference.
[0298] In certain embodiments, the composition comprises a first antibody or antigen-binding fragment of the present disclosure and a second antibody or antigen-binding fragment of the present disclosure, wherein the first antibody or antigen-binding fragment and the second antibody or antigen-binding fragment are different.
[0299] Methods and Uses
[0300] Also provided herein are methods that utilize the antibodies or antigen-binding fragments, nucleic acids, vectors, cells, or compositions of the disclosure in diagnosing influenza infection (e.g., in a human subject or in a sample obtained from a human subject).
[0301] Diagnostic methods (e.g., in vitro, ex vivo) can include contacting an antibody or antibody fragment (e.g., an antigen-binding fragment) with a sample. Such samples can be isolated from a subject, such as tissue samples isolated from the nasal cavity, paranasal sinuses, salivary glands, lungs, liver, pancreas, kidneys, ears, eyes, placenta, trachea, heart, ovaries, pituitary gland, adrenal gland, thyroid gland, brain, skin, or blood. Diagnostic methods can also include detecting antigen / antibody complexes, particularly after contacting the antibody or antibody fragment with the sample. Such detection steps can be performed on the bench, i.e., without contact with the human or animal body. Exemplary detection methods are well known to those skilled in the art and include, for example, ELISA (enzyme-linked immunosorbent assay; including direct, indirect, and sandwich ELISA).
[0302] Also provided herein are methods of treating a subject suffering from, suspected of suffering from, or at risk of infection with influenza using an antibody or antigen-binding fragment of the present disclosure, or a composition comprising the same. "Treating," "treatment," or "ameliorating" refers to the medical management of a disease, disorder, or condition in a subject (e.g., a human or non-human mammal, such as a primate, horse, cat, dog, goat, mouse, or rat). Generally, an appropriate dose or treatment regimen comprising an antibody or composition of the present disclosure is administered in an amount sufficient to induce a therapeutic or prophylactic benefit. Treatment or prophylactic / preventive benefit includes improved clinical outcome; reduction or alleviation of symptoms associated with the disease; reduced occurrence of symptoms; improved quality of life; a longer disease-free state; reduced disease extent, stabilization of the disease state; delay or prevention of disease progression; remission; survival; extended survival; or any combination thereof. In certain embodiments, treatment or prophylactic / preventive benefit includes a (statistically significant) reduction or prevention of hospitalization related to treatment of influenza infection. In some embodiments, therapeutic or prophylactic / preventive benefit includes a (statistically significant) reduction in hospital stay for treatment of infection. In some embodiments, therapeutic or prophylactic / preventive benefit includes a reduction or cessation of respiratory intervention (such as intubation) and / or use of a ventilator. In some embodiments, therapeutic or prophylactic / preventive benefit includes a reversal of late-stage disease symptoms and / or a reduction in mortality.
[0303] A "therapeutically effective amount" or "effective amount" of an antibody, antigen-binding fragment, polynucleotide, vector, host cell, or composition of the present disclosure refers to the amount of a composition or molecule sufficient to provide a therapeutic effect, including improved clinical outcome; reduction or alleviation of symptoms associated with the disease; reduced incidence of symptoms; improved quality of life; longer disease-free period; reduced spread of the disease; stabilization of the disease state; delayed disease progression; remission; survival; or statistically significantly prolonged survival. When referring to an individual active ingredient administered alone, a therapeutically effective amount refers to the effect of that ingredient or the effect of cells expressing that ingredient alone. When referring to a combination, a therapeutically effective amount refers to the combined amount of active ingredients, or the combination of complementary active ingredients and cells expressing one active ingredient, that results in a therapeutic effect, regardless of whether administered sequentially, sequentially, or simultaneously.
[0304] Thus, in certain embodiments, there is provided a method of treating influenza infection in a subject, the method comprising administering to the subject an effective amount of an antibody, antigen-binding fragment, polynucleotide, vector, host cell, or composition disclosed herein.
[0305] Subjects that can be treated according to the present disclosure are generally human and other primate subjects (such as monkeys and apes for veterinary purposes). Other model organisms (such as mice and rats) may also be treatable according to the present disclosure. In any of the above embodiments, the subject can be a human subject. The subject can be male or female and of any appropriate age, including infants, juveniles, adolescents, adults, and elderly subjects.
[0306] Numerous factors are believed to contribute to a greater risk of severe symptoms or death associated with influenza infection. Non-limiting examples include age, occupation, overall health, pre-existing health conditions, and lifestyle. In some embodiments, subjects treated according to the present disclosure include one or more risk factors.
[0307] In some embodiments, the subject treated according to the present disclosure is an infant, child, adolescent, middle-aged, or elderly. In some embodiments, the human subject treated according to the present disclosure is under 1 year old, or 1-5 years old, or 5-125 years old (e.g., 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, or 125 years old, including any age therebetween). In some embodiments, the human subject treated according to the present disclosure is 0-19 years old, 20-44 years old, 45-54 years old, 55-64 years old, 65-74 years old, 75-84 years old, or 85 years old or older. Middle-aged and elderly subjects, particularly the latter, are considered to be at particular risk. In particular embodiments, the human subject is 45-54 years old, 55-64 years old, 65-74 years old, 75-84 years old, or 85 years old or older. In some embodiments, the human subject is male. In some embodiments, the human subject is female.
[0308] In some embodiments, a subject treated according to the present disclosure has received an influenza vaccine, but the vaccine has been determined to be ineffective, e.g., by post-vaccine infection or symptoms in the subject, or by clinical diagnosis, or by scientific or regulatory consensus.
[0309] Prevention of influenza virus infection is particularly relevant in a preventative setting, where the subject has not been diagnosed with influenza virus infection (i.e., no diagnosis was made or the diagnosis was negative) and / or the subject is not showing or experiencing symptoms of influenza virus infection. Prevention of influenza virus infection is particularly useful in subjects who are at greater risk of severe illness or complications if infected, such as pregnant women, children (e.g., children under 59 months of age), elderly individuals with chronic physical illnesses (e.g., chronic cardiac, pulmonary, renal, metabolic, neurodevelopmental, liver, or blood disorders), and individuals with immunosuppressive conditions (e.g., HIV / AIDS, those receiving chemotherapy or steroids, or malignancies). Furthermore, prevention of influenza virus infection is particularly useful in subjects who are at greater risk of influenza virus infection, e.g., due to increased exposure, such as subjects working or staying in public places (e.g., healthcare workers).
[0310] In some embodiments, the treatment is administered as prophylaxis immediately before, after, or before exposure. In some embodiments, the treatment is administered as prophylaxis post-exposure.
[0311] Conversely, in a therapeutic setting, the subject is typically infected with, diagnosed with, and / or exhibiting symptoms of influenza virus infection. Notably, the terms "treatment" and "therapy" / "therapeutic" of influenza virus infection can refer to a (complete) cure of influenza virus infection and / or associated symptoms, as well as a reduction / reduction (e.g., a reduction / reduction in the severity of the infection and / or symptoms, the number of symptoms, the duration of the infection and / or symptoms, or any combination thereof) of the influenza virus infection and / or associated symptoms.
[0312] References herein to a reduction in the number and / or severity of symptoms resulting from administration of a pharmaceutical composition of the present disclosure will be understood to refer to a comparison with a reference subject who did not receive the disclosed pharmaceutical composition. The reference subject can be, for example, (i) the same subject from a previous period (e.g., a previous influenza A virus season), (ii) a subject with the same or similar age or age group, sex, pregnancy status, chronic physical illness (such as a chronic cardiac, pulmonary, renal, metabolic, neurodevelopmental, liver, or blood disease) or lack thereof, and / or immunosuppressive condition or lack thereof, or (iii) a typical subject within a population (e.g., a local, regional, or national population) for the influenza virus season, with the same or similar age or age range and / or overall health status. Prevention can be determined, for example, by the failure of a diagnosed influenza infection to progress and / or the lack of symptoms associated with influenza infection during part or all of the influenza season, or throughout the entire influenza season.
[0313] In some embodiments, the methods provided herein comprise administering a therapeutically effective amount of a composition according to the present disclosure to a subject at imminent risk of influenza infection. The imminent risk of influenza infection typically occurs during an influenza epidemic. Influenza viruses are known to circulate and cause seasonal epidemics of disease (WHO, Influenza (Seasonal) Fact Sheet, November 6, 2018). In temperate climates, seasonal epidemics occur primarily during the winter, whereas in tropical regions, influenza can occur throughout the year, causing more irregular outbreaks. For example, in the Northern Hemisphere, the risk of influenza epidemics is highest during November, December, January, February, and March, whereas in the Southern Hemisphere, the risk of influenza epidemics is highest during May, June, July, August, and September.
[0314] In some embodiments, treatment and / or prevention includes post-exposure prophylaxis.
[0315] In some embodiments, the subject has been, is being, or will be administered an antiviral agent. In some embodiments, the antiviral agent comprises a neuraminidase inhibitor, an influenza polymerase inhibitor, or both. In certain embodiments, the antiviral agent comprises oseltamivir, lanamivir, peramivir, zanamivir, baloxavir, or any combination thereof.
[0316] Non-limiting examples of typical routes of administration of the compositions of the present disclosure include oral, topical, transdermal, inhalation, parenteral, sublingual, buccal, rectal, vaginal, and intranasal. The term "parenteral," as used herein, includes subcutaneous, intravenous, intramuscular, and intrasternal injection or infusion techniques. In certain embodiments, administration includes administration by a route selected from oral, intravenous, parenteral, intragastric, intrathoracic, intrapulmonary, intrarectal, intradermal, intraperitoneal, intratumoral, subcutaneous, topical, transdermal, intravesical, intrathecal, intranasal, and intramuscular. In particular embodiments, a method includes orally administering the antibody, antigen-binding fragment, polynucleotide, vector, host cell, or composition to a subject.
[0317] Compositions according to certain embodiments of the present invention are formulated so that the active ingredients contained therein are bioavailable when the composition is administered to a patient. The composition administered to a subject or patient can take the form of one or more dosage units; for example, a tablet can be a single dosage unit, and a container of an antibody or antigen-binding compound described herein in aerosol form can hold multiple dosage units. Actual methods for preparing such dosage forms are known or will be apparent to those skilled in the art; see, for example, Remington: The Science and Practice of Pharmacy, 20th Edition (Philadelphia College of Pharmacy and Science, 2000). The composition administered will, in any event, contain an effective amount of an antibody or antigen-binding fragment, polynucleotide, vector, host cell, or composition of the present disclosure to treat the disease or condition of interest in accordance with the teachings herein.
[0318] The composition can be in solid or liquid form. In some embodiments, the base is particulate, so the composition is, for example, in the form of a tablet or powder. The base can be liquid, and in this case the composition is, for example, oral oil, injectable liquid, or aerosol (for example, useful for inhalation administration). When considering oral administration, the pharmaceutical composition is preferably in either solid or liquid form, and in this case, semi-solid, semi-liquid, suspension, and gel form are included in either solid or liquid form considered herein.
[0319] Pharmaceutical compositions can be formulated as solid compositions for oral administration, such as powders, granules, compressed tablets, pills, capsules, chewing gum, wafers, etc. Such solid compositions typically contain one or more inert diluents or edible bases. In addition, one or more of the following may be present: binders (such as carboxymethylcellulose, ethylcellulose, microcrystalline cellulose, tragacanth gum, or gelatin); excipients (such as starch, lactose, or dextrin); disintegrants (such as alginic acid, sodium alginate, Primogel, corn starch, etc.); lubricants (such as magnesium stearate or Sterotex); glidants (such as colloidal silicon dioxide); sweeteners (such as sucrose or saccharin); flavorings (such as peppermint, methyl salicylate, or orange flavoring); and colorings. When the composition is in the form of a capsule (e.g., a gelatin capsule), in addition to the above-mentioned materials, a liquid base (such as polyethylene glycol or oil) may be contained.
[0320] The composition can be in the form of a liquid (e.g., an elixir, syrup, solution, emulsion, or suspension). The liquid can be for oral administration or for delivery by injection, as two examples. When intended for oral administration, a preferred composition contains, in addition to the compound of the present invention, one or more of a sweetener, a preservative, a dye / colorant, and a flavoring agent. A composition intended for administration by injection can contain one or more of a surfactant, a preservative, a wetting agent, a dispersing agent, a suspending agent, a buffer, a stabilizer, and an isotonic agent.
[0321] Liquid pharmaceutical compositions, whether in solution, suspension, or other similar form, can contain one or more of the following adjuvants: sterile diluents (such as water for injection, saline solution (preferably saline), Ringer's solution, isotonic sodium chloride, fixed oils (such as synthetic mono- or diglycerides which can function as solvents or suspending media), polyethylene glycol, glycerin, propylene glycol, or other solvents); antibacterial agents (such as benzyl alcohol or methylparabens); antioxidants (such as ascorbic acid or sodium bisulfite); chelating agents (such as ethylenediaminetetraacetic acid); buffers (such as acetates, citrates, or phosphates), and agents for adjusting isotonicity (such as sodium chloride or dextrose). Parenteral preparations can be enclosed in ampoules, disposable syringes, or multiple-dose vials made of glass or plastic. Saline is one preferred adjuvant. Injectable pharmaceutical compositions are preferably sterile.
[0322] Liquid compositions intended for either parenteral or oral administration should contain an amount of the antibody or antigen-binding fragment disclosed herein to provide a suitable dosage. Typically, this amount is at least 0.01% of the antibody or antigen-binding fragment in the composition. When intended for oral administration, this amount may vary from 0.1 to about 70% by weight of the composition. Some oral pharmaceutical compositions contain from about 4% to about 75% of the antibody or antigen-binding fragment. In some embodiments, pharmaceutical compositions and preparations of the invention are formulated so that a parenteral dosage unit contains from 0.01 to 10% by weight of the antibody or antigen-binding fragment before dilution.
[0323] The composition may be intended for topical administration, in which case the carrier may suitably comprise a solution, emulsion, ointment, or gel base. Bases may include, for example, one or more of the following: petrolatum, lanolin, polyethylene glycol, beeswax, mineral oil, diluents (such as water or alcohol), and emulsifiers and stabilizers. A thickener may be present in the composition for topical administration. If transdermal administration is intended, the composition may include a transdermal patch or iontophoresis device. Pharmaceutical compositions may be intended for rectal administration, for example, in the form of suppositories that melt in the rectum to release the drug. Compositions for rectal administration may contain an oily base as a suitable non-irritating excipient. Non-limiting examples of such bases include lanolin, cocoa butter, and polyethylene glycol.
[0324] The composition can include various materials that modify the physical form of the solid or liquid dosage unit. For example, the composition can include a material that forms a coating shell around the active ingredient. The material that forms the coating shell is typically inert and can be selected from, for example, sugars, shellac, and other enteric coating agents. Alternatively, the active ingredient can be contained in a gelatin capsule. The composition, in solid or liquid form, can include an agent that binds to the antibody or antigen-binding fragment of the present disclosure and thereby aids in delivery of the compound. Suitable agents that may have this capability include monoclonal or polyclonal antibodies, one or more proteins, or liposomes. The composition can primarily consist of a dosage unit that can be administered as an aerosol. The term aerosol is used to refer to a variety of systems, ranging from systems with colloidal properties to systems consisting of a pressurized package. Delivery can be by liquefied or compressed gas or by a suitable pump system that delivers the active ingredient. To deliver the active ingredient, the aerosol can be delivered in a single-phase, two-phase, or three-phase system. Included in the delivery of the aerosol are the necessary containers, activators, valves, auxiliary containers, etc., which can be combined to form a kit. One of ordinary skill in the art can determine a preferred aerosol without undue experimentation.
[0325] It will be understood that the compositions of the present disclosure also encompass carrier molecules (e.g., lipid nanoparticles, nanoscale delivery platforms, etc.) for the polynucleotides described herein.
[0326] Pharmaceutical compositions can be prepared by methods well known in the pharmaceutical arts. For example, compositions intended to be administered by injection can be prepared by combining a composition containing an antibody, its antigen-binding fragment, or antibody conjugate described herein, and optionally one or more salts, buffers, and / or stabilizers, with sterile distilled water to form a solution. A surfactant can be added to facilitate the formation of a uniform solution or suspension. Surfactants are compounds that form non-covalent interactions with peptide compositions, thereby facilitating the dissolution or uniform suspension of an antibody or its antigen-binding fragment in an aqueous delivery system.
[0327] In general, an appropriate dosage and treatment regimen will provide the compositions in an amount sufficient to provide therapeutic and / or prophylactic benefit, which, as described herein, includes an improved clinical outcome (e.g., a reduction in the frequency, duration, or severity of diarrhea or associated dehydration, or inflammation, or a longer disease-free interval and / or overall survival, or a reduction in the severity of symptoms). For prophylactic use, the dose should be sufficient to prevent, delay the onset of, or reduce the severity of disease associated with a disease or disorder. The prophylactic benefit of the compositions administered in accordance with the methods described herein can be determined by conducting preclinical studies (including in vitro and in vivo animal studies) and clinical studies and analyzing the data obtained therefrom using appropriate statistical, biological, and clinical methods and techniques, all of which are readily practiced by one of ordinary skill in the art.
[0328] The compositions are administered in an amount effective (e.g., to treat influenza virus infection), which amount will vary depending on a variety of factors, including the activity of the specific compound used; the metabolic stability and duration of action of the compound; the age, weight, general health, sex, and diet of the subject; the mode and time of administration; the rate of excretion; the drug combination; the severity of the specific disorder or condition; and the subject being treated. In certain embodiments, after administration of therapy with the formulations and methods disclosed herein, test subjects will exhibit from about a 10% to about a 99% reduction in one or more symptoms associated with the disease or disorder being treated, compared to placebo-treated or other suitable control subjects.
[0329] Generally, a therapeutically effective dose of an antibody or antigen-binding fragment is from about 0.001 mg / kg (i.e., 0.07 mg) to about 100 mg / kg (i.e., 7.0 g) (for a 70 kg mammal); preferably, a therapeutically effective dose is from about 0.01 mg / kg (i.e., 0.7 mg) to about 50 mg / kg (i.e., 3.5 g) (for a 70 kg mammal); more preferably, a therapeutically effective dose is from about 1 mg / kg (i.e., 70 mg) to about 25 mg / kg (i.e., 1.75 g) (for a 70 kg mammal). For polynucleotides, vectors, host cells, and related compositions of the present disclosure, the therapeutically effective dose can differ from that of an antibody or antigen-binding fragment.
[0330] In certain embodiments, a method comprises administering the antibody, antigen-binding fragment, polynucleotide, vector, host cell, or composition to a subject 2, 3, 4, 5, 6, 7, 8, 9, 10, or more times.
[0331] In one embodiment, a method comprises administering the antibody, antigen-binding fragment, or composition to a subject multiple times, with the second or subsequent administration occurring about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 24, about 48, about 74, about 96 hours, or more, after the first or previous administration, respectively.
[0332] In certain embodiments, a method comprises administering the antibody, antigen-binding fragment, polynucleotide, vector, host cell, or composition at least once to a subject prior to influenza infection.
[0333] Compositions comprising an antibody, antigen-binding fragment, polynucleotide, vector, host cell, or composition of the present disclosure can also be administered simultaneously with, prior to, or following administration of one or more other therapeutic agents, such as a neuraminidase inhibitor (e.g., oseltamivir, zanamivir, peramivir, or laninamivir). Such combination therapy can include administration of a single pharmaceutical dosage form containing a compound of the present disclosure and one or more additional active agents, as well as administration of compositions comprising an antibody or antigen-binding fragment of the present disclosure and each active agent in its own separate dosage form. For example, an antibody or antigen-binding fragment thereof described herein and the other active agent(s) can be administered to a patient together in a single oral dosage composition (e.g., a tablet or capsule), or each agent can be administered in a separate oral dosage form. Similarly, an antibody or antigen-binding fragment thereof described herein and the other active agent(s) can be administered to a subject together in a single parenteral dosage composition (e.g., saline solution or other physiologically acceptable solution), or each agent can be administered in a separate parenteral dosage form. When separate dosage forms are used, the compositions comprising the antibody or antigen-binding fragment and one or more additional active agents can be administered at substantially the same time, i.e., simultaneously, or separately at staggered times, i.e., sequentially, in any order; combination therapy is understood to include all these regimens.
[0334] In some embodiments, the antibody (or one or more nucleic acids, host cells, vectors, or compositions) is administered to a subject who has previously been administered one or more anti-inflammatory agents and / or one or more antiviral agents. In some embodiments, the antiviral agent is a neuraminidase inhibitor (NAI) (e.g., oseltamivir, zanamivir, peramivir, or laninamivir). In some embodiments, the one or more anti-inflammatory agents and / or one or more antiviral agents are administered to a subject who has previously been administered the antibody (or one or more nucleic acids, host cells, vectors, or compositions). In some embodiments, the antiviral agent is a neuraminidase inhibitor (NAI) (e.g., oseltamivir, zanamivir, peramivir, or laninamivir).
[0335] In a related aspect, there is provided the use of the antibodies, antigen-binding fragments, vectors, host cells, and compositions of the disclosure (e.g., in the diagnosis, prevention, and / or treatment of influenza infection, and in the manufacture of a medicament for preventing or treating influenza infection).
[0336] In certain embodiments, an antibody, antigen-binding fragment, polynucleotide, vector, host cell, or composition is provided for use in a method of treating or preventing influenza infection in a subject.
[0337] In certain embodiments, an antibody, antigen-binding fragment, or composition is provided for use in a method for manufacturing or preparing a medicament for treating or preventing influenza infection in a subject.
[0338] The present disclosure also provides the following non-limiting embodiments.
[0339] Embodiment 1. An antibody or antigen-binding fragment thereof capable of binding to (i) an influenza A virus (IAV), including group 1 IAV, group 2 IAV, or both; and (ii) neuraminidase (NA) from an influenza B virus (IBV).
[0340] Embodiment 2. The antibody or antigen-binding fragment of embodiment 1, which is human, humanized, or chimeric.
[0341] Embodiment 3. The antibody or antigen-binding fragment of embodiment 1 or 2, wherein (i) the NA of Group 1 IAV comprises N1, N4, N5, and / or N8, and / or (ii) the NA of Group 2 IAV comprises N2, N3, N6, N7, and / or N9.
[0342] Embodiment 4. (i) The above N1 is A / California / 07 / 2009, A / California / 07 / 2009 I223R / H275Y, A / Swine / Jiangsu / J004 / 2018, A / Stockholm / 18 / 2007, A / Brisbane / 02 / 2018, A / Michigan / 45 / 2015, A / Mississippi / 3 / 2001, A / Netherlands / 603 / 2009, A / Netherlands / 602 / 2009, A / Vietnam / 1203 / 2004, A / G4 / SW / Shangdong / 1207 / 2016, A / G4 / SW / Henan / SN13 / 2018, A / G4 / SW / Jiangsu / J004 / 2018, and A / New (ii) the N4 is derived from any one or more of A / mallard duck / Netherlands / 30 / 2011; (iii) the N5 is derived from A / aquatic bird / Korea / CN5 / 2009; (iv) the N8 is derived from A / harbor seal / New Hampshire / 179629 / 2011;(v) The above N2 is A / Washington / 01 / 2007, A / HongKong / 68, A / South Australia / 34 / 2019, A / Switzerland / 8060 / 2017, A / Singapore / INFIMH-16-0019 / 2016, A / Switzerland / 9715293 / 2013, A / Leningrad / 134 / 17 / 57, A / Florid a / 4 / 2006, A / Netherlands / 823 / 1992, A / Norway / 466 / 2014, A / Switzerland / 8060 / 2017, A / Texas / 50 / 2012, A / Victoria / 361 / 2011, A / HongKong / 2671 / 2019, (vi) the N2 is from any one or more of A / SW / Mexico / SG1444 / 2011, A / Tanzania / 205 / 2010, A / Aichi / 2 / 1968, A / Bilthoven / 21793 / 1972, A / Netherlands / 233 / 1982, A / Shanghai / 11 / 1987, A / Nanchang / 933 / 1995, A / Fukui / 45 / 2004, and A / Brisbane / 10 / 2007; (vi) the N3 is from A / Canada / rv504 / 2004; (v) the N6 is from A / swine / Ontario / 01911 / 1 / 99; (vi) the N7 is from A / Netherlands / 078 / 03; and / or (vii) the N9 is from A / Anhui / 2013 and A / Hong Kong 4. The antibody or antigen-binding fragment of embodiment 3, which is N9 from any one or more of Kong / 56 / 2015;
[0343] Embodiment 5. The NA of the IBV is B / Lee / 10 / 1940(Ancestral);B / Brisbane / 60 / 2008(Victoria);B / Malaysia / 2506 / 2004(Victoria);B / Malaysia / 3120318925 / 2013(Yama gata);B / Wisconsin / 1 / 2010(Yamagata);B / Yamanashi / 166 / 1998(Yamagata);B / Brisbane / 33 / 2008;B / Colorado / 06 / 2017;B / Hubei-wujiang / 158 / 200 9; B / Massachusetts / 02 / 2012; B / Netherlands / 234 / 2011; B / Perth / 211 / 2001; B / Texas / 06 / 2011 (Yamagata); B / Perth / 211 / 2011; B / HongKong / 05 / 1972; B / Phuket / 3073 / 2013, B / Harbin / 7 / 1994 (Victoria), and B / Washington / 02 / 2019 (Victoria).
[0344] Embodiment 6. A vector capable of binding to each of: (i) the NA of a group 1 IAV; (ii) the NA of a group 2 IAV; and (iii) the NA of an IBV; EC 50 is in the range of about 0.1 μg / mL to about 50 μg / mL, or in the range of about 0.1 μg / mL to about 2 μg / mL, or in the range of 0.1 μg / mL to about 10 μg / mL, or in the range of 2 μg / mL to about 10 μg / mL, or in the range of about 0.4 μg / mL to about 50 μg / mL, or in the range of about 0.4 μg / mL to about 2 μg / mL, or in the range of 0.4 μg / mL to about 10 μg / mL, or in the range of 2 μg / mL to about 10 μg / mL, or in the range of 0.4 μg / mL to about 1 μg / mL, or in the range of 0.4 μg / mL to about 1 μg / mL, or 0.4 μg / mL or less.
[0345] Embodiment 7. (i) A vector capable of binding to the NA of said Group 1 IAV, and 50(ii) the NA of the Group 2 IAV is in the range of about 0.4 μg / mL to about 50 μg / mL, about 0.4 μg / mL to about 10 μg / mL, about 0.4 μg / mL to about 2 μg / mL, about 2 μg / mL to about 50 μg / mL, about 2 μg / mL to about 10 μg / mL, or about 10 μg / mL to about 50 μg / mL; (ii) the NA of the Group 2 IAV is in the range of about 0.4 μg / mL to about 50 μg / mL, about 0.4 μg / mL to about 10 μg / mL, about 0.4 μg / mL to about 2 μg / mL, about 2 μg / mL to about 50 μg / mL, or about 10 μg / mL to about 50 μg / mL; 50 is in the range of about 0.4 μg / mL to about 50 μg / mL, or about 0.4 μg / mL to about 10 μg / mL, or about 0.4 μg / mL to about 2 μg / mL, or about 2 μg / mL to about 50 μg / mL, or about 2 μg / mL to about 10 μg / mL, or about 10 μg / mL to about 50 μg / mL; and / or (iii) is capable of binding to the NA of said IBV and is capable of inhibiting EC 50 7. The antibody or antigen-binding fragment of embodiment 6, wherein the antibody or antigen-binding fragment has a saturation concentration of about 0.4 μg / mL, or about 0.1 μg / mL to about 1.9 μg / mL, or about 0.1 μg / mL to about 1.5 μg / mL, or in the range of about 0.1 μg / mL to about 1.0 μg / mL, or about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, or 1.0 μg / mL.
[0346] Embodiment 8. (i) A polypeptide capable of binding to N1 and capable of binding to EC 50 is about 0.4 μg / mL, or in the range of about 0.4 μg / mL to about 50 μg / mL, or in the range of about 0.1 μg / mL to about 1.9 μg / mL, or in the range of about 0.1 μg / mL to about 1.5 μg / mL, or in the range of about 0.1 μg / mL to about 1.0 μg / mL, or about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, or 1.0 μg / mL; (ii) capable of binding to N4 and having an EC 50 (iii) is capable of binding to N5 and has an EC 50 (iv) can bind to N8 and has an EC 50(v) can bind to N2 and has an EC 50 is in the range of about 0.4 μg / mL to about 20 μg / mL, or about 0.4 μg / mL to about 10 μg / mL, or about 0.4 μg / mL to about 2 μg / mL, about 1 μg / mL to about 10 μg / mL, or about 1 μg / mL to about 20 μg / mL, or about 1 μg / mL to about 5 μg / mL, or about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, or 20 μg / mL; (vi) capable of binding to N3, and EC 50 (vii) is capable of binding to N6 and has an EC 50 (viii) capable of binding to N7 and having an EC 50 (ix) capable of binding to N9 and having an EC 50 is about 0.4 μg / mL, or about 0.1 μg / mL to about 1.9 μg / mL, or about 0.1 μg / mL to about 1.5 μg / mL, or about 0.1 μg / mL to about 1.0 μg / mL, or about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, or 1.0 μg / mL; and / or (xi) is capable of binding to the NA of IBV and has an EC 50 8. The antibody or antigen-binding fragment of embodiment 7, wherein the antibody or antigen-binding fragment has a saturation concentration of about 0.4 μg / mL, or about 0.1 μg / mL to about 1.9 μg / mL, or about 0.1 μg / mL to about 1.5 μg / mL, or in the range of about 0.1 μg / mL to about 1.0 μg / mL, or about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, or 1.0 μg / mL.
[0347] Embodiment 9. (i)N1 A / California / 07 / 2009, N1 A / California / 07 / 2009 I223R / H275Y, N1 A / Stockholm / 18 / 2007, N1 A / Swine / Jiangsu / J004 / 2008, N4 A / mallard duck / Netherlands / 30 / 2011, N5 A / aquatic bird / Korea / CN5 / 2009, N2 A / Hong Kong / 68, N2 A / Leningrad / 134 / 17 / 57, N3 A / Canada / rv504 / 2004, N6 A / Swine / Ontario / 01911 / 1 / 99, N9 Able to bind to one or more of A / Anhui / 1 / 2013, B / Lee / 10 / 1940 (Ancestral), B / Brisbane / 60 / 2008 (Victoria), B / Malaysia / 2506 / 2004 (Victoria), B / Malaysia / 3120318925 / 2013 (Yamagata), B / Wisconsin / 1 / 2010 (Yamagata), and B / Yamanashi / 166 / 1998 (Yamagata), and EC 50 (ii) is capable of binding to N5 A / aquatic bird / Korea / CN5 / 2009 and is in the range of about 0.4 μg / mL, or about 0.1 μg / mL to about 1.9 μg / mL, or about 0.1 μg / mL to about 1.5 μg / mL, or about 0.1 μg / mL to about 1.0 μg / mL, or about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, or 1.0 μg / mL; (ii) is capable of binding to N5 A / aquatic bird / Korea / CN5 / 2009 and is in the range of about 0.4 μg / mL, or about 0.1 μg / mL to about 1.9 μg / mL, or about 0.1 μg / mL to about 1.5 μg / mL, or about 0.1 μg / mL to about 1.0 μg / mL; 50 (iii) capable of binding to N8 A / harbor seal / New Hampshire / 179629 / 2011 and having an EC 50 (iv) can bind to N2 A / Washington / 01 / 2007 and has an EC 50 (v) capable of binding to N7 A / Netherlands / 078 / 03 and EC 50(vi) capable of binding to N2 A / South Australia / 34 / 2019 and EC 50 (vii) capable of binding to N2 A / Switzerland / 8060 / 2017 and EC 50 (viii) capable of binding to N2 A / Singapore / INFIMH-16-0019 / 2016 and EC 50 (iv) capable of binding to N2 A / Switzerland / 9715293 / 2013 and EC 50 and / or (v) capable of binding to N1 A / Swine / Jiangsu / J004 / 2018 and EC 50 9. The antibody or antigen-binding fragment of embodiment 7 or 8, wherein the IgG antibody or antigen-binding fragment has a IgG antibody titer in the range of about 0.4 μg / mL to about 50 μg / mL, or is about 0.4, about 2, about 10, or about 50 μg / mL.
[0348] Embodiment 10. The antibody or antigen-binding fragment of any one of embodiments 1 to 9, wherein the NA is expressed on the surface of a host cell (e.g., a CHO cell) and binding to the NA is measured by flow cytometry.
[0349] Embodiment 11. The antibody or antigen-binding fragment of any one of embodiments 1 to 10, which can bind to NA, and has a KD of less than 1.0E-12 M, less than 1.0E-11 M, 1.0E-11 M, or 1.0E-12 M or less, 1.0E-11 M or less, or 1.0E-10 or less, or a KD of 1.0E-10 and 1.0E-13, or a KD of 1.0E-11 and 1.0E-13, and optionally, the binding is assessed by biolayer interferometry (BLI).
[0350] Embodiment 12. The antibody or antigen-binding fragment of embodiment 11, wherein the NA is N1, N2, and / or N9.
[0351] Embodiment 13. (1) (i) an NA epitope comprising any one or more of the following amino acids (N1 NA numbering): R368, R293, E228, E344, S247, D198, D151, R118; and / or (ii) an NA epitope comprising any one or more of the following amino acids (N2 NA numbering): R371, R292, E227, E344, S247, D198, D151, R118; and / or (2) (i) an NA epitope comprising amino acids R368, R293, E228, D151, and R118 (N1 NA numbering); and / or (ii) amino acids R371, R292, E227, D151, and R118 (N2 and / or (3) an epitope within or comprising the NA active site, optionally comprising the following amino acids (N2 numbering): R118, D151, R152, R224, E276, R292, R371, Y406, E119, R156, W178, S179, D / N198, I222, E227, H274, E277, D293, E425; and / or (4) the antibody or antigen-binding fragment of any one of embodiments 1-12, which is capable of binding to an NA epitope of IBV comprising (i) any one or more of the following amino acids: R116, D149, E226, R292, and R374; or (ii) amino acids R116, D149, E226, R292, and R374.
[0352] Embodiment 14. The antibody or antigen-binding fragment of embodiment 13, wherein (1) the epitope further comprises any one or more of the following NA amino acids (N2 numbering): E344, E227, S247, and D198; and / or (2) the antibody or antigen-binding fragment is capable of binding to an NA comprising a S245N amino acid mutation and / or an E221D amino acid mutation.
[0353] Embodiment 15. The antibody or antigen-binding fragment of any one of embodiments 1 to 14, which is capable of binding to an NA comprising an S245N amino acid mutation and / or an E221D amino acid mutation.
[0354] Embodiment 16. The antibody or antigen-binding fragment of any one of embodiments 1-15, which is capable of inhibiting (i) the sialidase activity of the NA of IAV, including Group 1 IAV, Group 2 IAV, or both, and / or (ii) the sialidase activity of the NA of IBV in an in vitro model of infection, an in vivo animal model of infection, and / or in humans.
[0355] Embodiment 17. (i) the NA of said Group 1 IAV comprises H1N1 and / or H5N1; (ii) the NA of said Group 2 IAV comprises H3N2 and / or H7N9; and / or (iii) the NA of said IBV is selected from the group consisting of B / Lee / 10 / 1940 (Ancestral); B / HongKong / 05 / 1972; B / Taiwan / 2 / 1962 (Ancestral); B / Brisbane / 33 / 2008 (Victoria); B / Brisbane / 60 / 2008 (Victoria); B / Malaysia / 2506 / 2004 (Victoria); B / New York / 1056 / 2003(Victoria);B / Florida / 4 / 2006(Yamagata);B / Jiangsu / 10 / 2003(Yamagata);B / Texas / 06 / 2011(Yam agata);B / Perth / 211 / 2011;B / Harbin / 7 / 1994(Victoria);B / Colorado / 06 / 2017(Victoria);B / Washington / 02 / 2019( The antibody or antigen-binding fragment of embodiment 16, comprising one or more of the following: B / Victoria; B / Perth / 211 / 2001 (Yamagata); B / Hubei-wujiagang / 158 / 2009 (Yamagata); B / Wisconsin / 01 / 2010 (Yamagata); B / Massachusetts / 02 / 2012 (Yamagata); and B / Phuket / 3073 / 2013 (Yamagata).
[0356] Embodiment 18. The sialidase activity of Group 1 IAV NAs; Group 2 IAV NAs; and / or IBV NAs can be inhibited, and the IC50 is about 0.0008 μg / mL to about 4 μg / mL, about 0.0008 μg / mL to about 3 μg / mL, about 0.0008 μg / mL to about 2 μg / mL, about 0.0008 μg / mL to about 1 μg / mL, about 0.0008 μg / mL to about 0.9 μg / mL, about 0.0008 μg / mL to about 0.8 μg / mL, about 0.0008 μg / mL to about 0.7 μg / mL, about 0.0008 μg / mL to about 0.6 μg / mL, about 0.0008 μg / mL to about 0.5 μg / mL. μg / mL, approximately 0.0008 μg / mL to approximately 0.4 μg / mL, approximately 0.0008 μg / mL to approximately 0.3 μg / mL, approximately 0.0008 μg / mL to approximately 0.2 μg / mL, approximately 0.0008 μg / mL to approximately 0.1 μg / mL, approximately 0.0008 μg / mL to approximately 0.09 μg / mL , about 0.0008μg / mL to about 0.08μg / mL, about 0.0008μg / mL to about 0.07μg / mL, about 0.0008μg / mL to about 0.06μg / mL, about 0.0008μg / mL to about 0.05μg / mL, about 0.0008μg / mL to about 0.04μg / mL, Approximately 0.0008μg / mL to approximately 0.03μg / mL, approximately 0.0008μg / mL to approximately 0.02μg / mL, approximately 0.0008μg / mL to approximately 0.01μg / mL, 0.002μg / mL to approximately 4μg / mL, approximately 0.001μg / mL to 50μg / mL, approximately 0.1μg / mL ~30μg / mL, approximately 0.1μg / mL~approximately 20μg / mL, approximately 0.1μg / mL~approximately 10μg / mL, approximately 0.1μg / mL~approximately 9μg / mL, approximately 0.1μg / mL~approximately 8μg / mL, approximately 0.1μg / mL~approximately 7μg / mL, approximately 0.1μg / mL~approximately 6μg / mL, approx. 0.1μg / mL to about 5μg / mL, about 0.1μg / mL to about 4μg / mL, about 0.1μg / mL to about 3μg / mL, about 0.1μg / mL to about 2μg / mL, about 0.1μg / mL to about 1μg / mL, about 0.1μg / mL to about 0.9μg / mL, about 0.1μg / mL to about 0 .8μg / mL, about 0.1μg / mL to about 0.7μg / mL, about 0.1μg / mL to about 0.6μg / mL, about 0.1μg / mL to about 0.5μg / mL, about 0.1μg / mL to about 0.4μg / mL, about 0.1μg / mL to about 0.3μg / mL, about 0.1μg / mL to about 0.2μg / mL, approximately 0.8μg / mL to approximately 30μg / mL, approximately 0.8μg / mL to approximately 20μg / mL, approximately 0.8μg / mL to approximately 10μg / mL, approximately 0.8μg / mL to approximately 9μg / mL , about 0.8μg / mL to about 8μg / mL, about 0.8μg / mL to about 7μg / mL, about 0.8μg / mL to about 6μg / mL, about 0.8μg / mL to about 5μg / mL, about 0.8μg / mL about 0.8 μg / mL to about 4 μg / mL, about 0.8 μg / mL to about 3 μg / mL, about 0.8 μg / mL to about 2 μg / mL, about 0.8 μg / mL to about 1 μg / mL, or about 0.1 μg / mL, about 0.2 μg / mL, about 0.3 μg / mL, about 0.4 μg / mL, about 0.5 μg / mL, about 0.6 μg / mL, about 0.7 μg / mL, about 0.8 μg / mL, about 0.9 μg / mL, about 1.0μg / mL, approximately 1.5μg / mL, approximately 2.0μg / mL, approximately 2.5μg / mL, approximately 3.0μg / mL, approximately 3.5μg / mL, approximately 4.0μg / mL, approximately 4.5μg / mL, approximately 5 .0μg / mL, approximately 5.5μg / mL, approximately 6.0μg / mL, approximately 6.5μg / mL, approximately 7.0μg / mL, approximately 7.5μg / mL, approximately 8.0μg / mL, approximately 8.5μg / mL, approximately 9.0 18. The antibody or antigen-binding fragment of any one of embodiments 1 to 17, wherein the antibody or antigen-binding fragment has a saturation concentration of about 10 μg / mL, about 11 μg / mL, about 12 μg / mL, about 13 μg / mL, about 14 μg / mL, about 15 μg / mL, about 16 μg / mL, about 17 μg / mL, about 18 μg / mL, about 19 μg / mL, about 20 μg / mL, about 25 μg / mL, and / or about 30 μg / mL.
[0357] Embodiment 19. A compound capable of inhibiting the sialidase activity of NA of one or more Group 1 and / or Group 2 IAVs, and / or one or more IBVs, having an IC50 of from about 0.00001 μg / ml to about 25 μg / ml, or from about 0.0001 μg / ml to about 10 μg / ml, or from about 0.0001 μg / ml to about 1 μg / ml, or from about 0.0001 μg / ml to about 0.1 μg / ml, or from about 0.0001 μg / ml to about 0.01 μg / ml, or from about 0.0001 μg / ml to about 0.001 μg / ml, or from about 0.0001 μg / ml to about 0.0001 μg / ml to about 25 μg / ml, or from about 0.0001 μg / ml to about 10 μg / ml, or about 0.0001 μg / ml μg / ml to about 1 μg / ml, or about 0.0001 μg / ml to about 0.1 μg / ml, or about 0.0001 μg / ml to about 0.01 μg / ml, or about 0.001 μg / ml to about 25 μg / ml, or about 0.001 μg / ml to about 10 μg / ml, or about 0.001 μg / ml to about 1 μg / ml, or about 0.001 μg / ml to about 0.1 μg / ml, or or from about 0.001 μg / ml to about 0.01 μg / ml, or from about 0.01 μg / ml to about 25 μg / ml, or from about 0.01 μg / ml to about 10 μg / ml, or from about 0.01 μg / ml to about 1 μg / ml, or from about 0.01 μg / ml to about 0.1 μg / ml, or from about 1 μg / ml to about 25 μg / ml, or from about 1 μg / ml to about 10 μg / ml, or about 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, 12, 12.5, 13, 13.5, 14, 14.5, or 15 μg / ml.
[0358] Embodiment 20. The antibody or antigen-binding fragment of any one of embodiments 1 to 19, which is capable of activating human FcγRIIIa.
[0359] Embodiment 21. The antibody or antigen-binding fragment of embodiment 20, wherein activation is determined using host cells (optionally Jurkat cells) comprising an NFAT expression control sequence operably linked to a sequence encoding (i) human FcγRIIIa (optionally the F158 allele) and (ii) a reporter (such as a luciferase reporter) after incubation (e.g., for 23 hours) with target cells (e.g., A549 cells) infected with IAV.
[0360] Embodiment 22. The antibody or antigen-binding fragment of embodiment 21, wherein activation is determined after incubation (optionally for about 23 hours) with target cells infected with H1N1 IAV, optionally wherein said H1N1 IAV is A / PR8 / 34, and / or optionally wherein said infection is at a multiplicity of infection (MOI) of 6.
[0361] Embodiment 23. The antibody or antigen-binding fragment of any one of embodiments 1 to 22, which is capable of neutralizing infection by IAV and / or IBV.
[0362] Embodiment 24. The antibody or antigen-binding fragment of embodiment 23, wherein the IAV and / or IBV is resistant to an antiviral agent, and optionally the antiviral agent is oseltamivir.
[0363] Embodiment 25. The antibody or antigen-binding fragment of any one of embodiments 1 to 24, wherein the IAV comprises an NA of N1 comprising the amino acid mutations: H275Y; E119D+H275Y; S247N+H275Y; I222V; and / or N294S, and optionally the IAV comprises CA09 or A / Aichi.
[0364] Embodiment 26. The antibody or antigen-binding fragment of any one of embodiments 1 to 25, wherein the IAV comprises an NA of N2 comprising the amino acid mutations E119V, Q136K, and / or R292K.
[0365] Embodiment 27. The antibody or antigen-binding fragment of any one of embodiments 1 to 26, which is capable of treating and / or preventing (i) IAV infection and / or (ii) IBV infection in a subject.
[0366] Embodiment 28. The antibody or antigen-binding fragment of any one of embodiments 1-27, which is capable of treating and / or ameliorating infection by (i) an H1N1 virus (optionally including A / PR8 / 34); and / or (ii) an H3N2 virus (optionally including A / Hong Kong / 68).
[0367] Embodiment 29. The antibody or antigen-binding fragment of any one of embodiments 1-28, which is capable of preventing weight loss in a subject infected with said IAV and / or IBV, optionally for (i) up to 15 days, or (ii) more than 15 days, after administration of an effective amount.
[0368] Embodiment 30. The antibody or antigen-binding fragment of any one of embodiments 1 to 29, which is capable of preventing weight loss in a subject infected with IAV and / or IBV by more than 10%, as measured relative to the subject's weight immediately before infection with the IAV and / or IBV.
[0369] Embodiment 31. The antibody or antigen-binding fragment of any one of embodiments 1 to 30, which is capable of prolonging survival of a subject infected with IAV and / or IBV.
[0370] Embodiment 32. In mice (e.g., tg32 mice), (i) a period of time ranging from about 10 days to about 14 days, from about 10.2 days to about 13.8 days, from about 10.5 days to about 13.5 days, from about 11 days to about 13 days, from about 11.5 days to about 12.5 days, between 10 days and 14 days, or between 10.5 days and 13.5 days, or between 11 days and 13 days, or about 10.0, 10.1, 10.2, 10.3, 10.4, 10.5, 10.6 , 10.7, 10.8, 10.9, 11.0, 11.1, 11.2, 11.3, 11.4, 11.5, 11.6, 11.7, 11.8, 11.9, 12.0, 12.1, 12.2, 12.3, 12.4, 12.5, 12.6, 12.7, 12.8, 12.9, 13.0, 13.1, 13.2, 13.3, 13.4, 13.5, 13.6, 13.7, 13.8, 13.9, or 14.0 days in vivo half-life; or (ii) from about 12 days to about 16 days, from about 12.5 days to 15.5 days, from about 13 days to 15 days, from about 13.5 days to about 14.5 days, ...
Claims
1. (i) influenza A virus (IAV), including group 1 IAV, group 2 IAV, or both; (ii) Influenza B virus (IBV) an antibody or antigen-binding fragment thereof capable of binding to neuraminidase (NA) from wherein the VH and VL comprise or consist of an amino acid sequence having at least 90% identity to: (i) SEQ ID NOs: 86 and 92, respectively; (ii) SEQ ID NOs: 2 and 8, respectively; (iii) SEQ ID NOs: 26 and 32, respectively; (iv) SEQ ID NOs: 134 and 140, respectively; (v) SEQ ID NOs: 146 and 152, respectively; (vi) SEQ ID NOs: 158 and 164, respectively; or (vii) SEQ ID NOs: 228 and 230, respectively.
2. A polypeptide capable of binding to influenza virus neuraminidase (NA), wherein the VH comprises the amino acid sequence set forth in SEQ ID NO: 219, the amino acid sequence set forth in SEQ ID NO: 220, and the amino acid sequence set forth in SEQ ID NO: 221, and the VL comprises the amino acid sequence set forth in SEQ ID NO: 222, the amino acid sequence set forth in SEQ ID NO: 223, and the amino acid sequence set forth in SEQ ID NO:
224.
3. The VH and the VL are (i) SEQ ID NOs: 86 and 92, respectively; (ii) SEQ ID NOs: 2 and 8, respectively; (iii) SEQ ID NOs: 26 and 32, respectively; (iv) SEQ ID NOs: 134 and 140, respectively; (v) SEQ ID NOs: 146 and 152, respectively; (vi) SEQ ID NOs: 158 and 164, respectively; or (vii) SEQ ID NOs: 228 and 230, respectively 3. The antibody or antigen-binding fragment of claim 1 or 2, comprising or consisting of an amino acid sequence having at least 92% identity to
4. The VH and VL are (i) SEQ ID NOs: 86 and 92, respectively; (ii) SEQ ID NOs: 2 and 8, respectively; (iii) SEQ ID NOs: 26 and 32, respectively; (iv) SEQ ID NOs: 134 and 140, respectively; (v) SEQ ID NOs: 146 and 152, respectively; (vi) SEQ ID NOs: 158 and 164, respectively; or (vii) SEQ ID NOs: 228 and 230, respectively The antibody or antigen-binding fragment of any one of claims 1 to 3, comprising or consisting of an amino acid sequence having at least 95% identity with:
5. The VH and VL are (i) SEQ ID NOs: 86 and 92, respectively; (ii) SEQ ID NOs: 2 and 8, respectively; (iii) SEQ ID NOs: 26 and 32, respectively; (iv) SEQ ID NOs: 134 and 140, respectively; (v) SEQ ID NOs: 146 and 152, respectively; (vi) SEQ ID NOs: 158 and 164, respectively; or (vii) SEQ ID NOs: 228 and 230, respectively The antibody or antigen-binding fragment of any one of claims 1 to 4, comprising or consisting of an amino acid sequence having at least 97% identity with
6. The VH and VL are (i) SEQ ID NOs: 86 and 92, respectively; (ii) SEQ ID NOs: 2 and 8, respectively; (iii) SEQ ID NOs: 26 and 32, respectively; (iv) SEQ ID NOs: 134 and 140, respectively; (v) SEQ ID NOs: 146 and 152, respectively; (vi) SEQ ID NOs: 158 and 164, respectively; or (vii) SEQ ID NOs: 228 and 230, respectively The antibody or antigen-binding fragment of any one of claims 1 to 5, comprising or consisting of an amino acid sequence having at least 98% identity with:
7. The VH and VL are (i) SEQ ID NOs: 86 and 92, respectively; (ii) SEQ ID NOs: 2 and 8, respectively; (iii) SEQ ID NOs: 26 and 32, respectively; (iv) SEQ ID NOs: 134 and 140, respectively; (v) SEQ ID NOs: 146 and 152, respectively; (vi) SEQ ID NOs: 158 and 164, respectively; or (vii) SEQ ID NOs: 228 and 230, respectively The antibody or antigen-binding fragment of any one of claims 1 to 6, comprising or consisting of an amino acid sequence having at least 99% identity with:
8. The VH and the VL are The antibody or antigen-binding fragment of any one of claims 1 to 7, comprising or consisting of an amino acid sequence having at least 99% identity to SEQ ID NOs: 86 and 92, respectively.
9. An antibody or antigen-binding fragment of any one of claims 1 to 8, capable of inhibiting the sialidase activity of IAV and IBV and / or neutralizing infection by IAV and IBV.
10. 10. The antibody or antigen-binding fragment of any one of claims 1 to 9, which is of the IgG, IgA, IgM, IgE, or IgD isotype.
11. 11. The antibody or antigen-binding fragment of any one of claims 1 to 10, which is an IgG isotype selected from IgG1, IgG2, IgG3, and IgG4.
12. The antibody or antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment is a human antibody, a monoclonal antibody, a purified antibody, a single chain antibody, a Fab, a Fab', a F(ab') 2 or Fv of any one of claims 1 to 11.
13. The antibody or antigen-binding fragment of claim 1, wherein the antibody or antigen-binding fragment comprises an Fc polypeptide (e.g., IgG1) or a fragment thereof.
14. The Fc polypeptide or fragment thereof (i) comprises a mutation that increases the binding affinity to human FcRn relative to a reference Fc polypeptide that does not contain that mutation (e.g., as measured using surface plasmon resonance (SPR) (e.g., on a Biacore T200 instrument using the manufacturer's protocol)); and / or (ii) comprises a mutation, which increases the binding affinity to a human FcγR (e.g., as measured using surface plasmon resonance (SPR) (e.g., on a Biacore, e.g., T200 instrument using the manufacturer's protocol)) relative to a reference Fc polypeptide that does not contain that mutation, and optionally (1) Mutations that increase binding affinity to human FcRn include M428L; N434S; N434H; N434A; N434S; M252Y; S254T; T256E; T250Q; P257I; Q311I; D376V; T307A; E380A; or any combination thereof, further optionally, wherein the mutations that increase binding affinity to human FcRn are: (i) M428L / N434S; (ii) M252Y / S254T / T256E; (iii) T250Q / M428L; (iv) P257I / Q311I; (vi) D376V / N434H; (vii) T307A / E380A / N434A; or (viii) any combination of (i) to (vii), preferably the mutations that increase binding affinity to human FcRn include M428L / N434S; and / or (2) The antibody or antigen-binding fragment of claim 13, wherein the mutations that enhance binding to FcγR include S239D; I332E; A330L; G236A; or any combination thereof, and further optionally, the mutations that enhance binding to FcγR include the following: (i) S239D / I332E; (ii) S239D / A330L / I332E; (iii) G236A / S239D / I332E; or (iv) G236A / A330L / I332E, and wherein the Fc polypeptide or fragment thereof further optionally includes Ser at position 239.
15. The antibody or antigen-binding fragment of any one of claims 1 to 14, comprising a glycosylation-altering mutation, wherein the glycosylation-altering mutation comprises N297A, N297Q, or N297G, and / or is deglycosylated and / or defucosylated.
16. Optionally, (1) the polynucleotide comprises deoxyribonucleic acid (DNA) or ribonucleic acid (RNA), optionally comprising messenger RNA (mRNA); and / or (2) The isolated antibody or antigen-binding fragment of any one of claims 1 to 15, wherein the polynucleotide comprises a modified nucleoside, a Cap 1 structure, a Cap 2 structure, or any combination thereof, and further optionally, the polynucleotide comprises pseudouridine, N6-methyladenosine, 5-methylcytidine, 2-thiouridine, or any combination thereof, or encodes the VH, heavy chain, VL, and / or light chain of the antibody.
17. A recombinant vector comprising the polynucleotide of claim 16.
18. A host cell comprising the polynucleotide of claim 16 and / or the vector of claim 17, wherein the polynucleotide is optionally heterologous to the host cell and / or the host cell is capable of expressing the encoded antibody or antigen-binding fragment, or polypeptide.
19. (i) the antibody or antigen-binding fragment of any one of claims 1 to 15; (ii) a polynucleotide according to claim 16; (iii) the vector according to claim 17; (iv) the host cell according to claim 18 and, A composition comprising a pharma- ceutically acceptable excipient, carrier, or diluent.
20. 16. A method of making the antibody or antigen-binding fragment of any one of claims 1 to 15, comprising culturing a host cell of claim 18 for a sufficient time and under sufficient conditions for the host cell to express the antibody or antigen-binding fragment.
21. The antibody or antigen-binding fragment of any one of claims 1 to 15, the polynucleotide of claim 16, the recombinant vector of claim 17, the host cell of claim 18, or the composition of claim 19 for use in the preparation of a medicament for treating or preventing IAV and / or IBV infection in a subject.
22. 1. A method for diagnosing IAV and / or IBV infection in vitro, comprising: (i) contacting a sample from a subject with the antibody or antigen-binding fragment of any one of claims 1 to 15; (ii) detecting a complex comprising an antigen and said antibody, or an antigen and said antigen-binding fragment.
23. (i) the IAV comprises a Group 1 IAV, a Group 2 IAV, or both, and optionally the NA of the Group 1 IAV comprises N1, N4, N5, and / or N8; and / or the NA of the Group 2 IAV comprises N2, N3, N6, N7, and / or N9, and further optionally the N1 is derived from A / California / 07 / 2009, e.g., A / California / 07 / 2009 derived from I223R / H275Y, derived from A / Swine / Jiangsu / J004 / 2018, derived from A / Stockholm / 18 / 2007, derived from A / Brisbane / 02 / 2018, derived from A / Michigan / 45 / 2015, derived from A / Mississippi / 3 / 2001, derived from A / Netherlands / 603 / 2 009, A / Netherlands / 602 / 2009, A / Vietnam / 1203 / 2004, A / G4 / SW / Shangdong / 1207 / 2016, A / G4 / SW / Henan / SN13 / 2018, A / G4 / SW / Jiangsu / J004 / 2018, and / or A / New N4 is derived from A / mallard duck / Netherlands / 30 / 2011; N5 is derived from A / aquatic bird / Korea / CN5 / 2009; N8 is derived from A / harbor seal / New Hampshire / 179629 / 2011;The N2 is derived from A / Washington / 01 / 2007, A / HongKong / 68, A / HongKong / 2671 / 2019, A / South Originating from Australia / 34 / 2019, Originating from A / Switzerland / 8060 / 2017, Originating from A / Singapore / INFIMH-16-0019 / 2016, Originating from A / Switzerland / 9715293 / 2013, Originating from A / Leningrad / 134 / 17 / 57, Originating from A / Florida / 4 / 2006, Originating from A / Netherlands / 823 / 1992, Originating from A / Norway / 466 / 2014, Originating from A / Texas / 50 / 2012, Originating from A / Victoria / 361 / 2011, Originating from A / SW / Mexico / SG1444 / 2011, Originating from A / Aichi / 2 / 1 968, A / Bilthoven / 21793 / 1972, A / Netherlands / 233 / 1982, A / Shanghai / 11 / 1987, A / Nanchang / 933 / 1995, A / Fukui / 45 / 2004, A / Brisbane / 10 / 2007, A / Tanzania / 205 / 2010; the N3 is from A / Canada / rv504 / 2004; the N6 is from A / swine / Ontario / 01911 / 1 / 99; the N7 is from A / Netherlands / 078 / 03; and / or the N9 is from A / Anhui / 2013, A / Hong Kong / 2012 / 12 / 1986; Originating from Kong / 56 / 2015; and / or; (ii) The NA of the IBV is B / Lee / 10 / 1940 (Ancestral); B / Brisbane / 60 / 2008 (Victoria); B / Malaysia / 2506 / 2004 (Victoria); B / Malaysia / 3120318925 / 2013 (Yamagata); B / Wisconsin / 1 / 2010 (Ya B / Yamanashi / 166 / 1998 (Yamagata); B / Brisbane / 33 / 2008 (Victoria); B / Colorado / 06 / 2017 (Victoria); B / Hubei-wujiang / 158 / 2009 (Yamagata); B / Massachusetts / 02 / 2012 (Ya 23. The method of claim 22, or the antibody or antigen-binding fragment, polypeptide, polynucleotide, recombinant vector, host cell, human B cell, and / or composition for use according to claim 21, derived from B / Netherlands / 234 / 2011; B / Perth / 211 / 2001 (Yamagata); B / Phuket / 3073 / 2013 (Yamagata); B / Texas / 06 / 2011 (Yamagata); B / HongKong / 05 / 1972; B / Harbin / 7 / 1994 (Victoria); B / Washington / 02 / 2019 (Victoria); B / Perth / 211 / 2011, or any combination thereof.
